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MIR193BHG: A NOVEL HYPOXIA-INDUCIBLE LONG NONCODING RNA 
INVOLVED IN THE 
FINE-TUNING OF CHOLESTEROL METABOLISM 
 
The human genome generates a vast number of functionally and 
structurally diverse noncoding transcripts, incorporated into complex networks 
which modulate the activity of classic pathways. Long noncoding RNAs (lncRNA) 
have been shown to exhibit diverse regulatory roles in various physiological and 
pathological processes. Hypoxia, a key feature of the tumor microenvironment, 
triggers adaptive responses in cancer cells that involve hundreds of genes. While 
the coding component of hypoxia signaling has been extensively studied, much 
less information is available regarding its noncoding arm. My doctoral work 
identified and functionally characterized a novel hypoxia-inducible lncRNAs 
encoded from the miR193b-host gene (MIR193BHG) locus, on chromosome 16. 
In the pursuit of understanding how MIR193BHG responds to hypoxia, we 
discovered a more complex transcriptional control of MIR193BHG by hypoxia. 
Ectopic expression of MIR193BHG in breast cancer cell lines in vitro and in 
xenografts significantly represses cell invasion, as well as the metastasis to lung 
and liver. Conversely, inhibition of MIR193BHG promotes cancer cell 
invasiveness and metastasis. RNAseq followed by pathway analysis revealed 
that MIR193BHG is a negative modulator of cholesterol biosynthesis pathway. 
MIR193BHG exerts a highly coordinated effect on the expression of cholesterol 
biosynthetic genes which leads to a measurable impact on the total cellular 
cholesterol content. The role of MIR193BHG in cholesterol metabolism also 
provided a mechanistic explanation for the sex maturation associated SNPs 
located in vicinity of this gene locus. Our work also provided preliminary insights 
into the functional mechanism of MIR193BHG by showing that its modulation of 
genes in cholesterol synthesis is predominantly at transcriptional level. Overall, 
my dissertation project identified a non-canonical hypoxia-inducible lncRNA, 
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MIR193BHG, which modulates breast cancer invasion and metastasis via fine-
tuning of cholesterol synthesis. 
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Chapter I. Introduction 
 
1. Long noncoding RNAs 
1.1 A brief history of noncoding RNA research 
Over the past 60 years, RNA molecules have continually surprised the 
research community with their dynamic and versatile regulatory functions. 
Noncoding RNAs, especially long noncoding RNAs (lncRNAs), have attracted 
enormous amount of interest and effort in the past decade. Currently, new 
lncRNAs with previously undescribed function are being identified on almost a 
daily base. However, underneath the rising attention and appreciation of 
lncRNAs is a long history comprised of hard work, bold projections and ongoing 
debate tracing back more than half a century.  
In the celebrated central dogma published in 1958, RNA was consigned to 
be the template and infrastructural platform for protein synthesis [1]. This 
remarkably accurate and durable doctrine unintentionally founded a long lasting 
protein-centered bias that restrained early RNA research. In the early 1970s, 
based on DNA-RNA hybridization experiments and calculations of mutational 
load in the genome, scientists made a remarkably accurate estimation that the 
human genome contains no more than 20,000~30.000 genes and less than 6% 
of human DNA sequences is utilized as genes [2, 3]. Thus, the term “junk DNA” 
was first coined in 1972 to represent the vast noncoding space [2, 4]. Despite 
being labeled as ‘junk’, noncoding sequences sustained continuous interest from 
then to the present. The discovery of heterogeneous nuclear RNA (hnRNA) was 
the first evidence that attracted attention to the notion that in complex organisms, 
RNA may play additional roles beyond that put forth in the central dogma [5, 6]. 
Shortly thereafter, the interest in the RNA field was quickly diverted to the 
surprising discovery of introns in 1977. This further led to a series of studies 
which revealed that the central cofactors in RNA splicing are small nuclear RNA 
(snRNAs), which are a class of small RNAs accidently identified back in 1966 [7-
11]. Despite the emerging interest, RNA functions discussed in these studies 
were still largely limited to the protein synthesis. Arguably the first revolutionary 
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milestone in noncoding RNA research is the discovery of microRNAs (miRNAs) 
in 1993, a class of highly conserved small RNAs which is only part of the RNA 
interference pathway contributing to a complex posttranscriptional network [12]. 
In the two decades since these discoveries, a considerable amount of knowledge 
has been gained on the components and mechanism of small RNA-mediated 
gene regulation as well as its implication in many physiological, developmental 
and disease processes [13-18].  
LncRNA, although being hailed as one of the most popular subjects in 
recent RNA research, in fact, is an old topic resurrected by new technology. 
Individual lncRNAs with specific functions have been documented since the 
1990s. Starting with the discovery of H19 in 1990 [19], a small number of 
lncRNAs, including the well-known XIST [20, 21], TSIX [22] and AIR [23], were 
slowly discovered in the following decade. The publication of the first human 
genome sequence in 2003 opened up a new perspective for systematically 
surveying genomic regions involved in various biological activities [24]. Assisted 
by newly developed technologies, such as genome tiling array and deep 
sequencing, several groups began elucidating such events by mapping observed 
transcriptional events to the genome [25-28]. These early efforts, by 
experimentally identifying thousands of long noncoding RNA transcripts, sparked 
the beginnings of the unprecedented focus on lncRNA research. These reports 
were further confirmed and extended by the Encyclopedia of DNA Elements 
(ENCODE) project [29-32]. In the latest Human GECODE release (version 25, 
March 2016, GRCh38, Ensembl 85), 15767 genes originating 27692 RNA 
transcripts are identified as lncRNAs genes 
(http://www.gencodegenes.org/stats/current.html).  
 
1.2 Current definition and classification of lncRNA. 
Under the current definition, lncRNAs are a heterogeneous class of RNAs 
that exceed 200 nucleotides in length and do not appear to contain a protein-
coding capacity. The length limit of 200 nucleotides was arbitrarily chosen on the 
basis of convenient practical cutoff in RNA purification protocols that excludes all 
3 
known classes of small RNA, such as tRNAs, snRNAs, snoRNAs and miRNAs 
[33]. The non-protein coding property is often characterized using bioinformatics 
approaches based on the lack of long open reading frames (>100 codons) and/or 
codon conservation. Recent analyses provide strong evidence that the majority 
of currently annotated lncRNAs do not translate into protein; nonetheless, some 
lncRNAs do encode small proteins that have not been detected by present 
bioinformatics analysis [34, 35].  
Similarly to mRNA, lncRNAs are transcribed by RNA polymerase II, 
spliced at canonical splicing sties and some polyadenylated [36]. In addition, 
lncRNAs genomic regions share similar chromatin marks to those found in active 
promoters and transcribed regions of protein-coding genes [37]. Compared to 
protein-coding genes, lncRNA expression is often more tissue-specific and at a 
lower level. The median lncRNA expression level is only about a tenth that of the 
mRNA [38, 39]. LncRNAs are often considered as less conserved at the level of 
primary sequence. The observation that most lncRNAs in vertebrate genomes do 
not have homologues in species separated by more than 50 million years of 
evolution suggested a high frequency of new lncRNA origination [40]. This 
evolutionary trait of lncRNA also echoes a model proposed by John Mattick back 
in 1994, in which he postulated that RNA-based regulatory system was the 
essential prerequisite of the emergence of developmentally complex organisms 
[41].  
Classification of lncRNAs has proven to be a challenging task as, at 
present, we have scant information regarding their precise scope of function. 
Currently, the most common practice is to categorize them according to genomic 
contexts – from where one lncRNA is transcribed and its positional relation with 
previously established genes. According loci of origin and transcription 
orientation, lncRNAs can be classified as: 1) promoter-associated lncRNAs (e.g. 
PANDA); 2) enhancer-associated lncRNAs (e.g.Evf2); 3) NATs (natural 
antisense transcripts, e.g.HIF1A-AS2); 4) gene body-associated (sense) 
lncRNAs (e.g. ecCEBPA); 5) lincRNAs (intergenic lncRNA, e.g. HOTAIR, 
MALAT1) [42, 43]. This system of classification is not exhaustive and only 
4 
reflects the genomic features, thus it does not have any bearing on their 
biological activity or functional mechanisms.  
 
1.3 Functional Mechanisms of lncRNAs 
The hypothesis that cells contain extensive RNA-based regulatory 
networks was first proposed by Britten and Davidson in 1969, long before the 
discovery of miRNA and lncRNAs [44]. During the decades prior to the 
sequencing of the human genome, a multitude of hypothesis were proposed in 
attempt to unravel the noncoding puzzle. The proposed functions of noncoding 
RNA included chromosomal pairing, genome integrity, gene regulation, mRNA 
processing, and a reservoir for evolutionary innovation. Surprisingly, many of 
these hypothesized functions have been proven true in lncRNAs. LncRNAs have 
been shown to regulate gene expression at multiple levels (epigenetic, 
transcriptional and post-transcriptional) through interaction with other 
biomolecules, such as proteins, regulatory DNA regions and microRNAs (Figure 
1).  
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Figure 1. Diverse mechanisms proposed for lncRNAs function. 
Studies have described a diverse range of mechanisms by which lncRNAs 
regulate their targets. (1) Assembly and Recruitment of chromatin-modifying 
complexes to their DNA targets in cis has been well-characterized in several 
mammalian lncRNAs. (2) Some lncRNAs act as RNA decoys, tethering 
transcription factors away from their DNA targets by directly binding to them as 
target mimics. (3) Others work at the post-transcriptional level as microRNA 
target site decoys. (4) A group of the enhancer-derived lncRNAs guide the 
physical looping that occurs between enhancers and targeted promoters. (5) 
Many lncRNAs bind to various protein partners to regulate RNA splicing, 
degradation and translation.  
(Image adapted from EMBO reports (2012) 13, 971– 983 and Nature Reviews 
Genetics 15, 423–437 (2014).) 
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LncRNAs are able to provide a docking platform for recruiting and 
assembling epigenetic modifiers to distinct genomic loci in a cis- or trans- manner 
and thus bring the chromatin modification complex and targeted DNA region into 
close proximity. One of the most frequently cited example of this scenario is the 
recruitment of the polycomb repressive complex 2 (PRC2) and LSD1-CoREST 
complexes by HOTAIR to HOXD [45]. This epigenetic modulation model might be 
more prevalent than expected as it has been show that ~20% of a set of over 
3000 lncRNAs examined were bound by PRC2 [46]. Moreover, a set of studies 
have revealed that a group of the enhancer-derived lncRNAs participate in the 
transcriptional activation by guiding the physical looping that occurs between 
enhancers and targeted promoters [47, 48]. Many studies have presented 
evidence supporting an inspiring model that lncRNAs are linked to the three 
dimensional organization of nucleus. Some of most compelling evidence includes 
the essential role of NEAT1 in paraspeckle formation as well as the organization 
of multi-chromosomal structure by Firre [49, 50]. The fact that transcription and 
nuclear architecture are tightly correlated also opens the possibility that the act of 
lncRNA transcription contributes to nuclear organization. A fitting example is Air, 
of which the act of transcription, rather than the RNA itself, triggers epigenetic 
silencing of the paternal allele [51]. Based on these observations, a thought-
provoking model was recently proposed by Marta Mele and John L. Rinn in which 
the act of transcription of lncRNAs itself can serve as a framework for genome 
organization/nuclear architecture, irrespective of the final RNA products [52]. 
LncRNAs have been shown to be involved in multiple steps of RNA 
metabolism, including RNA stability, RNA processing and the regulation of RNA 
decay. The upregulation of NATs often causes decreased gene expression on 
the opposite strand by the formation of RNA duplexes and thus triggering RNA 
interference (RNAi). Another posttranscriptional regulation model of lncRNAs 
was put forward in a hypothesis called “competing endogenous RNA (ceRNA)”, 
in which lncRNAs compete for a given pool of miRNAs with miRNA-targeted 
mRNAs thus relieve the miRNA-mediated degradation from the targeted mRNAs 
[53]. This model was first demonstrated in PTENP1 (PTEN pseudogene 1) [54]. 
7 
LncRNA-mediated RNA processing was demonstrated for MALAT1, which 
modulates alternative splicing via assembly of serine/arginine splicing factors 
within nuclear speckles. Moreover, a mRNA degradation process called Staufen-
mediated decay (SMD) has been described which involves lncRNAs binding to 
the 3’UTR of Staufen-targeted genes. The in vivo significance of this process 
was demonstrated with lncRNA TINCR as an example [55, 56].  
LncRNAs also function by directly binding to a protein (transcription 
factors in most cases) to disrupt its interaction with targeted DNA or proteins. For 
example, PANDA, a p53 induced lncRNA, acts as a decoy by binding to the 
transcription factor NF-YA and thus preventing NF-YA from activating target 
genes [57]. 
LncRNAs are often tasked with fine-tuning the genomic responses. Hence, 
they usually elicit more subtle phenotypic alterations when interrupted. Deletion 
of several well-characterized lncRNAs such as Neat1, Malat1 and H19 in mice 
cause no observable abnormalities [58].  
 
2. Hypoxia 
2.1 Hypoxia signaling 
Cellular response to hypoxia is mainly mediated by the oxygen-sensing 
transcription factors of hypoxia-inducible factor (HIF) family. Each HIF is 
composed of two subunits: an oxygen-sensitive α-subunit and a constitutively 
expressed β-subunit (HIF-1β/ARNT). There are three α-subunit isoforms: HIF-1α, 
HIF-2α and HIF-3α. HIF-1α and HIF-2α have been comprehensively 
characterized since first described in late 1990s while much less is known about 
HIF-3α [59, 60].  
Hypoxia activates HIF signaling by stabilizing HIF-α subunit proteins. In 
the presence of oxygen, prolyl hydroxylases (EGLN 1-3/PHD 1-3) hydroxylate 
two conserved proline residues on HIF-α subunits [61-63]. This hydroxylation 
modification allows the binding of von Hippel-Lindau tumor suppressor protein 
(VHL) to HIF-α, which subsequently targets HIF-α for ubiquitination-mediated 
proteasomal degradation [64-66]. The half-life of HIF-α protein under normoxia is 
8 
less than 5min [67]. Under hypoxia, without oxygen as substrate, PHDs cannot 
hydroxylate HIF-α, resulting in HIF-α protein stabilization and the subsequent 
nuclear translocation and dimerization with HIF-1β to form HIF transcription 
factor (Figure 2). In nucleus, HIFs bind to the A/GCGTG consensus motif, also 
known as hypoxia-responsive elements (HREs), in the promoter of the target 
genes. Together with transcriptional co-activators such as p300/CBP, HIFs 
regulate the expression of over 1500 genes involved in a wide range of activities 
[68, 69]. As noted above, VHL is a key component controlling the ubiquitination 
and degradation of HIF-α subunit. In some cancers such as renal cell carcinoma, 
loss of function of VHL by genetic mutation causes a pseudo-hypoxic phenotype 
marked by constitutive activation of HIFs regardless of oxygen status which leads 
to the development of highly vascularized tumors [70, 71].  
Apart from oxygen, the enzymatic activity of PHDs also requires iron and 
2-oxoglutarate to tag HIF-1α for VHL recognition. As a result, PHDs activity can 
also be inhibited by metabolites such as succinate and fumarate, which compete 
with 2-oxoglutarate (Figure 2) [72-74]. Therefore, tumor cells with mutations in 
succinate dehydrogenase (SDH) or fumarate hydratase (FH) which result in the 
accumulation of cytosolic succinate and fumarate exhibit inhibited activity of 
PHDs and HIF stabilization even under normoxia conditions [73]. In addition, 
hypoxia regulates HIF transcriptional activity via a second oxygen-dependent 
hydroxylation event mediated by factor inhibiting HIF-1 (FIH-1) (Figure 2). FIH-1 
belongs to the same 2-oxoglutarate-dependent oxygenase superfamily as PHDs 
and it hydroxylates asparagine residue in the C-terminal transactivation domain 
of HIF-1α. Hydroxylated asparagine prevents the interaction between HIF and 
the transcriptional coactivators [75, 76]. 
In addition to the major mode of PHD-VHL, HIF-centered hypoxia 
signaling can also be regulated by other factors via their impact on HIF protein 
stability. The expression of oncogenes such as HRAS, SRC and ERBB2 have 
been shown to be able to increase the accumulation of HIF-1α protein and HIF-
targeted gene expression in both normoxia and hypoxia conditions [77-79]. In 
addition, activation of PI3K/AKT pathway can also result in HIF-1α accumulation 
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under normoxia. This effect is thought to be mediated through increased HIF-1α 
protein translation due to AKT-dependent activation of mTOR [80].  
 
 
Figure 2. Mechanism of hypoxia sensing via hypoxia-inducible factor. 
Hypoxia sensing is mediated through VHL-mediated HIF degradation. Under 
normoxia, hydroxylation of HIF-1 by PHDs allows the binding of VHL to HIF-α, 
which subsequently targets HIF-α for ubiquitination-mediated proteasomal 
degradation. (Image adapted from Nature Reviews Cancer 8, 705-713, 2008.) 
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2.2 Hypoxia and Cancer 
Hypoxia, as one the hallmarks of tumor microenvironment, is clinically 
associated with aggressive tumor phenotype, poor prognosis and resistance to 
therapies [81-84]. Intratumoral hypoxia arises as a result of imbalance between 
high oxygen consumption rates of fast proliferating tumor cells and impaired 
oxygen delivery due to the abnormalities in tumor vasculature [85]. It has been 
estimated that 50 to 60% of solid tumors contain regions of hypoxia [86, 87]. 
Reduced O2 availability, through hypoxia signaling pathway and HIFs, exerts 
profound effects on tumor cell survival, angiogenesis/vascularization, tumor 
metastasis, tumor immune response, and metabolic reprogramming.  
 
2.2.1 Hypoxia and cell survival 
Hypoxia can decrease cell proliferation and promote apoptosis, which in 
turn serves as a selective pressure that leads to expansion of tumor cells with 
adapted survival strategies [88]. Downregulation of DNA repair pathway by 
hypoxia further facilitates the selection for more aggressive cancer cells. HIF-1 
has been shown to be involved in autophagy regulation through induction of 
BNIP3 and BNIP3L, which promotes release of a major autophagy regulator 
Beclin-1 [89]. In addition to directly influencing cell survival via HIF target genes, 
HIFs also function by interfering with other major transcription factors such as 
p53 and MYC. HIF-1α has been shown to increase p53 level by inhibiting MDM2-
mediated p53 degradation, whereas HIF-2α seems to have an opposing effect on 
p53 in an MDM2-independent manner [90]. The interplay between HIF and MYC 
has also been documented in several studies. HIF-1α interferes with MYC activity 
by inhibiting MYC transcription and promoting MYC protein degradation. HIF-1α 
can also indirectly inhibit MYC by interfering with its partner protein MYC-
associated protein X (MAX) [91].  
 
2.2.2 Hypoxia and angiogenesis 
Angiogenesis is an important event associated with cancer progression in 
solid tumors. Hypoxia upregulates the expression of multiple pro-angiogenic 
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factors, such as vascular endothelial growth factor (VEGF), platelet-derived 
growth factor-β (PDGF-β), angiopoietins (ANGPT1,2), stromal derived factor 1 
(SDF-1A/CXCL12) and stem cell factor (KITLG) [92-95]. In breast cancers, HIF-
1α level is associated with VEGF expression and micro-vessel density [96].   
 
2.2.3 Hypoxia and tumor metastasis 
 Several experiments with cell and mouse models have demonstrated that 
HIF expression in tumor cells promotes the metastatic potential of tumor cells in 
multiple cancer types [97-100]. Clinically, high HIF-1 expression in primary 
tumors has been associated with increased metastasis in patients with 
pancreatic, esophageal, lung and prostate cancers, whereas HIF-2 level is 
associated with distant metastasis in patients with small cell lung and breast 
cancers [101-105]. Hypoxia and the subsequent activation of HIF influence 
multiple steps during the process of tumor metastasis. Hypoxia induces 
epithelial-mesenchymal transition (EMT) through both direct and indirect 
mechanisms, which leads to the loss of E-cadherin and increase in cell migration 
and invasion. Several EMT transcription factors such as Snail, ZEB1 and Twist 
have been identified as HIF target genes [100, 106, 107]. The hypoxia signaling 
also indirectly promotes EMT through other pathways, including Notch [108], 
TGF-β [109], integrin-linked kinase [110], Wnt [111] and Hedgehog [112].  
Apart from directly regulating tumor cells metastatic capacities, hypoxia 
also facilitates tumor metastasis by remodeling the extracellular matrix. 
Intracellular procollagen polypeptide chains require post-translational 
modification and assembly before extracellular deposition. The expression of 
several enzymes involved in this process, including P4HA1, P4HA2, PLOD1 and 
PLOD2, have been shown to be induced by hypoxia in several cell types [113]. 
After secretion, extracellular collagen is further modified by lysine oxidase (LOX) 
and LOX-like proteins. This modification initiates collagen crosslinking which is a 
major mechanism to increase ECM stiffness and promote cancer progression. 
Similar as aforementioned collagen hydroxylases, expression of LOX, LOX2 and 
LOX4 are also upregulated by hypoxia [99]. In breast cancer models, increased 
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expression of LOX and LOX-like protein have also been shown as key factors in 
the establishment of pre-metastatic niche in lung and bone [114, 115]. 
 
2.2.4 Hypoxia and tumor immune evasion 
Tumor hypoxia creates an overall immunosuppressive microenvironment 
by recruiting immunosuppressive regulatory cells, suppressing the function of 
infiltrated immune cells and promoting tumor cells resistance to T cell-mediated 
anti-tumor response. Hypoxic tumor cells, by secretion of chemokines and 
cytokines such as CCL28, TGF-β and CXCL12 etc., attract regulatory T-cells, 
myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages 
with immunosuppressive functions to the hypoxic tumor microenvironment [116]. 
Hypoxic tumor microenvironment causes the accumulation of extracellular 
adenosine, which signals through A2A receptors on tumor-infiltrating 
lymphocytes, inhibiting T cell proliferation, expansion and cytokine secretion 
[117]. Hypoxia signaling can promote tumor cells resistance to T-cell mediated 
killing through upregulation of programmed death-ligand 1 (PD-L1) and by 
increasing CTLA-4 expression on CD8+ T cells [116]. It also promote tumor cell 
resistance to cytotoxic T lymphocyte-mediated cell lysis [118, 119].  
 
2.2.5 Hypoxia and metabolic reprogramming 
Metabolic reprogramming is critical for cancer cells to confront the 
compound challenges of high growth rates and limited supply of nutrients and 
oxygen. Hypoxia is a key factor in reshaping the metabolic profile in tumor cells 
(Figure 3). Here, we focus our review on how hypoxia affects glucose 
metabolism, mitochondrial function and lipid metabolism.  
13 
 
 
  
14 
Figure 3. Metabolic reprogramming regulated by hypoxia. 
This figure shows the metabolic processes that are upregulated in response to 
hypoxia. Proteins highlighted by red have increased expression or activity in 
hypoxia. Arrows in red denote increased flux in hypoxia. ALDOA, aldolase A; CA, 
carbonic anhydrase; CD36, fatty acid translocase; DCA, dichloroacetate; ENO1, 
enolase 1; FABP, fatty acid binding protein; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; GLUT, glucose transporter; GYS1, glycogen 
synthase; HK, hexokinase; HIF, hypoxia-inducible factor; IDH2, isocitrate 
dehydrogenase 2; LDHA, lactate dehydrogenase A; MCT, monocarboxylate 
transporter; NHE1, sodium hydrogen antiporter 1; PDH, pyruvate dehydrogenase; 
PDK1, pyruvate dehydrogenase kinase 1; PFK, phosphofructokinase; PFKFBP, 
phosphofructokinase bisphosphatase; PGK1, phosphoglycerate kinase 1; PGM, 
phosphoglycerate mutase; PKM2, pyruvate kinase M2; PYGL, liver glycogen 
phosphorylase. (Image adapted from EMBO Mol Med (2015) 7: 368–379.) 
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Glucose metabolism 
Glucose metabolism is one of the metabolic pathways that are most 
dramatically reshaped by hypoxia. Hypoxia increases glucose influx by 
increasing the expression of glucose transporters (GLUT1/SLC2A1 and 
GLUT3/SLC2A3) required for glucose uptake. Glycolysis is significantly 
upregulated by hypoxia through increased expression of the glycolytic enzymes 
that break down glucose to pyruvate. In fact, genes encoding glycolytic enzymes 
were identified as the first non-erythropoietin targets of the HIF system [120]. 
Glycolytic breakdown of glucose produces various intermediate metabolites, 
which are diverted into anabolic pathways as precursors for the de novo 
synthesis of nucleotides, amino acids, and lipids. At the last step of glycolysis, 
phosphoenolpyruvate (PEP) is catalyzed into pyruvate by pyruvate kinase. 
Cancer cells, with further help of hypoxia, express increased level of PKM2, 
which encodes a less active form of pyruvate kinase. The isoform switch is 
thought to facilitate redirecting glycolytic flux away from ATP synthesis and into 
production of biosynthetic intermediates [121, 122]. As the glycolytic rate 
increases, more pyruvate is produced at the end of the glycolysis. Hypoxia also 
increases the expression of lactate dehydrogenase A (LDHA), which converts 
cytosolic pyruvate to lactate and recycles NAD+ for additional cycles of glycolysis 
[123]. The excess lactate is further removed from the cell through 
monocarboxylate transporter 4 (MCT4) which is also a hypoxia-upregulated gene 
[124]. Under normoxic conditions, pyruvate enters mitochondria as a substrate 
for oxidative phosphorylation. However, hypoxia steers glucose metabolism away 
from TCA cycle by specifically blocking access of glycolytic end products to 
mitochondria. This effect is mediated through HIF-targeted pyruvate 
dehydrogenase kinase 1 (PDK1), which inhibits the conversion of pyruvate to 
acetyl-CoA by inactivating pyruvate dehydrogenase (PDH) [125]. This process 
has been clinically exploited as a potential therapeutic target using glycolysis 
inhibitor dichloroacetic acid (DCA) which functions by inhibiting PDK activity [126]. 
In cancer cells, the upregulated glucose uptake and glycolysis is observed 
regardless of oxygen status, which is also known as the Warburg effect [127].  
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Mitochondrial function 
Mitochondrial oxidative phosphorylation is inhibited in hypoxia by a shifted 
glucose metabolism toward glycolysis as described above. It can also be 
attenuated by the HIF-dependent downregulation of the activity of several 
electron transport chain components [128, 129]. An intriguing example of this 
regulation is the subunit switch of the last enzyme in the electron transport chain, 
cytochrome c oxidase (COX). As the final step of electron transport chain, COX 
utilizes oxygen as the terminal electron acceptor. When oxygen supply becomes 
insufficient, hypoxic subunit COX4-2 is induced by HIF; whereas the normoxic 
subunit COX4-1 is degraded by the hypoxia-induced mitochondrial LON protease 
(LONP1) [130]. Hypoxia can also influence mitochondrial function through effects 
at the whole organelle level, specifically by suppressing mitochondrial biogenesis. 
Such regulation involves the crosstalk between HIF and MYC, in which a HIF-
activated MYC repressor, MAX interactor 1 (MXI1), displaces MYC associated 
factor X (MAX). The negative control of mitochondrial mass by MYC-MXI1 is 
partly through the repression of TFAM (Transcription Factor A, Mitochondrial), a 
transcription factor regulating the expression of mitochondrial genome and the 
genes required for mitochondrial DNA replication [131, 132]. In addition, HIF-
induced BNIP3 expression contributes to reduced mitochondrial number by 
promoting mitochondrial autophagy [133].  
 
Lipid metabolism 
Increased lipid content is another common feature of cancer cells, which 
can be acquired endogenously from citrate or taken up from exogenous sources. 
Several studies have demonstrated that hypoxia enhances lipid uptake in 
multiple cell types [134-136]. Fatty acid binding proteins FABP3/7, which are 
essential for lipid storage, have been shown to be induced by hypoxia in a HIF-
dependent manner [134]. As oxygen supply diminishes, hypoxic cells also exhibit 
increasing uptake of unsaturated lipid, thus bypass the oxygen-dependent 
desaturation process [137]. De novo lipid synthesis are high energy demanding 
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processes and utilizing such an uneconomic pathway under energy-restricted 
conditions such as hypoxia in cancer cells seems to be a metabolic dilemma. 
The hypoxic lipogenic phenotype in cancer cells has been demonstrated to be 
the result of increased lipid scavenging activity, rather than an augmented 
lipogenesis [134, 137, 138]. However, there is also contradictory evidence 
suggesting otherwise. Some studies proposed that hypoxia redirects 
mitochondrial utilization of glutamine in favor of reductive cycle to generate 
citrate, which is subsequently transported to the cytoplasm to generate acetyl-
CoA for lipid synthesis [139]. A key transcription factor controlling lipid synthesis, 
SREPB-1 has been shown to be upregulated in hypoxia [140]. Fatty acid 
synthase (FASN), which catalyzes the condensation of acetyl-CoA and malonyl-
CoA, has been reported as either increased [140], reduced [141], or no changes 
in hypoxia [142]. A possible explanation for this inconsistency is that cancer cells 
constantly scavenge lipid from surrounding environment while maintain the 
capability to synthesize lipid endogenously. However whether to activate these 
pathways is likely determined by the nutrient availability and cellular energy 
reserve at a specific moment.  
 
2.3 Hypoxia-regulated noncoding RNA 
Hypoxia impact on noncoding transcriptome has been studied extensively 
in small noncoding RNAs such as miRNAs; whereas only a limited number of 
hypoxia responsive lncRNAs have been reported to date. Consistent with their 
demonstrated involvement in most physiological processes, both miRNAs and 
lncRNAs have been shown to fine-tune the adaption to low oxygen tension. 
 
2.3.1 Hypoxia-regulated miRNAs 
Several groups have reported specific alteration of miRNA profiles in 
response to hypoxia [143-148]. Over 50 miRNAs have been identified as 
hypoxia-regulated miRNAs, however, most of them seem to be cell-specific. 
Kulshreshtha et al. identified the first group of hypoxia-inducible microRNAs, 
including miR-210, 93, 30b, 181b, 181c, 192, 195 and 21 [146]. All subsequent 
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studies confirmed miR-210 as a universal responder to hypoxia, while a few 
others were identified by at least two groups (miR-373, 498, 181b, 30b) [146, 148, 
149]. As the most consistently induced miRNA by hypoxia, miR210 has been 
extensively studied for its functions involved in cell adaption to hypoxia. MiR-210 
induction in hypoxia is now widely accepted as a HIF-mediated response and 
recruitment of HIF at the promoter of miR-210 has been validated by multiple 
approaches [146-148, 150]. Using immunoprecipitation of RNA-induced silencing 
complex (RISC) in combination with microarrays and proteomics, Fasanaro et al. 
identified a diverse spectrum of potential miR-210 targets, including genes 
involved in proliferation, apoptosis, DNA repair, chromatin remodeling, 
angiogenesis and metabolism [151]. In addition to modulating the level of 
individual miRNAs, hypoxia also has a broad impact on miRNA biogenesis 
machinery which results in a downregulation of miRNA biogenesis. This influence 
was first indicated by the lack of correlation between pri-miRNA and mature 
miRNAs levels in hypoxia and confirmed by the observation that expression of 
several genes encoding the components in miRNA processing including Exportin 
5, Drosha, Dicer and AGO2 were significantly downregulated in hypoxia [152, 
153].  
 
2.3.2 Hypoxia-regulated lncRNAs 
Compared to miRNAs, there is much less known about hypoxia-regulated 
lncRNAs. To date, there are less than 20 lncRNAs that have been identified as 
hypoxia-responsive lncRNAs, including some of the relatively well-characterized 
lncRNAs such as H19, NEAT1, MALAT1 and HOTAIR. However, the majority of 
these lncRNAs have only been reported by one group, which requires further 
validation and investigation. Hypoxia-inducible lncRNAs that have been reported 
by more than one group and confirmed by our transcriptome profiling data 
includes NEAT1, MALAT1 and HIF1A-AS2 [154-157].  
Current investigation on how these hypoxia-regulated lncRNAs respond to 
hypoxia is mostly limited to understanding how HIF is involved in the response. 
Most of the currently identified hypoxia-inducible lncRNAs have been shown as 
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direct target genes of HIF (NEAT1, MALAT1, HIF1A-AS2, H19, HOTAIR, 
lincRNA-p21, HINCUT-1, and UCA1/CURD) [154-162]. Among these lncRNAs, 
H19 has been shown to have an intriguing p53 mutational status-dependent 
hypoxia response. Under hypoxia condition, H19 expression is only induced in 
p53 null cells but not in p53 wild type cells [158]. There are also two HIF-
indirectly involved cases reported, in which hypoxia regulates the expression of 
lncRNAs by hypoxia-mediated epigenetic alteration. Induction of lncRNA WT1, 
which is an antisense-orientated lncRNA that overlaps with intron 1 CpG island of 
Wilms Tumor 1 (WT1) gene, has been reported by McCarty and Loeb as a result 
of demethylation of this locus through hypoxia-regulated expression of DNMT1 
and TET2 in acute myeloid leukemia (AML) cell lines and primary AML samples 
[163]. LncRNA-LET (Low Expression in Tumor) is the only hypoxia-
downregulated lncRNA reported to date. Under hypoxia, its expression is 
suppressed due to activation of histone deacetylase 3 (HDAC3), which 
consequently silences lncRNA-LET expression by decreasing histone H3 and H4 
acetylation on the promoter. The same study reporting this regulatory mechanism 
also presented that lncRNA-LET expression was inversely correlated with CA9 
expression in primary hepatocellular carcinoma [164]. In addition to 
aforementioned lncRNAs, a few lncRNAs (linc-ROR, AK058003, and lncRNA 
EFNA3) have been reported as upregulated in hypoxia without a known 
mechanism [165-167].  
Given the importance of hypoxia in cancer research, it is no surprise that 
all currently identified hypoxia-regulated lncRNAs are cancer-related lncRNAs as 
well. In fact, many of these lncRNAs were firstly identified based on their aberrant 
expression in cancer cells lines or tumors. In response to hypoxia, these 
lncRNAs regulate multiple key signaling pathways through diverse mechanisms, 
contributing to tumor survival and progression (Figure 4). Deregulated expression 
of hypoxia-regulated lncRNAs and their impact on tumor were summarized in 
Table 1. A more detailed review on H19, HINCUT-1 and lincRNA-p21 were 
provided here for respective reasons listed below. 
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H19: miRNA-containing noncoding transcript 
As one of the first reported hypoxia-inducible lncRNAs, H19 
overexpression results in increased expression of the genes involved in cell 
survival, angiogenesis, and metastasis. High expression of H19 has been shown 
as a promotive factor in gastric, bladder, esophageal, lung, liver, and breast 
cancer [168-173]. It has been shown that H19 lncRNA can modulate chromatin 
structure within the imprinted gene network through interaction with methyl-CpG-
binding domain protein 1 (MBD1) [174]. Other studies also demonstrated that 
H19 functions as an endogenous miRNA sponge for let-7 tumor suppressor 
miRNAs [175]. It is worth mentioning that miR-675, which is processed from H19 
first exon, is significantly connected with H19 expression and function. Under 
hypoxia, the expression of miR-675 is elevated along with H19 RNA and 
expression of miR-675 also promotes EMT under hypoxia [173, 176]. Moreover, 
the ability of H19 to promote EMT via upregulation of Slug expression is also 
dependent on miR-675 [173]. Give the common origin, similar expressional 
response to hypoxia and partly overlapped functions between H19 and miR-675, 
the exact relation between this host lncRNA and its embedded miRNA remains to 
be elucidated.  
 
HINCUT-1: ultra-conserved lncRNA 
HINCUT-1 (hypoxia-induced noncoding ultraconserved transcript 1, also 
named as uc.475) belongs to a family of lncRNAs that are transcribed from 
regions exhibiting extremely high conservation between human, rat and mouse 
genomes [177]. In collaboration with GA Calin’s group, we have shown that 
HINCUT-1 is induced by HIF under hypoxia in HCT-116 and MCF-7 cells. 
HINCUT-1 is transcribed as a retained intron of O-linked N-acetylglucosamine 
transferase (OGT) mRNA. Repression of HINCUT-1 expression leads to reduced 
cell proliferation, G2/M blockade and reduced OGT gene and protein expression 
[162].  
 
lincRNA-p21: lncRNA involved in metabolic reprogramming 
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LincRNA-p21 was first reported by John L. Rinn’s group in 2010 as p53 
target lncRNA that in turn serves as part of a negative feedback control on p53-
dependent transcriptional response [178]. LincRNA-p21 was also identified as a 
posttranscriptional inhibitor of translation through its interaction with HuR in an 
independent study [179]. Yang’s group reported that lincRNA-p21 was induced 
under hypoxia condition in HeLa cells in a HIF-1α dependent manner. LincRNA-
p21 promotes glycolysis and functions a positive feedback signal to enhance 
HIF-1α accumulation in hypoxia by disrupting the VHL- HIF-1α interaction. 
Overexpression of lincRNA-p21 promotes tumor growth in mouse xenograft 
models [160]. However, we did not detect hypoxic induction of lincRNA-p21 in 
our transcriptome profiling data generated from MCF-7 cells.  
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Figure 4. The impact of hypoxia-regulated lncRNAs on cancer 
 (Image adapted from Molecular Aspects of Medicine 47-48 (2016) 35-53)  
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Table 1. Hypoxia-regulated lncRNAs and their role in cancer 
lncRNA Hypoxia 
respons
e 
Transcrip
tion 
control 
Cancer type Cancer impact Ref 
NEAT1 up HIF breast cancer cell survival  
apoptosis 
 [154] 
MALAT
1 
UP HIF breast cancer 
lung cancer 
cell cycle  
angiogenesis  
tumor metastasis 
 [155, 
156] 
H19 up|p53 
status 
HIF/MYC hepatocellular 
carcinoma 
bladder cancer 
colorectal 
cancer 
esophageal 
breast cancer 
cell survival and 
proliferation 
migration 
angiogenesis 
EMT 
 [158, 
168-
174, 
176] 
HOTAIR up HIF breast cancer 
lung cancer 
cell viability  
invasion  
apoptosis 
metastasis 
 [161, 
180] 
lnc-
ROR 
up - hepatocellular 
carcinoma 
RNA sponge 
(miR145) 
upregulate 
HIF1A mRNA 
cell survival 
 [165] 
HINCUT
1/uc.47
5 
up HIF colon cancer cell proliferation  [162] 
UCA1/C
URD 
up HIF bladder cancer cell proliferation 
migration and 
invasion 
 [159] 
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apoptosis 
AK0580
03 
up - gastric cancer modulate DNA 
methylation at 
SNCG CpG 
island 
migration and 
invasion 
tumor metastasis 
 [167] 
lincRNA
-p21 
up HIF breast cancer 
cervical cancer 
upregulate HIF-
1α 
enhance 
glycolysis 
tumor growth 
 [160] 
EFNA3 
lncRNA 
up - breast cancer  tumor metastasis  [166] 
HIF1A-
AS2 
up HIF glioblastoma maintain 
mesenchymal 
glioblastoma 
stem-like cells in 
hypoxia niches 
 [157] 
WT1 
lncRNA 
up hypoxia-
mediated 
epigenetic 
alteration: 
DNMT1, 
TET2 
Acute myeloid 
leukemia 
modulate histone 
methylation at 
WT1 TSS 
 [163] 
lncRNA-
LET 
down hypoxia-
mediated 
epigenetic 
Gallbladder 
cancer 
squamous-cell 
inhibit invasion 
and metastasis 
 [164] 
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alteration: 
HDAC3 
lung cancer 
hepatocellular 
carcinoma 
colorectal 
cancer 
(Adapted from Molecular Aspects of Medicine 47-48 (2016) 35-53) 
 
3. Cholesterol metabolism and Cancer 
3.1 Cholesterol synthesis and its regulation 
Cholesterol is the essential precursor for steroid hormone and bile acid 
biosynthesis. Every nucleated cell in human body is capable of cholesterol 
biosynthesis but not necessarily relies on this high energy demanding process to 
acquire it. Certain organs, such as adrenal and gonads, derive a significant 
proportion of cholesterol by uptake from plasma lipoproteins. Hepatic cholesterol 
synthesis in humans is thought to contribute 10-20% of the total daily synthesis 
[181]. At the cellular level, cholesterol is an essential component of mammalian 
cells. As the major lipid constituent of the plasma membrane and organelle 
membrane, it plays critical roles in the maintenance of membrane fluidity and 
membrane permeability, membrane trafficking, cell signaling, and lipid/protein 
sorting, and formation of lipid rafts.  
Mammalian cells synthesize cholesterol through a series of 21 enzymatic 
steps. Acetyl-CoA, the common precursor of lipid synthesis, is first catalyzed into 
lanosterol through mevalonate pathway, which can then be diverted into either 
the Bloch pathway, producing cholesterol via desmosterol, or the Kandutsch-
Russell pathway, via 7-dehydrocholesterol. Two other branches also diverge 
from the mevalonate pathway. Isoprenoids are produced by geranylgeranyl-
diphosphate synthase (GGPPS) acting twice to convert farnesyl diphosphate 
(FPP) to geranylgeranyl diphosphate (GGPP). Flux through the shunt pathway 
occurs when squalene monooxygenase (SM) acts twice to convert squalene 2,3-
epoxide into diepoxysqualene, eventually leading to the production of 24(S),25-
epoxycholesterol (Figure 5) [182].  
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Figure 5. Cholesterol synthesis pathway. 
Cholesterol is synthesized from acetyl-CoA. The mevalonate pathway leads to 
lanosterol, which can then be diverted into either the Bloch pathway or 
Kandutsch-Russell pathway. Stain inhibits cholesterol synthesis by targeting the 
rate-limiting enzyme HMGCR. The isoprenoid pyrophosphates generated from 
mevalonate pathway are substrates for protein prenylation. Cholesterol can be 
further metabolized into 25-hydroxycholesterol or 27- hydroxycholesterol by 
cholesterol 25-hydroxylase (CH25H) or Cytochrome P450 Family 27 Subfamily A 
Member 1 (CYP27A1). 
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Cholesterol biosynthesis from acetyl-CoA is strictly controlled because 
cholesterol is energetically expensive to make and is toxic in excess but also 
essential as a cellular structural component. Regulation of cholesterol synthesis 
can occur at multiple levels throughout the pathways. Sterol Regulatory Element-
binding Protein (SREBP) family of transcription factors are the master regulators 
coordinating lipid synthesis. Nearly all of the genes in cholesterol synthesis 
pathways are SREBP targets. There are three isoforms of SREBPs, among 
which SREBP-2 preferentially regulates genes in cholesterol synthesis. SREBP 
activation is regulated by the sterol content in the cell. When sterol is low, 
SREBP is transported to Golgi and the N-terminus is proteolytically cleaved from 
the membrane then enters the nucleus to perform its transcription factor function. 
In endoplasmic reticulum, the C-terminus of SREBP binds tightly to SREBP 
cleavage activating protein (SCAP), which functions as a sterol sensor. When 
cells have sufficient sterol, SCAP binds cholesterol/oxysterols, which promotes 
the binding of insulin induced gene (Insig) and the retention of SREBP in 
endoplasmic reticulum [183]. SREBPs are considered relatively weak activators 
of gene expression alone and thus often require the assistance of other cofactors, 
including NF-Y and SP1 [184, 185]. 3-Hydroxy-3-methylglutaryl-CoA reductase 
(HMGCR) catalyzes the rate-limiting step in cholesterol synthesis, which is also 
the target of the widely used cholesterol lower drug statins. As the key enzyme in 
this pathway, HMGCR is subjected to the feedback mechanism. HMGCR 
contains a sterol-sensing domain structure like SCAP and products of both sterol 
and isoprenoid branch pathway promote the degradation of HMGCR by an 
ubiquitin-proteasome dependent mechanism that requires Insig [186-188]. In 
addition to direct feedback regulation of SREBP and HMGCR by sterols, a 
number of intermediates, including the end product from shunt branch, can serve 
as activating ligands of the nuclear liver X receptor (LXR), which promotes the 
expression of cholesterol export genes [189, 190]. Alternative splicing has been 
proposed as a generalized mechanism for cholesterol synthesis regulation [191]. 
The alternative transcript of HMGCR with skipped exon 13 is produced by 
alternative splicing and is considered not functional. Evidence has suggested that 
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this alternative splicing event is regulated by sterols, with proportionally less of 
the defective transcript present when sterol level is low [191]. Similar sterol-
regulated alternative splicing events were also recorded in HMGCS1 and MVK 
[191]. MiRNA-mediated posttranscriptional control also contributes to the 
regulation of cholesterol synthesis. MiR122, the most abundant miRNA in liver, 
targets the mRNA of many cholesterol synthetic genes [192].  
Cholesterol synthesis is a highly oxygen-consumptive process. Synthesis 
of one molecule of cholesterol requires 11 molecules of oxygen, 9 of which are 
consumed during demethylation of lanosterol and its metabolites by lanosterol 
14α-demethylase and C4-methyl sterol oxidase. The demethylation of lanosterol 
has been implicated as a rate-limiting step in the post-squalene portion of 
cholesterol synthesis [193]. Hypoxia inhibits the cholesterol synthesis by slowing 
down this process, causing lanosterol and 24,25-dihydrolanosterol accumulation 
in cells [194]. The repression of cholesterol synthesis in hypoxia is also facilitated 
by HIF-mediated induction of Insig-1 and Insig-2, which in turn can promote 
degradation of HMGCR [195].  
 
3.2 Implication of cholesterol metabolism in cancer 
Cholesterol has important implication in cancer, as it is the structural 
component of cell membrane and the obligatory precursor of steroid hormones 
which are well characterized as key drivers of breast and prostate cancer. The 
mechanisms of cholesterol homeostasis are often dysregulated in tumors so that 
cholesterol deposition is favored [196, 197]. Several studies have shown that 
cholesterol tends to accumulate in solid tumor cells and is associated with cancer 
progression [198-202]. Hypercholesterolemia has been considered as an 
independent risk factor for breast cancer in postmenopausal women [203-205]. 
Several oncogenic signaling pathways, including PI3K/AKT/mTOR, 
RTK/RAS and TP53, have been shown to modulate cholesterol metabolism in 
cancer cells. Constitutive activation of PI3K/AKT signaling promotes intracellular 
cholesterol synthesis by activating of SREBP [202, 206]. Meanwhile, it also 
induces LDL receptor-mediated cholesterol import and inhibits cholesterol efflux 
30 
by repressing ABCA1 [207]. Mutant p53 increases expression of genes in the 
mevalonate pathway, which leads to the disruption of morphogenesis [208]. A 
more recent report identified SQLE as a bona fide oncogene in breast cancer 
and overexpression of SQLE was shown to be more prevalent in aggressive 
breast cancer [209].  
In addition to providing cholesterol for constructing new plasma 
membranes, activation of cholesterol synthesis pathway also generates 
intermediate metabolites and cholesterol derivatives that have oncogenic 
properties. The isoprenoid intermediates FPP and GGPP from the mevalonate 
pathway are used as activated isoprenoid substrates in protein prenylation. The 
enzymatic transfer of farnesyl- or geranylgeranyl- moieties to proteins enables 
proteins to anchor to membranes and to carry out their related functions. Many 
members of the Ras superfamily GTPase depend on prenylation for appropriate 
membrane targeting [210]. It has been reported that the oncogenic effect of 
dysregulated mevalonate pathway is via its contribution of protein prenylation 
substrates for Ras superfamily members [211]. Cholesterol derivatives 25-
Hydroxycholestersol (25-HC) increases estrogen receptor (ER) transcriptional 
activity via promoting ER recruitment to the target genes and this mechanism has 
been shown to increase ER positive cells resistance to estrogen deprivation 
therapies [212]. 27-Hydroxycholestersol (27HC), another primary metabolite of 
cholesterol, is a potent ligand for ER and LXR. It increases ER-dependent growth 
and LXR-dependent metastasis in mouse models of breast cancer. Increased 
expression of the enzyme that converts cholesterol to 27-HC, CYP27A1, has 
been observed in more aggressive mammary tumors [213].  
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Chapter II. Material and Methods 
 
Cell lines and cell culture 
Human breast cancer cell lines MCF-7, MDA-MB-231, and MDA-MB-468 
cell lines were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). All cells were maintained at 37°C in 5% CO2 and grown in 
DMEM/High glucose medium (Hyclone) with 10% (v/v) FBS (Biowest) and 100 
units/ml each penicillin and streptomycin. All three cell lines were routinely tested 
for mycoplasma contamination (MycoAlert™ Mycoplasma Detection Kit, Lonza). 
Ovarian cancer cell line SKOV3 was obtained from Dr. Daniela Matei’s lab. Renal 
clear cell carcinoma cells 786-O with control vector (RC3) and 786-O with 
reconstituted VHL (WT2) were obtained from Dr. Maria Czyzyk-Krzeska 
(University of Cincinnati). Human lung fibroblast cell line WI-38 was obtained 
from Dr. Shadia Jalal’s lab. Patient-derived pancreatic cancer cell lines Pa03C, 
Panc10.05, Panc 198 and cancer associated fibroblast cell line CAF19 were 
provided by Dr. Melissa L. Fishel. Hypoxia cell culture was performed at 0.2% or 
1% O2 for indicated time in an InVivo200 hypoxia workstation (Ruskin, Inc., 
Cincinnati, OH).   
 
Reagents 
The source and concentration of chemical compounds used in this study 
were listed as follows: Dimethyloxalylglycine (DMOG, Frontier Scientific D1070-
100mg) was used at 1mM; 2-Deoxy-D-glucose (2-DG, Sigma D3179) was used 
at 10mM; Dichloroacetate (DCA, Sigma #347795) was used at 10mM; 
Actinomycin D (Sigma A1410) was used at 2.5 µg/ml; Mithramycin A (Sigma 
M6891) was used at 200 nM; Simvastatin (Sigma S6196) was used at 1uM; 
TGF-β1 (PeproTech cat# 100-21, lot#0614209-1) was used at 10ng/ml; 
Metformin (Sigma D150959) was used at indicated concentration. SP1 
overexpression construct and its control vector were kindly provided by Dr. 
J.T.Zhang’s lab [214]. 
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5’ and 3’ Rapid Amplification of cDNA Ends (RACE) 
The RNA-ligase-mediated RACE (RLM-RACE) was carried out with total 
RNA extracted from MCF-7 cells to determine the transcription start and end 
position of MIR193BHG transcripts. Rapid amplification of 5’ or 3’ cDNA ends 
was carried out using a FirstChoice RLM-RACE kit (Ambion) according to the 
manufacturer’s instructions. Nested PCR was performed for each reaction and 
the resulting PCR products were visualized on 1% agarose gel. The visible 
bands were recovered and sequenced. Primers used include: 
5’ outer primer: 5’- ATC TTT GCA TCT CCC AAC CAG -3’ 
5’ inner primer: 5’- GGA GAG AGG ATT CCA AGC CAA -3’ 
3’ outer primer: 5’- AAC CTG CCA GTA ATT TCA GCA A -3’ 
3’ inner primer: 5’- ACA CGT CAA GGC CAG AGG ATG GA -3’ 
 
siRNA transfection 
Silencer®Select siRNAs were purchased from Thermo Fisher Scientific 
and transfected at 10nM final concentration using RNAiMAX reagent (Invitrogen, 
CA) with reverse transfection protocol. siRNAs used in the study includes: 
Silencer®Select negative control siRNA (4390843), SP1 siRNA (s13319), SP3 
siRNA (s13326), MYC(s9129), EGR1 siRNA(115234), MIR193BHG_siRNA1 
(GAGCGUGUAUAAAACCAAAtt) and MIR193BHG_siRNA2 
(GCAAAGAUGUUUCCAGAGAtt) 
 
Lentivirus production 
293T cells were seeded at 2.5 x 105/ well on 6-well tissue culture plate in 
no-antibiotic growth medium on Day 0. The next day, a mixture of 3 transfection 
plasmids were introduced into cells using Lipofectamine®2000 (Thermo Fisher 
Scientific, cat.11668027). Such plasmid mix includes 460ng packaging plasmid 
(pCMV-r8.74psPAX2), 40ng envelope plasmid (pMD2.G) and 500ng of either 
pLKO.1 shRNA scramble control vector or pLKO_shRNA_MIR193BHG. About 18 
hours after transfection, the medium was replaced with 3mL 30% FBS growth 
medium for viral harvests. Medium containing lentivirus was harvested at ~40 
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hours post-transfection. Another 3mL 30% FBS growth medium was added and 
the viral harvesting was repeated again after 24 hours. After the final harvest, 
virus-containing medium from two harvests were pooled, centrifuged at 2,000 
rpm for 5min to pellet any packaging and then passed through 0.45 µm filter.  
 
Stable cell lines establishment  
To generate MIR193BHG stable knockdown cell lines, cells were plated 
on 6-well tissue culture plate at 2 x 105/well with medium containing 8 µg/ml 
Polybrene. Then 100µl lentivirus was added to cells. Medium was changed 24 
hours post-infection with fresh medium containing 1ug/ml puromycin (Gibco, 
A1113803). Growth medium with puromycin was replaced every 2 days to 
maintain the selection. Selection process was considered completed when the 
non-transduced control cells were all killed by puromycin. The shRNA stable cell 
lines were maintained with medium containing 1ug/ml puromycin in subsequent 
cultures. For overexpression, cDNA sequence of MIR193BHG was amplified 
using primers: forward: 5’-CGG GAT CCG TCG GCT GCG CGC TCT CTG-3’; 
reverse: 5’-GCT CTA GAC TCA ATA AAA TGC TGC TTA TTT ATT-3’ and 
subsequently cloned into pcDNA3.1 vector. Cells were plated on 6-well tissue 
culture plate and transfected with 4ug of either pcDNA3 or pcDNA3_MIR193BHG 
plasmid using Lipofectamine®2000. Medium was changed 24 hours post-
transfection with fresh medium containing G418 (CORNING 61234RG). The 
concentration of G418 used in selection was as follows: MCF-7: 0.7mg/mL; 
MDA-MB-231/MDA-MB-468: 1.0mg/mL; SKOV3: 0.6mg/ml. Selection process 
was considered completed when the non-transduced control cells all died. The 
overexpression stable cell lines were maintained with medium containing 
0.5mg/mL G418 in subsequent cultures. 
 
shRNA construction 
The scramble shRNA control vector was purchased from Sigma-Aldrich 
(SHC002). shRNA against MIR193BHG was designed using the designing tool 
available from the RNAi consortium (TRC, Broad Institute). Each final shRNA 
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construct requires two complementary oligonucleotides containing a sense (in 
red) and an antisense (in green) sequence. The sense and antisense sequences 
are connected by a spacer capable of forming a loop.  
 
The sequence of MIR193BHG shRNA are: forward: 5’-CCG GGA TTA 
AAG CAA CAT GTT ATT CCT CGA GGA ATA ACA TGT TGC TTT AAT CTT 
TTT G-3’; reverse: 5’-AAT TCA AAA AGA TTA AAG CAA CAT GTT ATT CCT 
CGA GGA ATA ACA TGT TGC TTT AAT C-3’. The hairpin template 
oligonucleotides were synthesized by Integrated DNA Technologies and inserted 
into pLKO.1 puro vector according to the protocol suggested by the RNAi 
consortium (TRC, Broad Institute). Briefly, the oligos was resuspended at 1µg/µL 
and then 3µL of each oligos was mixed 
together with 5 µL NEBuffer 2 (New 
England Biolabs Restriction 
Endonuclease Reaction Buffer 2) and 39 
µL water. The mixture was incubated at 
95 ºC for 4 min then at 70 ºC for 10 min. 
After this incubation, the mixture of oligos 
was allowed to cool down gradually to 
room temperature. To generate pLKO.1 
puro vector (addgene plasmid #8453) 
with shRNA inserted, pLKO.1 was digested with AgeI and EcoRI, then mix the 
recovered 7kb vector with annealed shRNA oligos, together with T4 ligase and 
corresponding ligation buffer, incubated at 16 ºC overnight. 5 µL of the ligation 
mix was transformed into competent bacteria and the successful ligation was 
confirmed by sequencing using LKO.5 primer: 5’-TGG ACT ATC ATA TGC TTA 
CCG TAA C-3’.  
 
 5’-CCGGxxxxxxxxxxxxxxxxxxxxxCTCGAGxxxxxxxxxxxxxxxxxxxxxTTTTTG-3’ 
             3’-xxxxxxxxxxxxxxxxxxxxxGAGCTCxxxxxxxxxxxxxxxxxxxxxAAAAACTTAA-
 
Forward oligo 
Reverse oligo 
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Bioinformatic Analysis of public data 
Level 1 RNAseq data of several cancer datasets including BRCA were 
downloaded from TCGA under NIH dbGAP approval, project #5187: "Landscape 
of tumor hypoxia in the TCGA dataset (P.I. M. Radovich)”. Sequenced reads 
were aligned against human genome (hg19) and the RNA level of each transcript 
was calculated using NGSUtils. Expressional correlation (Spearman) between 
MIR193BHG and each protein coding gene was calculated using R. Spearman 
correlation between MIR193BHG and well-established hypoxia-inducible genes 
was presented as correlation plot generated using corrplot package in R. 
MIR193BHG correlated protein coding genes (|r|>0.2, p<0.01) were ranked by 
correlation coefficient and subjected to GSEApreranked analysis. BRCA patient 
clinical data used in our analysis was downloaded from TANRIC (The Atlas of 
ncRNA in Cancer), which is the same clinical data of BRCA in TCGA with a 
better-organized format. Clinical data and the gene expression data were merged 
by matching patient barcode ID.  
Expression of MIR193BHG and its neighboring genes in 16 human tissues 
were obtained from Illumina Human Body Map Project (HBM) (www.illumina.com; 
ArrayExpress ID: E-MTAB-513).  
HIF ChIP-Seq data (GSE28352, NCBI GEO database), which provides a 
genome-wide mapping of HIF binding sites in MCF-7 cells, was used to assess 
whether HIF is directly involved in MIR193BHG induction by hypoxia. Raw data 
of HIF-1α ChIP-Seq (GSM700944), HIF-2α ChIP-Seq (GSM700945) and pre-
immune ChIP-seq control for HIF-1α/HIF-2α (GSM700946) were downloaded 
and analyzed using MACS on Galaxy (https://usegalaxy.org/) [215]. The result 
was visualized in UCSC genome browser. Long-range chromatin interaction in 
MCF-7 was determined by ChIA-PET data published by Ruan Y et al. and 
visualized in WashU EpiGenome Browser.  
 
Hypoxia score calculation 
Hypoxia metagene proposed by FM Buffa et al. was used in hypoxia sore 
calculation [216]. The hypoxia score for each sample was calculated as follows: 
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𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = �𝑔𝑔𝑆𝑆𝑔𝑔𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒,𝑛𝑛𝑁𝑁
𝑛𝑛=1
  
Where, N is the number of genes in the hypoxia metagene list, 𝑔𝑔𝑆𝑆𝑔𝑔𝑆𝑆𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒,𝑛𝑛 is 1 if 
the sample has a level of gene n above the median for all samples in the dataset 
and -1 otherwise [217].  
 
RNA extraction and qPCR analysis 
RNA extraction was performed by addition of 700uL of QIAzol to each well 
of a 6-well plate. The lysate was collected and 140ul (1/5 of QIAzol volume) of 
chloroform was added. The mix was then centrifuged at 4 °C at 13,000 rpm for 
15 min. The aqueous layer was transferred onto the RNAeasy Mini columns 
(QIAGEN, cat.no. 74104) and processed according to the manufacturer’s 
instructions. In some experiments, RNA was also manually extracted by adding 
500ul isopropanol (1/2 of QIAzol volume) to precipitate RNA, followed by two 
times washes with 75% RNase-free ethanol. Pelleted RNA was air-dried and 
resuspended in RNase-free water. The extracted RNA was quantified using 
Qubit fluorometer (Invitrogen). For long RNA, first-strand cDNA was prepared 
from 1ug of RNA using random hexamers and TaqMan® Reverse Transcription 
Reagent (Applied Biosystems, CA). cDNA was used as template for conventional 
PCR or qPCR. qPCR was performed using gene-specific primers (Table 2) and 
SYBR green master mix (Applied Biosystems). Conventional PCR was 
performed using AmpliTaq Gold 360 Master Mix (Thermo Fisher Scientific) 18S 
rRNA or B2M expression was used as an endogenous control. For microRNA 
analysis, cDNA of each small RNA was prepared TaqMan® MicroRNA Reverse 
Transcription Kit with TaqMan target-specific stem-loop reverse transcription 
primer and 10ng RNA; qPCR was performed using TaqMan® Gene Expression 
Master Mix. U6 or RNU48 expression was used as endogenous control.  
 
Cellular fractionation 
Cells were collected using trypsin and washed once with ice-cold PBS. 
Cell pellets were resuspended in five pellet-volume of ice-cold cytoplasmic 
37 
extraction buffer (20 mM Tris pH7.6, 0.1 mM EDTA, 2 mM MgCl2; 0.6% NP-40, 
protease inhibitor cocktail (Thermo #78442) and 0.5U/µL RNase inhibitor 
(Thermo #EO0381) and incubated at room temperature for 2 min, then on ice for 
10 min. The sample was then homogenized by passing through 1mL syringe and 
centrifuged at 500g for 5min at 4 ºC. The supernatant were collected as the 
cytoplasmic lysis. Pellets were further washed twice with cytoplasmic extraction 
buffer. After washing, the pellet was then resuspended in two pellet-volume of 
nuclear suspension buffer (10 mM Tris pH7.5, 150 mM NaCl, 0.15% NP-40, 
protease inhibitor cocktail and 0.5U/µL RNase inhibitor). The nuclear suspension 
was then layered on five pellet-volume of sucrose cushion buffer (10 mM Tris 
pH7.5, 150 mM NaCl, 24% (w/v) sucrose, protease inhibitor cocktail and 0.5U/µL 
RNase inhibitor) and pelleted at 14,000 rpm for 10min at 4 ºC. The supernatant 
was discarded and the pellet was washed with ten pellet-volume of ice-cold PBS 
containing 1 mM EDTA. The sample was centrifuged at 500g for 5min at 4 ºC 
and the final pellet was collected as nuclear fraction.  
 
RNA stability Assessment 
Total RNA was harvested at various times after RNA transcription was 
inhibited by addition of 2.5 µg/mL actinomycin D. The remaining amount of a 
particular transcript at each time point was measured by qPCR and used to 
calculate the RNA half-life. RNA half-life was calculated from the equation: t1/2 = 
ln2/ kdecay 
The decay rate constant is obtained from the slope of a semi-logarithmic plot of 
RNA amount as a function of time. 
 
MTT Assay 
Cells were plated in 96-well plates (10,000~20,000 cells per well) and 
relevant treatment (siRNA transfection or drug treatment) was performed as 
described in each experiment.  4 hours prior to the end points, 10uL of MTT 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (5mg/mL in 
PBS, Sigma-Aldrich M5655) was added to each well containing 100uL medium 
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and incubated for 4 hours. The medium was aspirated and 100uL acidic 
isopropanol (0.04N HCl in isopropanol) was added to dissolve the insoluble 
purple formazan product into a colored solution. Absorbance was recorded at 
570 nm, with a reference at 630 nm. The effect of manipulated MIR193BHG level 
on cell viability was assessed as the percentage of cell viability compared to the 
corresponding control cells, which was arbitrarily assigned 100%. The mean 
value of 6-9 wells was calculated, and each experiment was repeated 3-4 times. 
 
Cell detachment Assay 
Stable cell lines with various MIR193BHG status were plated on 96-well 
plates (5,000 ~ 20,000 cells per well) and allowed to attach to the plate for 
overnight then followed by 24 hours culture in either normoxia or hypoxia 
condition. At the end of the incubation, plates were washed with PBS once and 
50uL 0.1% Trypsin (in HBSS) was added to each well and incubated at 37°C for 
5 ~ 10 min. Then 100uL medium containing 10% FBS was added to terminate 
the trypsinization and the plates were washed twice with PBS to remove the 
detached cells then air-dried. The residual cells still attached to the plate was 
fixed and stained with 0.1% crystal violet (dissolved in 
formaldehyde:methanol=1:9 solution) for 30min. Plates were washed twice with 
water after staining and 100uL methanol was added to the plate to solubilize the 
crystal violet from stained cells. The relative amount of residual cells was 
determined using absorbance readings at 540nm.  
 
Cell attachment assay using xCELLigenece System 
MCF-7 cells stably expressing either pcDNA3 or MIR193BHG were plated 
at 10,000 and 20,000 per well onto xCELLigene E-Plate_16. The extent of cell 
adhesion and spreading, measured as changes in impedance was monitored 
every 15 minutes for the first 5 hours after plating. The assay system expresses 
impedance in arbitrary Cell Index (CI) units. The CI at each time point is defined 
as (Rn-Rb)/15; where Rn is the cell-electrode impedance of the well when it 
contains cells and Rb is the background impedance of the well with the media 
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alone. The cell index at 4 hours after plating was arbitrarily selected to represent 
the cell attachment difference among groups.  
 
Cell cycle analysis 
For cell cycle analysis, samples (1×106 cells) were fixed and 
permeabilized by the addition of 1 ml of ice-cold 70% ethanol and incubated for 
15 min on ice. Following washing, the cells were resuspended in 125 μl of 1.12% 
(w/v) sodium citrate containing 0.2 mg/ml RNase (Roche) and incubated for 15 
min at 37°C. Propidium iodide (PI; 50 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) 
was added to the cells and incubated for 30 min at room temperature in the dark. 
The cells were then stored at 4°C until they were assayed by flow cytometry 
(FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA). Cell cycle analysis 
was performed using ModFit LT software (Verity Software House, Inc., Topsham, 
ME, USA). 
 
Apoptosis assay 
The effect of MIR193BHG knockdown on MCF-7 and MDA-MB231 cells 
cultured in hypoxia was determined by flow cytometry using Alexa Fluor® 488 
Annexin V/Dead Cell Apoptosis Kit (Invitrogen, cat. V13241) according to the 
manufacturer’s instruction. Briefly, following siRNA transfection, cells were 
cultured in hypoxia (0.2% O2) for 48hr. The cells were then collected, washed in 
cold PBS, diluted in 1X annexin-binding buffer to 1x106 cells/mL and stained with 
Alexa Fluor® 488 annexin V and Propidium iodine (PI) at room temperature in 
dark for 15min. The stained cells were analyzed by FACS using a BD 
FACSCalibur APC (BD Biosciences) equipped with CellQuest software. The 
result was analyzed using Flowjo software.  
 
Invasion assay 
Invasion assays were performed in a 24-well plate with BD Falcon cell 
culture inserts (Corning 353097 pore size 8um) coated with Matrigel (BD 
Bioscience 356237). Cells were starved in serum-free medium for overnight 
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before the experiment. At the start of the assay, cells were washed with serum-
free medium and plated into the upper chamber of transwell inserts at 1x105 in 
0.5mL serum-free DMEM medium. 0.75mL complete medium with 10% FBS was 
added to the lower chamber. Cells were allowed to invade for 20 hours under 
either normoxia or hypoxia culture condition. After the incubation period, the 
medium in the upper chamber was aspirated and the non-invaded cells on the 
upper side of the filter were removed with a cotton swab. Then the transwell 
membranes were fixed and stained with 0.25% crystal violet in 
formaldehyde:methanol (1:9) solution for 30min. After the staining, the 
membranes were washed three times with water and air dried. Invaded cells 
were visualized using light microscopy. 150ul 2% SDS was then added to the 
membrane, incubated for 20 min to solubilize the crystal violet from stained 
invaded cells then transferred to a new 96-well plate for reading. Relative 
invasion was determined using absorbance readings at 550nm.  
 
Western blot analysis 
Proteins were extracted with RIPA buffer containing protease inhibitor 
cocktail (Thermo Fisher Scientific). For HIF western blot, cells were first 
fractionated using RLN buffer (10mM Tris-HCl pH 8.0, 140mM NaCl, 1.5mM 
MgCl2, 0.5% NP-40, proteinase inhibitor cocktail). Nuclear fraction was collected 
for protein extraction. Protein concentrations were measured by a BCA Protein 
Assay Kit (Thermo Fisher Scientific). 25ug protein was resolved by SDS-
polyacrylamide gel (Bio-rad 4%-20%) electrophoresis and transferred onto 
nitrocellulose membranes. Membranes were blocked then probed with a series of 
primary antibodies. Antibodies used for western blotting includes HIF-1α (R&D 
AF1935), HIF-2α (R&D AF2886), β-actin (Thermo MA5-15739), Lamin-B1 
(Abcam 16048), SREBP-2 (R&D AF7119), hnRNPC (Santa Cruz sc-32308) and 
MS2 binding protein (Millipore ABE76). Primary antibodies were detected using 
horseradish peroxidase-conjugated secondary antibodies and visualized 
using ChemiDoc imager (Bio-rad). 
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RNAseq and data analysis 
In hypoxia-induced lncRNA study, libraries were constructed using 
Illumina TruSeq Stranded Total RNA Library Prep Kit / Ribo-Zero Gold kit as per 
manufacturer’s instructions. Libraries were quantified using an Agilent 2200 
TapeStation, pooled equimolar and sequenced on an Illumina NextSeq500 
instrument using a NextSeq75-v2 High Output reagent kit and flowcell. Reads 
were mapped to genome using TopHat2 version 2.1.1. Read counts for each 
gene were created using HTSeq-Count from the HTSeq package version 0.6.1p1 
and Gencode v23 as the annotation [153, 218]. Custom perl scripts were used 
for estimation of transcript abundances based on Fragments Per Kilobase of 
exon per Million fragments mapped (FPKM). Initial differential expression 
analysis was carried out using the DESeq2 package (version 1.12.3) in 
R/Bioconductor (R version 3.3.1). For MIR193BHG function study, 1000ng total 
RNA was prepped for RNA sequencing. RNA quality and sizing were assessed 
using Agilent Tape Station and RNA ScreenTape Kit (5067-5576, Agilent 
Technologies). ERCC ExFold RNA Spike-In Mixes (4454739, Life Technologies) 
was used for expression control. Ribosomal depletion was conducted with the 
Low Input Ribominus Eukaryote System v2 (A15027, Life Technologies). RNA 
library preparation was constructed using the ABI Library Builder System and the 
Ion RNA-Seq for AB Library Builder (4482416, Life Technologies) with 1 min 
fragmentation time. Template preparation was performed using the Ion PI 
Template OT2 200 Kit v2 (4485146, Life Technologies) and quantified using 
standard methods. RNA sequencing was performed using The Ion PI 
Sequencing 200 Kit v2 Kit (4485149, Life Technologies) on the Proton according 
to the kit instructions using the Ion PI Chip Kit v2 (4482321, Life Technologies). 
Reads were aligned to transcriptome using SALMON and differential expression 
was analyzed in R using EdgeR. Differential expression with FDR < 0.05 was 
considered significant.  
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AmpliSeq and data analysis 
RNA quality and sizing were assessed using Qubit BR RNA Kit and 
TapeStation RNA Kit. Automated library preparation was performed according to 
the protocol available with the Ion Chef (MAN0013432) and using the Ion 
AmpliSeq Kit for Chef DL8 (A29024).  Library was further diluted to 50 pM for 
sequencing. Template preparation and sequencing were executed using the Ion 
PI Hi-Q Chef Kit (A27198, Thermo-Fisher Scientific) with template quantitation 
using the IonSphere Quality Control Kit (4468656, Thermo-Fisher Scientific). 
Standard workflow for gene-level expression was conducted using Torrent Suite 
Version 4.4. The AmpliSeq Transcriptome Plugin was used to generate standard 
expression files.  Differential expression was analyzed in R using DESeq2. 
Differential expression with FDR < 0.05 was considered significant.   
 
Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis was performed following GSEA User 
Guide (The Broad Institute). Briefly, each condition was considered as a group 
and gene list was ranked with GSEA default ranking metrics. Gene sets from 
Molecular Signature Database were used in the analysis to identify the pathways 
significantly enriched in each group. Statistical significance (nominal P value) of 
the ES (enrichment score) was calculated using an empirical geneset-based 
permutation test. 
 
Animal Study 
All animal experiments were approved and carried out in accordance with 
the Institutional Animal Care and Utilization Committee (IACUC study number: 
10583) at Indiana University School of Medicine. All the cell lines used in animal 
experiments were tested negative for mycoplasma. 1x106 cells/30uL serum-free 
medium was injected into the mammary fat pad of ~4 weeks old female NSG 
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) female mice. Tumor growth was monitored 
twice weekly by measurement of the long and short diameters of the tumor using 
digital calipers. At the end of the experiments, animals were euthanized and 
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primary tumor, lung, and liver were resected. Lung and liver tissue were formalin 
fixed, paraffin embedded, sectioned, and stained with hematoxylin and eosin 
(H&E) for analyzing metastatic burden. The percentage of lung or liver tissue 
containing tumor metastasis was analyzed using Aperio (Leica Biosystems). 
 
Total Cholesterol quantitation 
Cells were washed twice with PBS and lipids were extracted using 750ul 
chloroform:methanol (2:1). After extraction for 30min on a rocker, samples were 
centrifuged for 10min at 4,000 rpm at 4°C, then the lower chloroform phase was 
collected and air-dried in the fume hood until all liquid evaporated. Then the lipids 
was resuspended in 10% Triton-X100 in isopropanol. Total cholesterol content 
was measured using Wako Cholesterol assay kit (WAKO, #439-17501) 
according to the manufacturer’s instruction. The cholesterol levels were 
normalized to amounts of total cellular protein and the data was presented as 
cholesterol (ug)/protein (mg).  
 
Bromouridine(BrU)-RNA Immunoprecipitation 
BrU labeling of newly synthesized RNA and BrU-RNA isolation were 
performed following the method established by Ljungman’s group [219, 220]. 
MCF-7 cells were transfected with either control siRNA or MIR193BHG siRNA 
and exposed to hypoxia. Cells were grown to approximately 80% confluency 
before the addition of BrU. After 24 hours culture in hypoxia, 3~4 ml of medium 
was removed from each plate and BrU was added to a final concentration of 2 
mM. Cell culture was maintained under hypoxia condition for another 30 min to 
allow BrU labeling RNA newly synthesized within this period. After 30 min 
labeling, cells were harvested with QIAzol lysis buffer and total RNA was 
manually extracted as previously described. RNA pellet was resuspended in 
200ul DEPC-water and incubated at 55 ºC to ensure RNA was fully dissolved. 50 
ul of Dynabeads® Goat anti-mouse IgG beads (Invitrogen #11033) per sample 
was transferred to a 1.5 ml tube and washed three times with 200 ul 0.1% BSA in 
DEPC-PBS. In each wash, beads were captured with a magnetic stand (Millipore) 
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and the washing buffer was aspirated. After the final wash, beads were 
resuspended in 200 ul 0.1% BSA in DEPC-PBS supplemented with 0.5 ul 
RiboLock RNase inhibitor (40U/ul, Thermo #EO038). 2ug mouse anti-BrdU 
antibody (BD Pharmingen, 555627) was added to each tube and incubated with 
gentle rotation for 1 hour at room temperature. After incubation, beads were 
washed three times with 0.1% BSA in DEPC-PBS to remove unbound antibody. 
The conjugated beads were resuspended in 200 ul 0.1% BSA in DEPC-PBS 
supplemented with 0.5 ul RiboLock RNase inhibitor. Total RNA was heated in an 
80 ºC heat block for 10 min then immediately transferred on ice. 90% of the RNA 
was then added to the antibody-conjugated beads and incubated with gentle 
rotation for 1 hour at room temperature. 10% of the RNA was saved as input 
RNA in the upcoming analysis. After incubation, beads were washed with 0.1% 
BSA in DEPC-PBS for 5 min with rotation followed by two brief washes with 0.1% 
BSA in DEPC-PBS. The final wash was completely removed and the beads were 
resuspended in 40 ul DEPC-water then incubated for 10 min at 95 ºC to recover 
the BrU-RNA from the beads. The BrU-RNA and the input RNA were analyzed 
using qPCR.  
 
SREBP-2 DNA binding activity assessment 
SREBP-2 DNA binding activity was determined using SREBP-2 
Transcription Factor Assay Kit (Cayman Chemical #10007819) following the 
manufacturer’s instruction. Briefly, cellular nuclear extracts was purified from 
~107 cells using Nuclear Extraction kit (Cayman Chemical #10009277). Nuclear 
extracts was added onto the plate coated with consensus double strand DNA 
sequencing containing SREBP response element provided by the manufacturer 
then incubated at 4 ºC for overnight. Then the plate was washed five times with 
washing buffer to remove unbound components. SREBP-2 antibody was added 
to each well and incubated at room temperature followed by five times washes. 
Then secondary antibody was added to the plate followed by the same 
incubation and wash procedure. After the last wash, transcription factor 
development solution was added and the plate was incubated at room 
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temperature in dark for 40min before adding stop solution. The amount of 
SREBP-2 bound to the DNA sequences was determined by absorbance 
measurements at 450 nm normalized to the protein concentration in the nuclear 
extracts.  
 
MS2-tagged RNA affinity purification 
RNA pulldown using MS2-tagged RNA affinity purification was performed 
following the previously described protocol (Yoon, 2012). MIR193BHG cDNA 
sequence was cloned into the pMS2 vector, upstream of the MS2 tag. MCF-7 
cells were co-transfected with MIR193BHG-MS2 vector or the empty vector with 
pMS2-GST vector. 48 hours post-transfection, cells were washed twice with PBS 
and lysed in NP-40 lysis buffer (20 mM Tris–HCl at pH 7.5, 100 mM KCl, 5 mM 
MgCl2, 2% NP-40, protease inhibitors, RNase inhibitor, and10 mM DTT) and 
incubated for 10 min on ice. Cell lysate was collected by scraping then 
centrifuged at 10,000g for 15 min at 4ºC. The supernatant was collected and the 
protein concentration was measured. 1000 ul of lysate containing 2 mg protein 
was used for subsequent RNA pulldown. Glutathione sepharose beads (GE 
Healthcare) were washed with ice-cold PBS three times and resuspended with 
equal volume of PBS to make 50% slurry. 2 mg lysate was incubated with 60 ul 
Glutathione beads for 3 hours at 4ºC with gentle rotation, followed by five times 
washes with NP-40 lysis buffer to remove unspecific bound proteins. Beads were 
further treated with 20 units of RNase-free DNase (QIAGEN) at 37 ºC for 15 min, 
followed by two times washes with NT2 buffer (50 mM Tris–HCl at pH 7.5, 150 
mM NaCl, 1 mM MgCl2, and 0.05% NP-40) to remove the DNase. For western 
blot analysis, beads were resuspended in SDS loading buffer, heated up to 95 ºC 
for 5 min and centrifuged for 1 min at 14,000g. The supernatant was loaded on 
SDS-PAGE gel. For RNA analysis, 700 ul QIAzol lysis buffer was added to the 
beads and RNA was extracted as previously described.  
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Statistical analysis 
Statistical analysis was performed in Excel, R (version 3.0.1, 
http:///www.rproject.org/) or GraphPad Prism (version 5). Statistical significance 
of differences was determined by Student’s t-test or one-way ANOVA with 
indicated post hoc comparison unless stated otherwise. The difference was 
considered statistically significant when p-value less than 0.05. Data was 
presented as mean + SD unless stated otherwise.  
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Table 2. Primers sequence 
Gene Forward primer Reverse primer 
3' inner  ACACGTCAAGGCCAGAGGA
TGGA 
 
3'outer  AACCTGCCAGTAATTTCAGC
AA 
 
5' inner  GGAGAGAGGATTCCAAGCC
AA 
 
5' outer  ATCTTTGCATCTCCCAACCA
G 
 
B2M TGCTGTCTCCATGTTTGATG
TATCT 
TCTCTGCTCCCCACCTCTAAG
T 
CA9  TTTGCCAGAGTTGACGAGG
C 
GCTCATAGGCACTGTTTTCTT
CC 
GAPDH    AAGGACTCATGACCACAGT
CCAT 
CCATCACGCCACAGTTTCC 
HMGCR ACAATAAGATCTGTGGTTG
GAATTATGA 
GCTATGCATCGTGTTATTGTC
AGAA  
HMGCR 
E12^14_F 
ATTACTCCTTGCTTGGTGGA
GGT 
 
HMGCR 
E13(+) F 
GCAGGACCCCTTTGCTTAG
ATG 
 
HMGCR 
E14_R 
CTGTCAAATGCCTCCTTTAT
CACT 
 
HMGCR 
intron 
AGCAATAGGTGTAAGTTGG
CA 
CTCCACCAAGCTACACAGTA 
HMGCS1 CTCTTGGGATGGACGGTAT
GC 
GCTCCAACTCCACCTGTAGG 
LSS GACGACCGATTCACCAAGA
GCA 
AGACATGCTCCTGGAAGGCA
GT 
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MIR193B
HG 
AACCTGCCAGTAATTTCAGC
AA 
GGAGAGAGGATTCCAAGCCA
A 
MIR193B
HG clone  
CGGGATCCGTCGGCTGCG
CGCTCTCTG 
GCTCTAGACTCAATAAATGCT
GCTTATTTATT 
MSMO1 GCTGCCTTTGATTTGTGGAA
CCT 
CTGCACAACCAAAGCATCTT
GCC 
MVD AAGCGCGATGAAGAGCTGG
TTC 
TCCTCGGTGAAGTCCTTGCT
GA 
NEAT1  CTAAATTGAGCCTCCGGTC
ATAC 
AACAGGTGGGTAGGTGAGAG
GTC 
RN18S1  ACCCGTTGAACCCCATTCG
TGA 
GCCTCACTAAACCATCCAATC
GG 
SP1 AGTTCCAGACCGTTGATGG
G 
GTTGCCTCCACTTCCTCGAT 
SP3  AGTGGGCAGTATGTTCTTC
CC 
GACTGGATCTGTGGTATCAC
TTG 
SQLE CTCCAAGTTCAGGAAAAGC
CTGG 
GAGAACTGGACTCGGGTTAG
CT 
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Chapter III. Results 
 
1. MIR193BHG is a hypoxia-inducible lncRNA  
1.1 Identify hypoxia-inducible lncRNAs from RNAseq data 
In principle, full transcriptome analysis such as RNAseq possesses the 
capability of profiling all classes of transcripts without bias from prior knowledge. 
However, the scale of the information one can extract from such a study is 
largely determined by the annotation of the transcripts used in the analysis. 
Therefore, previously generated RNAseq data has the potential to provide new 
information when tapped with newly updated gene annotation.  
Our lab has previously generated RNAseq data from MCF-7 cells 
transfected with scrambled oligonucleotides (Dharmacon # 001005-01-05) then 
cultured for 24 hours in normoxia (21% O2) or hypoxia (0.2% O2). The scrambled 
oligonucleotides transfection did not disrupt the normal cellular response to 
hypoxia of MCF-7 cells, as a panel of well-established hypoxia signature genes 
were induced in the hypoxia samples without exception compared to the 
normoxia control (Figure 6A). Pathway analysis using Gene Set Enrichment 
Analysis (GSEA) also confirmed that the hallmark hypoxia gene set was also 
significantly enriched in the hypoxia samples (Figure 6B). Therefore, this 
‘salvaged’ data, if reanalyzed with lncRNA annotation, could provide us with the 
first glimpse of the lncRNA players involved in hypoxia response. In the past few 
years, along with the emerging interest in this field, lncRNA annotation has been 
greatly improved. In early 2011, we first analyzed the aforementioned RNAseq 
data using the first lncRNA exon annotation published by Eric Lander and John 
Rinn’s group [46]. Later, we re-evaluated the same data with the annotation from 
LNCipedia, an integrated database of 111,685 human annotated lncRNA 
transcripts obtained from various sources [221, 222]. Differentially expressed 
lncRNAs (FDR < 0.25, p < 0.005) from this analysis are presented in Figure 6C 
and 6D. To establish a more accurate lncRNA expression profile in response to 
hypoxia without any potential interference from other treatments, recently we 
performed RNAseq of MCF-7 cells incubated in normoxia or hypoxia (1% O2) for 
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24 hours. As a routine procedure, we first confirmed the hypoxia response in the 
corresponding samples by assessing the expression of hypoxia signature genes 
as well as pathway analysis using GSEA (Figure 7A and 7B). To minimize the 
complexity caused by sequence overlapping with coding genes, we focused on 
intergenic lncRNAs which are categorized as “lincRNAs” in GENCODE (release 
25). Our analysis identified 161 lncRNAs (average rpkm across all samples >=1, 
FDR < 0.05) that were differentially expressed in hypoxia versus normoxia, 
among which, 47 lncRNAs displayed a fold change of ≥ 2 or ≤ 0.5 (Figure 7C). 
Previously reported hypoxia-inducible lncRNAs such as HIF1A-AS1 (Hypoxia-
inducible Factor 1A Antisense RNA 1), NEAT1 (Nuclear Paraspeckle Assembly 
Transcript 1) and MALAT1 (Metastasis Associated Lung Adenocarcinoma 
Transcript 1) were also observed in this list of 47 hypoxia-regulated lncRNAs. 
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Figure 6. Preliminary attempt to identify hypoxia-inducible lncRNAs from 
previously generated RNAseq data. 
A. Heatmap showing expression of a panel of hypoxia signature genes in 
scrambled oligo transfected MCF-7 cells cultured in normoxia or hypoxia (0.2 % 
O2). Each condition had two biological replicates, represented by the individual 
column in the heatmap. Color intensity represents rpkm scaled by the row. 
B. GSEA analysis showing that hypoxia hallmark gene set is enriched in hypoxia 
samples.  
C. Volcano plot representation (log2(fold change) vs. –log10(p-value)) of lncRNA 
expression profile between normoxia and hypoxia. Red dots represent lncRNAs 
with FDR < 0.25.  
D. Heatmap showing expression of lncRNAs differentially expressed between 
hypoxia and normoxia (p < 0.005, FDR < 0.25). Each condition had two biological 
replicates, represented by the individual column in the heatmap. Color intensity 
represents rpkm scaled by the row.  
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Figure 7. Identification of hypoxia-inducible lncRNAs in MCF-7 cells. 
A. Heatmap showing expression of a panel of well-established hypoxia-inducible 
genes in MCF-7 cells cultured in normoxia versus hypoxia (1% O2) for 24 hours. 
Each condition had three biological replicates, represented by the individual 
column. Color intensity represents rpkm scaled by the row.  
B. GSEA analysis showing that hypoxia hallmark gene set is enriched in hypoxia 
samples.  
C. Heatmap presenting 47 hypoxia-regulated lncRNAs that showed a fold 
change ≥2 or ≤ 0.5 between hypoxia versus normoxia. Color intensity represents 
rpkm scaled by the row. Gene name of previously described lncRNAs and 
MIR193BHG are added next to the Ensembl ID.  
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1.2 MIR193BHG is a hypoxia-inducible lncRNA.  
We selected a few candidates for further validation based on the following 
criteria: 1) This lncRNA has not been previously reported in the literature; 2) 
ESTs (Expressed Sequence Tags) have been found in the genomic locus of this 
lncRNA, which is evidence supporting its existence. When we expanded the test 
to a panel of cell lines with various tissue origin, 
ENSG00000262454/MIR193BHG emerged as the transcript that is most 
consistently induced by hypoxia. This lncRNA was designated as ‘lnc1721’ in the 
early stages of our study according to its ranking in the lncRNA exon annotation 
used in our initial analysis. In an early version of LNCipedia (v2.0), it was 
annotated as lnc-MKL2-1:1 based on the protein coding gene MKL/Myocardin-
Like 2 (MKL2) in the proximity, without implying any functional connection. In 
most of the current databases including LNCipeida (v4.0), this locus is annotated 
as MIR193BHG (MIR193B-host gene), because the MIR193B-MIR365A 
microRNA cluster resides within the intronic region of this gene. In keeping with 
existing annotation as well as preventing confusion caused by multiple gene 
names, we chose to refer to this lncRNA using MIR193BHG throughout this 
dissertation.  
Induction of MIR193BHG by hypoxia was detected in multiple cancer cell 
lines and its induction increased along with the hypoxia exposure time in most of 
the cell lines tested (Figure 8A and 8B). Similar induction in hypoxia was also 
detected in 3 different patient-derived pancreatic cancer cell lines, cancer-
associated fibroblasts (Figure 8C) as well as non-tumorigenic cell lines such as 
human breast epithelial cell line MCF10A and human normal lung fibroblast cell 
line WI-38 (Figure 8D). Increased expression within this locus was also reported 
by Choudhry et al. in an independent study [155]. 
Although annotated as MIR193B host gene, evidence suggests that the 
MIR193BHG transcript is more than a microRNA precursor. MIR193BHG and its 
intron-embedded microRNAs have distinct expression controls. Neither miR193b 
nor miR365a showed any response to hypoxic exposure whereas the host gene 
exhibited a robust induction by hypoxia (Figure 9A). Moreover, siRNAs knocking 
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down MIR193BHG expression did not affect the level of either miR193b or 
miR365a. MCF-7 cells transfected with the MIR193BHG overexpression 
construct (MIR193BHG_OE) which comprises only the exon sequence, as 
expected did not display any change in the miR193b or miR365a level (Figure 
9B). Therefore we postulated that although being labeled as a microRNA host 
gene, MIR193BHG is an independent lncRNA whose regulation and functions 
are distinct from its embedded microRNA. 
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Figure 8. MIR193BHG is a hypoxia-inducible lncRNA. 
A. qPCR validation of induction of MIR193BHG by hypoxia across a diverse 
panel of cancer cell lines cultured in either normoxia (21% O2) or hypoxia (0.2% 
O2) for 24 hours.  
B. qPCR measuring MIR193BHG expression in various cell lines (MDA-MB-231, 
T47D, SKOV3, A549, HT-29 and PaCa-2) cultured in normoxia (21% O2) or 
hypoxia (0.2% O2) for 24 or 48 hours. Data represents mean+ SD from three 
technical replicates.  
C. RT-PCR measuring MIR193BHG expression in patient-derived pancreatic 
ductal adenocarcinoma cell lines and cancer-associated fibroblasts (CAF) 
cultured in normoxia or hypoxia (0.2% O2) for 24 hours.  
D. MIR193BHG expression in non-tumorigenic human cell lines MCF10A and 
WI-38 cultured in normoxia or hypoxia (1 % O2) were measured by qPCR. Data 
represents mean + SD from three biological replicates (**p < 0.01, Student’s t-
test). 
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Figure 9. MIR193BHG transcript is not a microRNA precursor. 
A. Expression of miR193b, miR365a, miR210 and MIR193-HG in MCF-7 cells 
cultured in normoxia or hypoxic conditions was determined using qPCR. MiR210 
served as a positive control for hypoxia-induced miRNA. Schematic 
representation of the MIR193BHG locus and the intronic miRNAs is presented on 
top. Data represents mean + SD from three biological replicates (**p < 0.01, 
Student’s t-test). 
B. Knockdown MIR193BHG by two siRNAs (top) and overexpression of 
MIR193BHG (bottom) had no impact on miR193b and miR365a expression in 
MCF-7 cells. Gene expression was determined by qPCR. Data represents mean 
+ SD from three biological replicates. 
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1.3 In vivo correlation between MIR193BHG and tumor hypoxia 
To explore the connection between MIR193BHG expression and hypoxia 
from an in vivo perspective, we first examined the expression correlation 
between MIR193BHG and hypoxia signature genes in patient tumor samples. 
Using level 1 RNAseq data from The Cancer Genome Atlas (TCGA) we were 
able to obtain the expression of MIR193BHG in multiple cancer datasets. We 
calculated the expression correlation between MIR193BHG and each protein 
coding gene, including the hypoxia signature genes. At the transcriptional level, 
MIR193BHG exhibited a general inclination towards a positive association with 
well-established hypoxia responsive genes in several cancer types, including two 
highly hypoxic tumor types TNBC (triple negative breast cancer) and PAAD 
(pancreatic adenoductal adenocarcinoma) (Figure 10A). We further sought to 
estimate the association between MIR193BHG and the severity of tumor hypoxia 
in vivo. Since the prognostic power of hypoxia was recognized in cancer patients, 
several groups have developed multiple hypoxia-related gene sets in order to 
evaluate the degree of intratumoral hypoxia and thus provide a quantifiable 
prognostic value [216, 217, 223, 224]. Using hypoxia score calculated based on 
the hypoxia metagenes established by Buffa et al. to estimate the degree of 
intratumoral hypoxia [216], we further showed that in vivo MIR193BHG level was 
associated with the severity of the intratumoral hypoxia in TNBC (n = 84, 
Spearman’s ρ = 0.344, p = 0.0013 ) and PAAD (n = 41, Spearman’s ρ = 0.324, p 
= 0.041) datasets. TNBC and PAAD were chosen for their highly hypoxic nature. 
The correlation between MIR193BHG and intratumoral hypoxia is even stronger 
than that of a previously reported hypoxia-induced lncRNA, NEAT1 (Figure 10B). 
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Figure 10. MIR193BHG is associated with tumor hypoxia in vivo. 
A. Spearman’s correlation between MIR193BHG and well-established hypoxia-
induced genes expression in triple-negative breast cancer (TNBC), pancreatic 
adenocarcinoma (PAAD), glioblastoma (GBM) and lung adenocarcinoma (LUAD) 
from TCGA. The size and color density of the dots are correlated with the 
strength of the Spearman’s coefficient. The red color represents a positive 
correlation while the blue color represents a negative correlation. The 
corresponding scale is presented next to the image. “NS” was added in the dots 
where the correlation is not significant. The significance is defined as p < 0.05.  
B. Expression of MIR193BHG, NEAT1 or CA9 as a function of the tumor hypoxia 
score in 84 TNBC and 41 PAAD tumor samples. Spearman’s correlation and p-
value are reported.  
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2. Preliminary characterization of MIR193BHG 
2.1 Genomic features of MIR193BHG 
The partial sequence of MIR193BHG based on lncRNA exon annotation 
[46] placed MIR193BHG on chr16 p13.12, between MKL2 (MKL/Myocardin-Like 
2, 35 kb upstream from MIR193BHG) and PARN (PolyA-Specific Ribonuclease, 
109kb downstream from MIR193BHG). It was one of the only two loci showing 
significant hypoxia-induced transcription within a 1000 kb range in MCF-7 (Figure 
11A). This gene has the basic features of an RNA polymerase II transcription unit, 
including an enrichment of H3K4me3 histone marker around the transcription 
start site and a canonical polyadenylation signal at the 3’ end. Multiple cataloged 
ESTs at this locus indicate the presence of more than one transcript variant 
(Figure 11A). To determine the full length sequence of MIR193BHG, we 
performed 5’ RNA-ligation mediated rapid amplification of cDNA ends (5’ RLM-
RACE) and classical 3’ RACE. Both 5’ RLM-RACE and 3’ RACE captured more 
than one major product from the PCR, which confirmed the existence of multiple 
transcript variants (Figure 11B and 11C). 5’ RLM-RACE identified two major 
transcription start sites (TSS): one concurred with the TSS signals of Cap 
Analysis of Gene Expression (CAGE)1 data from FANTOM5 project as well as 
ENST00000570945/MIR193BHG-001 in Ensembl (release 84); the other one 
overlapped with the TSS of ENST00000634265/MIR193BHG-004. Two 
polyadenylation (polyA) sites identified through 3’RACE overlapped with the two 
polyA signals on the second exon from Cancer genome polyA site & usage data 
(Figure 11C). Transcribing from a specific strand is a feature commonly used to 
distinguish a regulated transcription event from a byproduct of an active 
regulatory region. To test the strandedness of MIR193BHG’s transcription, 
strand-specific RT-PCR was performed. cDNA generated using an antisense 
primer contained the majority of MIR193BHG transcription product while a sense 
primer failed to produce any measurable quantity of MIR193BHG cDNA.(Figure 
                                            
1 Cap Analysis of Gene Expression (CAGE) developed by RIKEN utilizes the cap-trapper method 
to capture the 5’ end of cDNA. In combination with next generation sequencing, this technology 
presents a comprehensive mapping of vast majority of human transcription start sites (FANTOM5 
project). 
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11D). This result was further supported by ENCODE/CSHL (Cold Spring Harbor 
Lab) long RNA sequencing which showed this locus was mostly transcribed from 
the positive strand of chr16p13 in MCF-7 cells (Figure 11E).  
MIR193BHG’s non-coding nature was suggested through the analysis 
using Coding Potential Assessment Tool (CPAT) [225]. The coding probability of 
MIR193BHG is comparable to that of well-characterized lncRNAs such as 
MALAT1 and NEAT1, suggesting the absence of a protein product from the 
MIR193BHG transcript (Figure 11F).  
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Figure 11. Genomic characterization of MIR193BHG. 
A. Top: genomic neighborhood of MIR193BHG locus and the RNAseq tracks 
showing expression within this area in normoxia (black) and hypoxia (red). 
Bottom: MIR193BHG locus zoom in. The tracks presented are (from top to 
bottom): RNAseq tracks showing expression of MIR193BHG in MCF-7 cells 
cultured under normoxia (black) or hypoxia (red); annotation tracks; TSS peaks 
track from FANTOM5 project; poly(A) track from ENCODE Cancer genome polyA 
site & usage data; H3K4me3 track from ENCODE. 
B. 5’ RLM-RACE was performed to determine the transcription start sites of 
MIR193BHG transcript. Agarose gel image shows two major products from the 
PCR step which were sequenced to determine the 5’ start sites. Schematic 
diagram of 5’ RACE is shown on the right. CIP: Calf Intestine Alkaline 
Phosphatase. TAP: Tobacco Acid Pyrophosphate. 
C. 3’RACE was performed to determine the end sites of MIR193BHG transcript. 
Agarose gel image shows two major products from the PCR step which were 
sequenced to determine the 3’ end sites. Schematic diagram of 3’RACE is shown 
on the right.  
D. Agarose gel image showing strand-specific RT-PCR using cDNA generated 
from primers targeting either sense or antisense strand of MIR193BHG locus. 
cDNA generated with oligo-dT and PCR using genomic DNA (gDNA) served as 
positive controls in this experiment. NTC stands for no template control. 
E. RNAseq tracks from CSHL long RNAseq (MCF-7) demonstrating the strand-
specific transcription of MIR193BHG. Tracks presented are: (from top) MCF-7 
whole cell polyA+ RNA minus strand signal; MCF-7 whole cell polyA+ RNA plus 
strand signal.  
F. Table showing analysis using the Coding-Potential Assessment Tool (CPAT). 
Known lncRNAs NEAT1, MALAT1 and coding gene GAPDH are presented as 
references.  
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2.2 Subcellular distribution and tissue-specific expression of MIR193BHG 
Subcellular distribution of a RNA often indicates its potential function. 
Therefore, we measured MIR193BHG RNA distribution between cytoplasm and 
nucleus in MCF-7 and MDA-MB-231 cells using cell fractionation followed by 
qPCR. The result showed that although MIR193BHG RNA can be detected in 
both cytoplasm and nucleus, the majority (~70%) of MIR193BHG transcripts 
resided in the nucleus and this distribution was not affected by hypoxic stress 
(Figure 12A). ENCODE/CSHL long RNA sequencing of nuclear and cytosolic 
RNA in MCF-7 also confirmed the presence of MIR193BHG RNA in both 
fractions. The mature RNA transcript captured in the cytoplasmic fraction showed 
a clear two-exon structure which resembled the sequence we identified 
experimentally by RACE (Figure 12B). 
Several studies have revealed that lncRNAs exhibit more tissue-specific 
expression patterns than protein-coding genes [218]. Human Body Map 2.0 data 
(Illumina) consists of RNAseq data from the following 16 human tissues: 
including adrenal, adipose, brain, breast, colon, heart, kidney, liver, lung, lymph, 
ovary, prostate, skeletal muscle, testes, thyroid, and white blood cells 
(https://www.ebi.ac.uk/gxa/experiments/E-MTAB-513). Using this data, we 
showed that the expression pattern of MIR193BHG across 16 human tissues 
bore no similarity to that of its neighboring protein coding genes, MKL2 and 
PARN. MIR193BHG expression is relatively enriched in sexual organs including 
testis, breast and prostate, whereas organs such as liver and adrenal gland 
express relatively low levels of MIR193BHG (Figure 13A). Apart from its 
expression in various normal tissues, we also observed large variations in 
MIR193BHG expression across 13 different human cell lines including 3 breast 
cancer cell lines (MCF-7, T47D, and MDA-MB-231), ovarian cancer cell line 
SKOV-3, glioblastoma cell line U87, 2 colon cancer cell lines (HCT116 and 
HT29), 2 lung cancer cell lines (A549 and H460), head and neck carcinoma cell 
line SQ20B, embryonic kidney cell line HEK293, renal carcinoma cell line 786-O 
and pancreatic cancer cell line PACA2  (Figure 13B).  
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Figure 12. Subcellular distribution of MIR193BHG. 
A. MCF-7 cells (top) or MDA-MB-231 cells (bottom) were harvested and 
fractionated after 24 hours culture in normoxia or hypoxia (1% O2). The levels of 
MIR193BHG, NEAT1 and GAPDH in the cytoplasmic and nuclear fractions were 
assessed by qPCR. NEAT1 and GAPDH were included as nuclear and 
cytoplasmic controls, respectively. Data represents mean + SD from three 
biological replicates. 
B. RNAseq tracks from CSHL long RNAseq (MCF-7) showing MIR193BHG 
expression in whole cell, cytosol and nucleus. Tracks presented are: (from top) 
MCF-7 whole cell, polyA+RNA, plus signal; MCF-7 cytosol, polyA+RNA, plus 
signal; MCF-7 nucleus, polyA+RNA, plus signal. 
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Figure 13. Cell line and tissue specific expression of MIR193BHG. 
A. Barplot of Human Body Map2.0 data presenting the expression of 
MIR193BHG and its two neighboring protein coding genes PARN and MKL2 in 
different tissues.  
B. MIR193BHG expression in 13 cell lines was measured by qPCR. Cell lines 
tested include: breast cancer cell lines (MCF-7, T47D, MDA-MB-231), 
glioblastoma cell line (U87), colon cancer cell lines (HCT116, HT29), lung cancer 
cell lines (A549, H460), head and neck cancer cell line (SQ20B), human 
embryonic kidney cell (HEK293), renal cancer cell line (786-O) and pancreatic 
cancer cell line (PACA-2).  
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3. Transcriptional regulation of MIR193BHG  
3.1 De novo transcription or RNA stability 
Next we sought to explore the transcriptional regulation of MIR193BHG 
underlying the hypoxia-induced expression. First, we needed to determine 
whether the induction we observed was a de novo transcription event or due to 
other factors such as increased RNA stability. In the presence of RNA 
transcription blocking agent actinomycin D, MIR193BHG level did not increase in 
response to hypoxia. (Figure 14A). On the other hand, the RNA stability of 
MIR193BHG exhibited no dramatic difference between normoxia and hypoxia 
conditions (Figure 14B). Thus, the observed induction of MIR193BHG under 
hypoxia condition is a de novo transcription event rather than a reflection of RNA 
stability changes.  
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Figure 14. MIR193BHG induction by hypoxia a de novo transcription event. 
A. MCF-7 (left) or MDA-MB-231 (right) cells were pre-treated with either 
actinomycin D (2.5ug/mL) or vehicle control (DMSO) for 1 hour before exposing 
to hypoxia (1% O2). RNA were harvested at indicated time points and the RNA 
level of MIR193BHG was measured by qPCR.   
B. MCF-7 cells were cultured in the presence of actinomycin D (2.5ug/mL) for 
indicated time periods in normoxia or hypoxia (1% O2). The half-life of 
MIR193BHG was quantified by measuring the decline in transcript levels after 
actinomycin D treatment.  
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3.2 Hypoxia-inducible factors involvement in MIR193BHG induction 
The majority of hypoxia-inducible genes reported to date are regulated by 
hypoxia-inducible factors (HIFs), which are the most well-studied transcription 
factors in the central hub of hypoxia signaling pathways. HIF is primarily 
regulated via oxygen-dependent modification of the HIF-α subunit (HIF-1α, HIF-
2α), by 2-oxoglutarate-dependent dioxygenase PHDs (Prolyl Hydroxylase 
Domain). Small-molecule analogs of 2-oxoglutarate such as 
dimethyloxalylglycine (DMOG) inhibit these enzymes, thus stabilizing HIF-α and 
activating HIF target genes [226, 227]. The effect of DMOG on gene expression 
matches those of hypoxia both qualitatively and quantitatively to a very high 
degree [228].  
HIFs have also been demonstrated as the direct regulator of several 
hypoxia-induced non-coding transcripts such as miR210, HIF1A-AS2 and NEAT1 
[146, 154, 157]. Therefore, we first examined whether HIFs were involved in 
MIR193BHG response to hypoxia. Unexpectedly, we observed lines of evidence 
against this hypothesis. MIR193BHG was irresponsive to DMOG treatment while 
HIF target genes such as CA9 (Carbonic Anhydrase 9) was dramatically 
upregulated (Figure 15A). In MCF-7 cells MIR193BHG showed no significant 
changes to DMOG treatment, while in MDA-MB-231 cells DMOG was able to 
increase MIR193BHG by ~ 2 fold which is much less than the response elicited 
by a real oxygen deprivation. This suggested an indirect, if not absent, 
involvement of HIFs in the hypoxic induction of MIR193BHG. To further support 
this claim, we first used TFM-Explorer (Transcription Factor Matrix Explorer, 
http://bioinfo.lifl.fr/TFM/TFME/) to scan the promoter of MIR193BHG for 
evolutionarily conserved HIF-binding motifs [229]. The analysis revealed no HIF 
binding site in the vicinity (-5000bp to +200 bp) of the MIR193BHG TSS (Figure 
15B). The absence of HIF-binding in the promoter was also confirmed by ChIP-
seq data of HIF-1α and HIF-2α binding sites in MCF-7 cells published by 
Johannes Schödel et al. (GSE28352) (Figure 15C) [230].  
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Figure 15. Hypoxia-inducible factors do not bind to MIR193BHG promoter. 
A. Cells were treated with either 1mM DMOG or vehicle control DMSO for 24 
hours. RNA was isolated and MIR193BHG and CA9 expression were measured 
by qPCR. Data are shown as mean + SD from three biological replicates (*p < 
0.05, **p < 0.01, Student’s t-test). 
B. Visualization of promoter analysis using TFM-Explorer. MIR193BHG promoter 
region (-5000bp to +200bp) was scanned using weight matrices from 
TRANSFAC. 
C. UCSC genomic track display ChIP-seq data (Johannes Schödel, et al.) of HIF-
1α and HIF-2α binding in MIR193BHG, CA9 and miR210 promoters in MCF-7. 
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To directly assess HIF involvement in MIR193BHG expression, we 
generated HIF-1α/HIF-2α stable knockdown cell lines with lentivirus packed with 
corresponding shRNAs. The knockdown efficiency was confirmed by qPCR as 
well as western blot. In the absence of HIF-1α, CA9 expression under hypoxic 
condition was drastically reduced in MCF-7 cells, while MIR193BHG maintained 
a similar induction to that seen in hypoxia (Figure 16A). In MDA-MB-231 cells, in 
which previously MIR193BHG showed a partial response to DMOG treatment, 
HIF-1α knockdown was able to partly suppress MIR193BHG induction by 
hypoxia. However the strength of the suppression was far weaker compared to 
the effect on the CA9 level (Figure 16A). On the other hand, HIF-2α knockdown 
was able to inhibit MIR193BHG induction by hypoxia in both MCF-7 and MDA-
MB-231 cell lines with similar efficacy, suggesting a broader influence of HIF-2α 
on MIR193BHG induction than HIF-1α (Figure 16B). Additional evidence 
supporting the potential involvement of HIF-2α in MIR193BHG transcriptional 
regulation was observed from a clear cell renal carcinoma cell line 786-O, which 
maintains stable expression of HIF-2α protein regardless of oxygen status due to 
VHL mutation. Reconstitution of wild-type VHL (Von Hippel-Lindau Tumor 
Suppressor) in 786-O (WT2, VHL+) significantly reduced the basal level of 
MIR193BHG under normoxia compared to 786-O cells expressing control vector 
(RC3, VHL-). Moreover, MIR193BHG level was more sensitive to hypoxic stress 
in VHL-restored 786-O compared to the VHL-defective cells (Figure 16C). 
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Figure 16. Involvement of HIF-1α and HIF-2α in MIR193BHG induction by 
hypoxia. 
A. MCF-7 (left) or MDA-MB-231(right) cells stably expressing HIF1A shRNA or 
control shRNA were cultured in normoxia or hypoxia (1% O2) for 48 hours. HIF1A 
knockdown was confirmed by western blot and qPCR. Representative western 
blot and qPCR analysis are shown on top. MIR193BHG and CA9 expression 
were measured by qPCR. Data are shown as mean + SD from three biological 
replicates (*p < 0.05, **p < 0.01, Student’s t-test). 
B. MCF-7 (top) or MDA-MB-231(bottom) cells stably expressing HIF2A shRNA or 
control shRNA were cultured in normoxia or hypoxia (1% O2) for 48 hours. HIF2A 
knockdown was confirmed by western blot and qPCR. Representative western 
blot and qPCR analysis are shown. MIR193BHG expression were measured by 
qPCR. Data are shown as mean + SD from three biological replicates (*p < 0.05, 
**p < 0.01, Student’s t-test) 
C. QPCR measuring MIR193BHG expression in 786-O VHL- (RC3) or 786-O 
VHL+ (WT2) cells cultured in normoxia or hypoxia for 24hrs or 48hrs. Data are 
shown as mean + SD from three biological replicates (*p < 0.05, **p < 0.01, one-
way ANOVA followed by Tukey’s test). Representative western blot of HIF-2α 
expression in 786-O VHL- (RC3) or 786-O VHL+ (WT2) cells is shown on the 
right.  
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According to the classic model of HIF-regulated gene expression in which 
HIF directly binds to the target gene promoter, neither HIF-1α nor HIF-2α is 
directly involved in the transcriptional regulation of MIR193BHG expression in 
response to hypoxia. However, our experimental data suggested a partial 
contribution of HIF, in particular HIF-2α to MIR193BHG induction. In fact, ChIP-
seq analysis has shown that HIF binding sites exist outside of the promoter 
region and HIF binds to sites other than the core A/GCGTG motif. This was 
particularly true for HIF-2α as 70% of the identified HIF-2 binding sites lay outside 
promoter sequences [230]. To explore the possibility that HIFs affect 
MIR193BHG level by binding to areas outside the promoter, we revisited the 
ChIP-seq data of HIF-1α and HIF-2α published by Johannes Schödel with an 
expanded search range. The only HIF binding signal within a 200kb region 
centered at MIR193BHG is ~38kb downstream of MIR193BHG, inside the intron 
of another lncRNA LOC105447648 which also appears to be induced by hypoxia 
according to our RNAseq analysis. It is worth noting that long range chromatin 
interaction was detected between the MIR193BHG promoter and this HIF binding 
region by ChIA-PET (Chromatin Interaction Analysis by Paired-End Tag) 
sequencing of RNA polymerase II (RNAPII)-immunoprecipitated complex from 
MCF-7 cells (GSE33664/GSM832458) (Figure 17) [231]. ChIA-PET sequencing 
was first developed in 2009 for genome-wide investigation of chromatin 
interaction that involves specific protein factors [232]. ChIA-PET analysis of 
genome-wide chromatin interactions associated with RNAPII provided insights 
into how active promoters dynamically interact with their respective regulatory 
regions. Therefore, it is very likely that the observed HIF involvement in 
MIR193BHG induction is mediated via the interplay between MIR193BHG 
promoter and a HIF binding region farther downstream of the gene body.  
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Figure 17. HIF binding and chromatin interaction around MIR193BHG locus. 
UCSC genomic track display ChIP-seq data (Johannes Schödel, et al.) of HIF-1α 
and HIF-2α binding within a 200kb region centered on MIR193BHG. Chromatin 
interaction detected by ChIA-PET sequencing (GSM832458) was visualized as 
arches between two locations. MIR193BHG gene locus is highlighted in yellow.  
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3.3 MIR193BHG induction by hypoxia is restricted by glucose availability 
Hypoxia, low extracellular pH and limited glucose availability are three key 
features of the tumor microenvironment. Tumor cells respond to these stresses 
through a complex regulatory network, which greatly affects how cancer cells 
survive, adapt and eventually overcome the stresses posed by the environment. 
How MIR193BHG responds to hypoxia in combination with other environmental 
factors could provide informative insight into its regulation and function. We first 
ruled out extracellular acidosis as a factor regulating MIR193BHG expression 
(Figure 18).  
 
 
Figure 18. Low pH does not affect MIR193BHG expression. 
A. MCF-7 cells were cultured in normoxia or hypoxia (1% O2) for 24 hours with 
pH-adjusted growth medium. MIR193BHG level was measured by RT-PCR and 
visualized by agarose gel electrophoresis. 18s rRNA level was included as a 
loading control.  
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Next, we investigated the role of glucose in MIR193BHG expression, the 
result of which led to the surprising revelation that MIR193BHG induction by 
hypoxia is restricted by glucose availability. Typical in vitro cancer cell studies 
use media that contains high levels of glucose (10-25mM) which are replenished 
every 2-3 days. However, this condition does not reflect the environment that 
cancer cells are normally exposed to while growing in situ. In vivo circulating 
glucose levels rarely exceed 5mM and intratumoral glucose levels are usually 
lower than 1mM. Thus by inference, tumors are in a constant state of metabolic 
stress, especially from limited availability of glucose [233, 234]. However, the 
observed repressive effect of low glucose concentration on MIR193BHG 
expression is likely not due to the metabolic stress from decreased glycolysis. 
When MCF-7 cells were exposed to hypoxia in the presence of either the 
glycolysis inhibitor 2-Deoxy-D-glucose (2-DG), or the pyruvate dehydrogenase 
kinase inhibitor sodium dichloroacetate (DCA), or low glucose concentration 
(5mM), MIR193BHG expression was significantly suppressed only in the low 
glucose condition when cultured in hypoxia (Figure 19A). A similar inhibitory 
effect of low glucose was not observed in the case of miR210, a well-studied 
hypoxia-inducible small noncoding RNA (Figure 19A). Moreover, this effect was 
only manifested when combining low glucose and hypoxia stress as glucose 
abundance by itself had no significant impact on MIR193BHG levels (Figure 19B). 
A similar result was also observed in two additional breast cancer cell lines MDA-
MB-231 and MDA-MB-468. However in normal cells such as human normal lung 
fibroblast WI-38 cells, 5mM glucose was sufficient to support hypoxia to induce 
MIR193BHG (Figure 19C). 
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Figure 19. MIR193BHG induction by hypoxia is restricted by glucose 
availability. 
A. MCF-7 cells were cultured in normoxia or hypoxia (1% O2) for 24 hours in 
either regular growth medium, medium supplemented with 10mM 2-DG, low 
glucose medium, low glucose medium supplemented with 10mM 2-DG or regular 
growth medium with 10mM DCA. Regular growth medium contains 25mM (4.5g/L) 
glucose and low glucose medium contains 5.5mM (1.0g/L) glucose. MIR193BHG 
and miR210 level was detected by qPCR. Data are shown as mean + SD from 
2~3 biological replicates (*p < 0.05, **p < 0.01, one-way ANOVA followed by 
Tukey’s test).  
B. MCF-7 cells were cultured in normoxia or hypoxia (1%O2) for 24 hours with 
medium containing 25mM, 5.5mM, 1mM or 0mM glucose. MIR193BHG level was 
detected by qPCR. Data are shown as mean + SD from 2 to 3 biological 
replicates (*p < 0.05, **p < 0.01, one-way ANOVA followed by Tukey’s test).  
C. MDA-MB-231, MDA-MB-468 and WI-38 cells were cultured in normoxia or 
hypoxia (1%O2) for 24 hours with with medium containing high (25mM) or low 
(5.5mM) glucose concentration. MIR193BHG level was detected by qPCR. Data 
are shown as mean + SD from two biological replicates.  
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3.4 Sp1 and Sp3 are involved in MIR193BHG transcriptional regulation 
With HIFs disproved as the direct transcription factor that binds to 
MIR193BHG’s proximal promoter, we reviewed the promoter analysis result from 
the TFM-Explorer program. One striking feature revealed by this analysis was 
that MIR193BHG promoter has a high GC content which is dotted with multiple 
GC-box sequences (Figure 20A). Mithramycin A specifically binds to GC-rich 
elements and displace any potential transcription factors from their GC-rich 
putative binding sites on the promoter [235]. Blocking GC-box with mithramycin A 
completely nullified MIR193BHG induction in response to hypoxia, suggesting 
that the GC-rich elements are crucial for MIR193BHG expression (Figure 20A). 
MIR193BHG promoter belongs to a large subclass of RNA polymerase II 
promoters which lack both TATAA and CCAAT sequence motifs but contain 
multiple GC rich elements. In such promoters, apart from transcriptional 
activation, GC-rich elements also regulate transcriptional initiation and start site 
utilization [236]. Therefore the complete abrogation of MIR193BHG response to 
hypoxia by mithramycin A is likely due to the inhibition of both transcriptional 
initiation as well as activation. 
Several factors have been found to interact with GC rich elements, most 
notably transcription factor Sp1 (specificity protein 1). Sp1 is ubiquitously 
expressed in mammalian cells and has been shown to be important for the 
regulation of TATA-less promoter activity [236]. Sp1 binds GC-rich element as a 
multimer and is capable of synergic activation of promoters containing multiple 
binding sites [237, 238]. Genes regulated by Sp1 are involved in a wide range of 
cellular processes such as cell metabolism, proliferation and differentiation [239]. 
Relevant to our previous observation, Sp1 is reported to mediate hypoxia-
induced gene expression via both HIF-dependent and HIF-independent 
mechanisms [240-242]. Sp1 activity is also reported to be regulated by glucose 
availability, which could present a potential explanation for the observed 
shutdown of MIR193BHG response to hypoxia in low glucose condition. High 
glucose concentration enhances Sp1 DNA binding activity and transcriptional 
activation through glucose-induced dephosphorylation by protein phosphatase 
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1[243, 244]. Glucose starvation also induces deglycosylation of Sp1 which 
renders Sp1 more susceptible to proteasome degradation [245].  
siRNA mediated knockdown of Sp1 partially attenuated MIR193BHG 
induction by hypoxia in MCF-7 cells, but did not reach statistical significance in 
MDA-MB-231 cells; while overexpression of Sp1 was able to increase the 
hypoxia-induced MIR193BHG expression in both cell lines (Figure 20B). Another 
member of the SP family, Sp3, also binds to GC-rich elements and is shown to 
coordinately function together with Sp1 in both repressive and promotive 
manners [237]. Knocking down Sp3, also significantly mitigated MIR193BHG 
hypoxic response, to an even larger degree than the effect seen with Sp1 siRNA 
in both MCF-7 and MDA-MB-231 cell lines (Figure 20C). 
Together, the aforementioned results indicated that MIR193BHG is not a 
canonical HIF-regulated hypoxia inducible gene. Its hypoxic response is 
restrained by glucose abundance and the GC-rich element in the promoter. GC-
box binding transcription factors Sp1 and Sp3 are involved in the MIR193BHG 
transcriptional regulation in response to oxygen stress. Even though there is no 
evidence of direct HIF binding to MIR193BHG promoter, HIFs, especially HIF-2α 
is highly likely to bind to a distal enhancer element and thus regulated 
MIR193BHG expression via long range chromatin interaction.  
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Figure 20. GC-box-binding transcription factors Sp1 and Sp3 are involved 
in MIR193BHG transcriptional regulation. 
A. Top: Diagram depicts the positions of GC-boxes within MIR193BHG proximal 
promoter. Bottom: MCF-7 or MDA-MB-231 cells were treated with 200nM 
mithramycin A then cultured in normoxia or hypoxia for 24hours. MIR193BHG 
expression was measured by qPCR. Data are shown as mean + SD from three 
biological replicates (*p < 0.05, **p < 0.01, Student’s t-test). 
B. MCF-7 (top) or MDA-MB-231 (bottom) cells were transfected with Sp1 siRNA 
or Sp1 overexpression construct then cultured in normoxia or hypoxia (1% O2) 
condition for 48 hours. MIR193BHG expression was determined by qPCR. Data 
are shown as mean + SD three biological replicates (*p < 0.05, Student’s t-test). 
The effect of the siRNA or overexpression in each experiment were confirmed by 
RT-PCR. Representative results from RT-PCR are shown on top.  
C. MCF-7 (top) or MDA-MB-231 (bottom) cells were transfected with Sp3 siRNA 
then cultured in normoxia or hypoxia (1% O2) for 48hours. MIR193BHG 
expression were determined by qPCR. Data are shown as mean + SD three 
biological replicates (*p < 0.05, Student’s t-test). The effect of the siRNA or 
overexpression in each experiment was confirmed by RT-PCR. Representative 
results from RT-PCR are shown on top.  
  
89 
3.5 TGF-β and MIR193BHG expression 
Transforming growth factor-beta (TGF-β) significantly activates 
MIR193BHG expression however such effect was only observed in selected cell 
lines such as MDA-MB-231. The induction of MIR193BHG by TGF-β is 
comparable to the effect of hypoxia (Figure 21A) and independent from oxygen 
status or glucose availability (Figure 21B). Therefore, it is likely that TGF-β 
regulates MIR193BHG through a separate pathway. So far we do not have any 
evidence supporting if any canonical transcriptional factors in TGF-β signaling 
pathway are involved in MIR193BHG transcriptional regulation.  
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Figure 21. TGF-β induces MIR193BHG expression in MDA-MB-231 cells. 
A. MDA-MB-231 cells were cultured in normoxia or hypoxia (0.2% O2) for 24 
hours with no-FBS medium supplemented with or without 10ng/ml TGF-β. 
MIR193BHG level was detected by qPCR.  
B. MDA-MB-231 cells were cultured in normoxia or hypoxia (0.2% O2) for 24 
hours with indicated no-FBS medium (High glucose: 25mM; low glucose: 5.5mM; 
TGF-β: 10ng/ml). MIR193BHG level was measured by RT-PCR and visualized 
by agarose gel electrophoresis. 18s rRNA level was included as loading control.  
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4. Functional characterization of MIR193BHG 
4.1 Generation of molecular reagents for the study of MIR193BHG 
The molecular reagents to overexpress or knockdown MIR193BHG 
expression were designed based on the sequence and gene structure obtained 
from the genomic characterization of this locus. This task was complicated by the 
presence of multiple isoforms. However, one feature shared by all the transcript 
variants cataloged to date is the start site of the last exon. Even though the 
length of the last exon slightly varies among different transcript variants, the 
majority of this exon is shared across all the variants. This suggested that the last 
exon might be the most indispensable part for a functional transcript from this 
locus. Thus all siRNA and shRNA designed to knockdown this lncRNA target 
different regions of this exon. For transient knockdown of MIR193BHG, we used 
two independent siRNAs. To establish stable cell lines with repressed 
MIR193BHG, we generated shRNA targeting MIR193BHG using vector pLKO.1 
and utilized the lentiviral system to transduce the shRNA into cells.  
For overexpression studies, we chose to clone the transcript that bears 
the closest similarity with GENCODE transcript annotation: ENST00000570945.1. 
Our cDNA clone has the same TSS as ENST00000570945.1. Two slight 
differences are that our cloned sequence contains a 63bp sequence gap in the 
first exon compared to ENST00000570945.1 and the last exon has an additional 
160bp at the 3’ end, which is matched to the second polyA signal. We generated 
MIR193BHG overexpressing cell lines by transfecting cells with MIR19BHG 
construct followed by antibiotic selection.  
The full length cDNA sequence of cloned MIR193BHG and the targeted 
location of each siRNA or shRNA were shown in Figure 22A. The confirmation of 
knockdown by siRNAs/shRNA and overexpression of MIR193BHG is shown in 
Figure 9B and Figure 22B.  
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Figure 22. Molecular reagents for knockdown and overexpression of 
MIR193BHG 
A. Sequence of MIR193BHG cDNA cloned and introduced into cells for 
MIR193BHG overexpression study is shown. The target sequence of two siRNA 
and shRNA are highlighted by the indicated colors.  
B. The knockdown or overexpression in MDA-MB-231 (left) or MDA-MB-468 
(right) stable cell lines was confirmed by RT-PCR. Knockdown of MIR19BHG 
was only tested in hypoxia since the normoxic level of MIR193BHG is too low to 
visualize the difference.  
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4.2 MIR193BHG and clinical outcome of breast cancer patients. 
Analysis of TCGA breast cancer (BRCA) dataset revealed a significantly 
lower level of MIR193BHG in tumor samples compared to normal breast tissue 
(tumor/normal ratio = 0.48, p < 0.0001, Figure 23A), suggesting that MIR193BHG 
may possess some tumor suppressor properties. In order to view the connection 
between MIR193BHG and breast cancer from a clinical perspective, we further 
analyzed the MIR193BHG level in BRCA tumors together with patients’ clinical 
data from TCGA database. MIR193BHG level varied significantly among different 
subtypes of BRCA. Basal-like, the most aggressive subtype of BRCA expresses 
the lowest level of MIR193BHG (Figure 23B). Among the BRCA patients, we 
observed that those whose tumors express a higher level of MIR193BHG tend to 
have better clinical outcome in terms of distant metastasis and tumor stage 
(Figure 23C). Unfortunately, due to the small number of patients in the 
metastasis-positive and higher tumor stage groups, there is not enough statistical 
power to draw a conclusion. 
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Figure 23. MIR193BHG expression in clinical samples and its association 
with clinical data 
A. Expression of MIR193BHG in TCGA normal and tumor breast tissue (p < 
0.0001, Mann-Whitney U test). 
B. Expression of MIR193BHG in different subtypes of BRCA tumors. Statistical 
significance was calculated by one-way ANOVA.  
C. Expression of MIR193BHG in TCGA breast tumors with or without detected 
distant metastasis (left) and in different tumor stages (right).  
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4.3 In vitro assessment of MIR193BHG function 
The observation that patients with tumors expressing a high level of 
MIR193BHG tended to have a lower chance of distant metastasis prompted us to 
examine the impact of MIR193BHG on tumor metastasis in breast cancer. To 
achieve this purpose, we established stable MIR193BHG knockdown or 
overexpression in two metastatic breast cancer cell lines MDA-MB-231 and 
MDA-MB-468. In vitro invasion assay using Matrigel-coated Boyden chamber 
showed that in both cell lines tested, there was a significant increase in invasive 
capability of cells with stable MIR193BHG knockdown compared to the cells 
expressing control shRNA, whereas overexpression of MIR193BHG inhibited cell 
invasiveness (Figure 24A and 24B). Hypoxia has been long recognized as a 
promoting factor for cell invasion in several cancer types. What is noteworthy is 
that under normoxia, knockdown of MIR193BHG was able to increase cell 
invasiveness to a similar level as that observed in the cells exposed to hypoxia.  
We also tested if MIR193BHG level affects cell viability, especially under 
hypoxic conditions. In MCF-7 cells, repression of MIR193BHG by two siRNAs 
significantly increased cell survival under hypoxia, which was measured by either 
cell number count or MTT assay (Figure 25A and 25B). Similar survival-
promoting effect of MIR193BHG knockdown in hypoxia was also observed in 
MDA-MB-231 and SKOV-3 cell lines (Figure 25B). Conversely, cells with ectopic 
expression of MIR193BHG exhibited decreased cell viability compared to the 
empty vector control in all three cell lines mentioned above (Figure 25C). MDA-
MB-231 or MDA-MB-468 cells with stable MIR193BHG knockdown by shRNA 
also showed increased cell viability compared to the shRNA control cell line 
(Figure 25D). Manipulation of MIR193BHG level in normoxia yielded minor 
differences which varied across the three cell lines tested. Cell cycle analysis 
showed that apart from a slight decrease in S phase in MIR193BHG knockdown 
cells, MIR193BHG level did not affect cell cycle (Figure 26A). Under hypoxic 
condition, MDA-MB-231 cells with MIR193BHG knockdown had a significant 
lower percentage of apoptotic cells compared to the siRNA control (Figure 26B). 
However we did not observe a similar result in MCF-7 cells.  
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Figure 24. MIR193BHG represses cell invasion in metastatic breast cancer 
cell lines. 
A. MIR193BHG impact on cell invasion in MDA-MB-231 cells. MDA-MB-231 cells 
with either knockdown or overexpression of MIR193BHG or its related controls 
were plated in Boyden chambers with Matrigel and cultured in normoxia or 
hypoxia (1 O2 %). The cells that invaded through Matrigel were quantified 20hrs 
after plating. Data are shown as mean + SD from three biological replicates (*p < 
0.05, **p < 0.01, Student’s t-test). 
B. MIR193BHG impact on cell invasion in MDA-MB-468 cells. MDA-MB-468 cells 
with either knockdown or overexpression of MIR193BHG or its related controls 
were plated in Boyden chambers with Matrigel and cultured in normoxia or 
hypoxia (1 O2 %). The cells that invaded through Matrigel were quantified 20hrs 
after plating. Data are shown as mean + SD from three biological replicates (*p < 
0.05, **p<0.01, Student’s t-test). 
 
99 
 
  
100 
Figure 25. MIR193BHG decreases cell survival in hypoxia. 
A. MCF-7 cells transfected with 10uM control siRNA or siRNAs targeting 
MIR193BHG were cultured under normoxia or hypoxia (1% O2) for 48hr. 
Representative image of the cells visualized using light microscope is shown on 
the left. The number of viable cells was determined with a hemocytometer 
following trypan blue staining. Data are shown as mean + SD from three 
biological replicates (*p < 0.05, **p < 0.01, one-way ANOVA with Dunnett’s test).  
B. MCF-7, MDA-MB-231 or SKOV3 cells were transfected with MIR193BHG 
siRNAs or control siRNA then cultured under normoxia or hypoxia (1% O2 ) for 48 
or 72 hours. Cell viability was measured by MTT assay. Data are shown as mean 
+ SEM from 3 to 4 independent experiments (*p < 0.05, **p < 0.01, one-way 
ANOVA with Dunnett’s test). 
C. MCF-7, MDA-MB-231 or SKOV3 cells overexpressing MIR193BHG or control 
vector were cultured in normoxia or hypoxia (1% O2) for 48 hours. Cell viability 
was measured by MTT assay. Data are shown as mean + SEM from 3 to 4 
independent experiments (**p < 0.01, Student’s t-test). 
D. MDA-MB-231 or MDA-MB-468 cells with stable expression of MIR193BHG 
shRNA or control shRNA were cultured in hypoxia (1% O2) for 48 hours. Cell 
viability was measured by MTT assay. Data are shown as mean + SEM from 3 to 
4 independent experiments (**p<0.01, Student’s t-test). 
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Figure 26. The effect of MIR193BHG on cell cycle and apoptosis. 
A. MIR193BHG has no significant impact on cell cycle. MCF-7(top) or MDA-MB-
231 (bottom) cells with MIR193BHG knockdown or overexpression were cultured 
in normoxia or hypoxia (1% O2) for 48 hours then harvested for cell cycle 
analysis by flow cytometry. Data are shown as mean + SD from three biological 
replicates (one-way ANOVA with Dunnett’s test for siRNA data, Student’s t-test 
for OE data).  
B. Knockdown of MIR193BHG decreases MDA-MB-231 cell apoptosis in hypoxia. 
MDA-MB-231 cells were transfected with MIR193BHG siRNAs or control siRNA 
then cultured in hypoxia (1% O2) for 48 hours. Cells were then harvested for 
apoptosis analysis by flow cytometry. Data are shown as mean + SD from three 
biological replicates (**p < 0.01, one-way ANOVA with Dunnett’s test).  
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During generation of MIR193BHG stable cell lines we observed that 
MIR193BHG overexpressing cells were more resistant to trypsinization and thus 
often took a longer time to detach from tissue culture plates. We used an 
adapted detachment assay to translate this observation into a quantifiable 
feature. Wells plated with MIR193BHG overexpressing cells had more residual 
cells after trypsinization compared to the vector control (Figure 27A). Using 
xCELLigence system (Roche) which employs an impedance-based method that 
allows dynamic monitoring of cell events including cell attachment in real time, 
we were able to monitor cell attachment in real time after plating. MCF-7 cells 
with MIR193BHG overexpression displayed stronger attachment to the plate 
compared to vector control cells (Figure 27B).  
In summary, MIR193BHG negatively regulates cell invasion and survival 
in hypoxia, which is consistent with our initial speculation that MIR19BHG has 
tumor suppressor properties. The observed impact on cell attachment, although 
not dissected in full detail, is likely to be a contributing factor to MIR193BHG’s 
inhibition on cell invasion.   
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Figure 27. MIR193BHG overexpression increases cell attachment on tissue 
culture plate. 
A. MCF-7, MDA-MB-231 or SKOV3 cells were plated in 96-well plates at 
indicated cell densities then incubated in normoxia for 24 hours. Cells were 
trypsinized with 0.1% Trypsin and the detached cells were washed away. The 
residual cells were quantified by crystal violet staining. Data are shown as mean 
+ SEM from three independent experiments ((*p < 0.05, **p < 0.01, Student’s t-
test). 
B. MCF-7 cells stably expressing MIR193BHG or the control vector were plated 
in xCELLigene E-Plate_16 at indicated cell densities. The extent of cell adhesion 
and spreading was measured in real time and presented as cell index. Data are 
shown as mean + SD from three independent experiments (*p < 0.05, **p<0.01, 
Student’s t-test). 
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4.4 In vivo assessment of MIR193BHG function  
Based on the above in vitro assessment, MIR193BHG appeared to display 
certain characteristics of tumor-suppressor genes, including repression of cell 
survival and invasion. Therefore we were interested in validating the function of 
MIR193BHG in tumorigenesis and metastasis in vivo. To achieve this goal, we 
implanted MDA-MB-231 cells with manipulated expression of MIR193BHG or 
their respective control cells into the mammary fat pad of NSG (NOD scid 
gamma, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. Tumor growth was monitored, 
and lungs and livers were harvested at the endpoint for metastasis assessment.   
Mice that received MIR193BHG knockdown cells presented with a higher 
degree of breast-to-lung and breast-to-liver metastasis compared to the shRNA 
control group (Figure 28A), consistent with our observation in the in vitro invasion 
assay. On the other hand, the MIR193BHG overexpression group showed 
significantly less metastatic burden in both lung and liver compared to the group 
that received cells expressing the control vector (Figure 28B). The discrepancy in 
metastasis was likely not due to tumor progression, since MIR193BHG level 
imposed only a marginal effect on tumor growth in the middle to later stage of 
tumor development (Figure 29A). The weight of the primary tumors harvested 
from mice that received MIR193BHG shRNA transduced MDA-MB-231 cells was 
higher than the tumors from the control group while the weight of metastasized 
organs (lung and liver) showed minimal difference between these two groups 
(Figure 29B). Primary tumor and liver weights of the MIR193BHG overexpressing 
group and its control group  were very similar result, whereas the lungs 
harvested from the MIR193BHG overexpression group weighted slightly less 
than those from the control group (Figure 29B).  
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Figure 28. MIR193BHG inhibits metastasis in breast cancer mouse model. 
A. Representative H&E-stained lung and liver sections from mice implanted with 
MDA-MB-231 cells stably expressing either MIR193BHG_shRNA or control 
shRNA (bars in the top panel, 3mm; bars in the lower panel, 200µm). Percentage 
of metastatic tumor burden over total section area was analyzed using Aperio. 
Data is plotted as mean + SD (* p < 0.05, by Mann-Whitney U test). 
B. Representative H&E-stained lung and liver sections from mice implanted with 
MDA-MB-231 cells stably expressing MIR193BHG or vector (bars in the top 
panel, 3mm; bars in the lower panel, 200µm). Percentage of metastatic tumor 
burden over total section area was analyzed using Aperio. Data is plotted as 
mean + SD (*p < 0.05, **p<0.01, Mann-Whitney U test). 
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Figure 29. MIR193BHG level has marginal influence on primary tumor 
growth. 
A. Tumor growth curve of mice implanted with MDA-MB-231 cells with either 
MIR193BHG knockdown or overexpression or their related controls. Data are 
shown as mean + SD. 
B. Weight (g) of the primary tumors, lungs and livers harvested from mice 
bearing tumors expressing either MIR193BHG knockdown or overexpression and 
their related control groups. Data is plotted as mean + SD.  Statistical 
significance was analyzed by Mann-Whitney U test. 
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Interestingly, several studies have shown that the intronic microRNA, 
miR193b is a tumor suppressor and is downregulated in several types of cancer 
[246-249]. However, miR193b level in the xenografts developed from either 
MIR193BHG knockdown or overexpressing cells was virtually unchanged 
compared to that in their respective control groups. As expected, the knockdown 
or overexpression of MIR193BHG was maintained in the xenografts (Figure 30). 
This suggested that the impact on tumor metastasis was mediated by 
MIR193BHG, rather than the embedded miR193b.  
 
 
Figure 30. MIR193BHG and miR193b expression in tumor xenografts. 
A. MIR193BHG and miRNA193b levels in tumors from mice that received MDA-
MB-231 cells expressing MIR193BHG shRNA or control shRNA were measured 
by qPCR. Data is plotted as mean + SD (**p < 0.01, by Student’s t-test). 
B. MIR193BHG and miRNA193b levels in tumors from mice implanted with MDA-
MB-231 cells overexpressing MIR193BHG or control vector were measured by 
qPCR. Data is plotted as mean + SD (**p < 0.01, by Student’s t-test). 
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5. Mechanistic insights into MIR193BHG function 
5.1 Inference of MIR193BHG-associatedpathway from in vivo correlation 
Our first strategy to uncover the molecular mechanism underlying 
MIR193BHG function involved the correlation coefficient between MIR193BHG 
and all the protein-coding genes with known functional annotation, calculated 
from 935 breast cancer tumor samples recorded in TCGA database. We first 
ranked the coding genes by their expression correlation with MIR193BHG then 
used GSEApreranked to determine the pathways associated with MIR193BHG 
expression. This analysis revealed that genes positively correlated with 
MIR193BHG were enriched in several classical cancer-related pathways, 
including epithelial mesenchymal transition (EMT), p53 pathway and apoptosis 
(Figure 31A). Several cell metabolism pathways including fatty acid metabolism, 
glycolysis and bile acid metabolism also showed significant enrichment in 
MIR193BHG-correlated genes. The hypoxia geneset was also a positively 
associated pathway but was not the most prominent one. This is consistent with 
our early observation that MIR193BHG was correlated with several hypoxia 
signature genes but the strength of such correlation was not as strong as some 
canonical HIF regulated genes (Figure 10A). One intriguing outcome from the 
analysis was the potential involvement of TGF-β signaling pathway in 
MIR193BHG expression and function. Our earlier study showed that in some cell 
lines, MIR193BHG is markedly induced by TGF-β, independently of the oxygen 
status (Figure 21). Thus, this unexpected result indicated that there might be an 
intricate link between MIR193BHG and TGF-β signaling pathway. We also 
applied the same strategy to a specific subtype of breast cancer – triple-negative 
breast cancer (TNBC). Using the expression correlation calculated from 84 
TNBC samples, we observed the reoccurrence of several cell metabolic 
pathways, including fatty acid metabolism and bile acid metabolism pathways 
(Figure 31B). The positive association between the hypoxia geneset and 
MIR193BHG-correlated genes was much more prominent in TNBC data 
compared to BRCA data, likely due to the highly hypoxic nature of TNBC.  
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The analysis using the in vivo correlation revealed the molecular programs 
in which MIR193BHG is potentially integrated. The result indicated that apart 
from the classical cancer-associated pathways, MIR193BHG is also likely 
involved in the metabolic reprogramming in tumors. This analysis also shed lights 
on the potential feedback signals that MIR193BHG participates.  
 
  
113 
 
  
114 
Figure 31. GSEApreranked analysis of MIR193BHG-correlated coding 
genes. 
Expression correlation between MIR193BHG and coding genes was calculated 
from 935 BRCA (A) or 84 TNBC (B) samples from TCGA database. The 
MIR193BHG-correlated genes were first ranked by the correlation coefficient 
then subjected to GSEApreranked analysis. The NES (normalized enrichment 
score) of the enriched hallmark genesets (FDR < 0.1) was plotted. The color of 
bar represents negative of Log10 transformed normalized p-value. 
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5.2 RNAseq followed by pathway analysis revealed the connection between 
MIR193BHG and cholesterol biosynthesis. 
In order to better understand the molecular mechanisms governing the 
observed MIR193BHG functions and to identify the cellular pathways that are 
altered upon MIR193BHG activation or repression, we performed full 
transcriptome profiling of MIR193BHG knockdown or overexpressed MCF-7 cells. 
Total RNA was isolated from MCF-7 cells transfected with either MIR193BHG 
siRNA or control siRNA then cultured for 24 hours in hypoxia. MIR193BHG 
knockdown by siRNA was validated before the samples were subjected to 
RNAseq (Figure 32A). We identified 1112 differentially expressed genes (FDR < 
0.05), consisting of 517 upregulated and 595 downregulated genes (Figure 32B). 
The neighboring genes MKL2 and PARN were not affected by MIR193BHG 
knockdown (Figure 32C), suggesting MIR193BHG acts upon other genes 
through a trans mechanism. Among all the genes that were significantly affected 
by MIR193BHG knockdown, only ~20% exhibited a fold change ≥2 or ≤ 0.5. This 
prompted us to focus on the coordinated changes in pathways rather than 
individual genes. Both GSEA and Ingenuity Pathway Analysis (IPA) revealed a 
striking association between MIR193BHG knockdown and cholesterol 
metabolism (Figure 33A and 33B). Mammalian cells synthesize cholesterol 
through a series of 21 enzymatic steps. We undertook a further examination of 
the 21 genes encoding enzymes involved in cholesterol synthesis and found that 
most of these genes showed a general trend of upregulation in MIR193BHG 
siRNA transfected cells, more than one third of which had a significant increase 
in RNA level compared to that in the control siRNA cells (Figure 33C and 33D). 
Using AmpliSeq followed by GSEA analysis, we confirmed an activation of 
cholesterol homeostasis pathways with MIR193BHG knockdown in another 
breast cancer cell line MDA-MB-468 cultured in hypoxia (Figure 34A). Similar 
pathway-wide upregulation of cholesterol synthesis genes was also observed in 
MDA-MB-468 cells transfected with MIR193BHG siRNA from AmpliSeq data 
(Figure 34B). Upregulation of a few selected genes in the cholesterol synthesis 
pathway was also tested by qPCR in three breast cancer cell lines with different 
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MIR193BHG knockdown approaches (Figure 35A and 35B). We confirmed that 
the increased expression of HMGCR, HMGCS1, MVD, LSS and MSMO1 
observed in cells with MIR193BHG transient knockdown could be duplicated in 
the tumor xenografts derived from MDA-MB-231 cells with stable knockdown of 
MIR193BHG. Interestingly, SQLE showed an opposite changes in MDA-MB-231 
compared to the other two breast cancer cell lines (Figure 35C).  
On the other hand, we analyzed MIR193BHG overexpressing MCF-7 cells 
using similar approach. Total RNA was extracted from MCF-7 cells stably 
overexpressing MIR193BHG or control vector then subjected to RNAseq (Figure 
36A and 36B). Subsequent analysis using IPA and GSEA revealed a 
downregulation of the cholesterol synthesis pathway in MIR193BHG 
overexpression samples (Figure 36C and 36D). However, expression changes of 
individual genes in the cholesterol synthesis pathway was more subtle and less 
consistent compared to that observed in MIR193BHG knockdown data (Figure 
37A and 37B). In MIR193BHG overexpressing MDA-MB-231 cells and 
corresponding tumor xenografts, we did not detect significant changes in 
individual gene expression compared to the control cells or tumors.  
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Figure 32. RNAseq of MCF-7 cells transfected with MIR193BHG siRNA or 
control siRNA then cultured in hypoxia for 24 hours 
A. Knockdown of MIR193BHG by siRNA in the MCF-7 cells used in RNAseq was 
confirmed by qPCR in each biological replicate.  
B. Heatmap showing differentially expressed genes (FDR < 0.05) in MCF-7 cells 
transfected with MIR193BHG siRNA versus control siRNA. 
C. RNAseq track showing expression of MIR193BHG and its neighboring genes 
in MCF-7 cells transfected with MIR193BHG siRNA or control siRNA.  
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Figure 33. Pathway analysis revealed that the cholesterol synthesis 
pathway was upregulated in MCF-7 cells upon MIR193BHG knockdown. 
A. IPA analysis of differentially expressed genes between MCF-7 cells 
transfected with MIR193BHG siRNA versus control siRNA revealed by the 
RNAseq. Cholesterol synthesis-related pathways are marked with red rectangles.  
B. Left: Significantly enriched hallmark genesets in MCF-7 cells with MIR193BHG 
knockdown versus the control from GSEA. Right: Enrichment plots showing 
enrichment of cholesterol homeostasis geneset in MCF-7 with MIR193BHG 
knockdown. 
C. Heatmap showing expression of genes in cholesterol synthesis pathway in 
MCF-7 cells transfected with either MIR193BHG siRNA or siRNA control. A 
schematic diagram of cholesterol synthesis pathway is shown on the left, genes 
which showed significantly increased expression in MIR193BHG knockdown 
versus control are marked in red.  
D. RNAseq track showing expression of HMGCR, HMGCS1, MSMO1 and SQLE 
in MCF-7 cells transfected with MIR193BHG siRNA or control siRNA.  
 
120 
 
 
Figure 34. AmpliSeq followed by pathway analysis showed that cholesterol 
synthesis pathway was activated in MDA-MB-468 cells with MIR193BHG 
knockdown. 
A. Left: Significantly enriched hallmark genesets in MDA-MB-468 cells with 
MIR193BHG knockdown versus the control from GSEA. Right: Enrichment plots 
showing enrichment of cholesterol homeostasis geneset in MDA-MB-468 with 
MIR193BHG knockdown. 
B. Heatmap showing expression of genes in the cholesterol synthesis pathway in 
MDA-MB-468 cells transfected with MIR193BHG siRNA or siRNA control.  
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Figure 35. Genes in cholesterol synthesis pathway were upregulated in 
MIR193BHG inactivated cells and tumor xenografts. 
A. MCF-7, MDA-MB-231 and MDA-MB-468 cells were transfected with either 
MIR193BHG siRNA or control siRNA then cultured in hypoxia for 24 hours. 
Expression of HMGCR, HMGCS1, MVD, SQLE, LSS and MSMO1 in these 
samples was measured by qPCR. 
B. MDA-MB-231 and MDA-MB-68 cells with stable expression of MIR193BHG 
shRNA or control shRNA were cultured in hypoxia for 24 hours. Expression of 
HMGCR, HMGCS1, MVD, SQLE, LSS and MSMO1 was measured by qPCR. 
C. Expression of HMGCR, HMGCS1, MVD, SQLE, LSS and MSMO1 in tumor 
xenografts developed from MDA-MB-231 cells with stable knockdown of 
MIR193BHG or control cells was measured by qPCR. Data is plotted as mean + 
SD (*p < 0.05, **p < 0.01, Student’s t-test). 
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Figure 36. RNAseq and pathway analysis of MCF-7 with stable 
overexpression of MIR193BHG or control vector. 
A. Overexpression of MIR193BHG in the MCF-7 cells used in RNAseq was 
confirmed by qPCR in each biological replicate.  
B. Heatmap showing differentially expressed genes (FDR < 0.05) in MCF-7 cells 
overexpressing MIR193BHG versus control vector.  
C. IPA analysis of differentially expressed genes between MCF-7 cells 
overexpressing MIR193BHG versus control vector revealed by the RNAseq. 
Cholesterol synthesis-related pathways are marked with red rectangles.  
D. Left: Significantly enriched hallmark genesets in MCF-7 cells with 
MIR193BHG overexpression versus the control from GSEA. Right: Enrichment 
plot showing negative association of cholesterol homeostasis gene set in 
MIR193BHG overexpressing samples. 
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Figure 37. Expression of genes in cholesterol synthesis pathway in 
MIR193BHG overexpressing cells. 
A. Heatmap showing expression of genes in cholesterol synthesis pathway in 
MCF-7 cells with MIR193BHG overexpression versus control vector.  
B. RNAseq track showing expression of HMGCR, HMGCS1, MSMO1 and SQLE 
in MCF-7 with stable overexpression of MIR193BHG or control vector. 
C. Expression of HMGCR, HMGCS1, MVD, SQLE, LSS and MSMO1 was 
measured by qPCR in MCF-7 (top) or MDA-MB-468 (bottom) with MIR193BHG 
overexpression or control vector.  
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We measured cellular total cholesterol content as another assessment of 
the cholesterol synthesis pathway activity. MDA-MB-231 cells with MIR193BHG 
knockdown has slightly higher total cholesterol content compared to the control 
cells, whereas both MIR193BHG-overexpressing MDA-MB-231 and MCF-7 cells 
contained less total cholesterol then the cells expressing the control vector 
(Figure 38A). In order to explore the connection between cholesterol content and 
MIR193BHG expression from an in vivo perspective, we found matched 
metabolomics profiles for 18 of the BRCA patients’ tumors of which we also had 
the MIR193BHG expression data. MIR193BHG level and cholesterol content in 
these samples exhibited an inclination towards negative correlation. However, 
the sample size was too small to make a statistically valid conclusion (Figure 
38B).  
Taken together, our results indicate that MIR193BHG is a negative 
regulator of cholesterol biosynthesis activity. This revelation provides a potential 
explanation for why organs such as liver and adrenal gland have lower levels of 
MIR193BHG expression. In an ideal scenario, we would further evaluate the 
correlation between MIR193BHG level and the cholesterol synthesis rate in 
different tissues to support this notion. Unfortunately, we could not find such 
tissue-specific cholesterol synthesis rate data in human tissues. However, we 
were able to find similar data for several animals including squirrel monkey 
(Saimiri sciureus), in which the sterol/cholesterol synthesis rate was measured as 
3H incorporation into digitonin-precipitable sterols (DPS) 1 hour after 
administrating 3H water to the animals [250]. Under the assumption the monkey 
and human have similar relative tissue sterol/cholesterol synthesis rates across 
tissues, we plotted MIR193BHG level (human tissue) against sterol synthesis 
rate (squirrel monkey) of the 10 tissues that we could find matched entries in 
both datasets. The plot indicated a potential negative correlation between 
MIR193BHG level and the tissue sterol synthesis rate (Figure 38C). However, 
due to the small tissue numbers and the ties in MIR193BHG expression in 
several organs, the correlation (Spearman) did not reach significant level.  
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Figure 38. MIR193BHG level is negatively correlated with total cholesterol 
content. 
A. Total cholesterol in MDA-MB-231 cells with MIR193BHG overexpression or 
knockdown (top) or MIR193BHG overexpressing MCF-7 cells and the related 
controls was quantified using Wako Cholesterol assay and presented as ug 
cholesterol per mg protein. Cells treated with simvastatin (1uM) or DMSO control 
were included as a positive control for the assay. Data represents mean + SD 
from three biological replicates (*p < 0.05, **p<0.01, Student’s t-test). 
B. MIR193BHG level was plotted against cholesterol content in 18 BRCT tumors. 
Pearson correlation and p-value are reported.  
C. Human tissue-specific MIR193BHG level was plotted against tissue sterol 
synthesis rate in 10 monkey tissues. Sterol synthesis rate was quantitated by 3H 
incorporation into digitonin-precipitable sterols (DPS) 1 hour after administration 
of 3H water to the animals.  
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5.3 MIR193BHG modulates cell survival and invasion via cholesterol 
biosynthesis pathway 
Cholesterol, as a component of cell membranes and the obligatory 
precursor for steroid hormones, has been shown to be involved in cancer cell 
growth and metastasis and implicated as a breast cancer risk factor [213, 251-
253].  Based on this connection, we hypothesized that the knockdown of 
MIR193BHG promotes cell invasion and cell survival in hypoxia through its 
activation of the cholesterol synthesis pathway. Under such hypothesis, blocking 
the cholesterol synthesis pathway, which is the channel for MIR193BHG to carry 
out its function, could alleviate the increase in cell invasiveness and viability. 
Simvastatin is one of the statin class of drugs which are used to lower cellular 
cholesterol level by inhibiting the rate-limit enzyme HMG-CoA reductase 
(HMGCR). In the presence of simvastatin, both MDA-MB-231 and MDA-MB-468 
cells with stable MIR193BHG knockdown lost their previous significant 
advantage in cell invasion ability and survival in hypoxia over the control cells 
(Figure 39).  
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Figure 39. Blocking cholesterol synthesis with statin antagonized the 
functions of MIR193BHG knockdown. 
A. MDA-MB-231 (top) or MDA-MB-468 (bottom) cells with stable expression of 
MIR193BHG shRNA or control shRNA were plated in Boyden chamber with 
Matrigel in the presence of either 1uM simvastatin or DMSO control. The cells 
that invaded through Matrigel were quantified 20 hours after plating. Data are 
shown as mean + SD from three biological replicates (*p < 0.05, **p < 0.01, 
Student’s t-test). 
B. MDA-MB-231 (top) or MDA-MB-468 (bottom) cells with stable expression of 
MIR193BHG shRNA or control shRNA were cultured in hypoxia (1% O2) for 48 
hours in the presence of simvastatin or DMSO control. Cell viability was 
measured by MTT assay. Data are shown as mean + SEM from 3 independent 
experiments (**p < 0.01, Student’s t-test). 
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5.4 Sex maturation and adult height associated SNPs are located in close 
proximity to MIR193BHG. 
Genome-wide association studies (GWAS) have reported several genomic 
loci associated with sexual development, puberty timing and adult stature in the 
vicinity of MIR193BHG. Rs246185, located only 963bp upstream of MIR193BHG 
TSS, is significantly associated with delayed puberty onset (menarche in 
women/age at voice breaking in men) and diminished growth during puberty 
[254-256]. The Genotype-Tissue Expression (GTEx) project data showed that, at 
least in muscle tissue, MIR193BHG expression is significantly correlated with the 
rs246185 genotype (p = 1.6x10-6) (Figure 40A). Rs246185 reference allele (T) is 
associated with early puberty onset and a lower expression level of MIR193BHG. 
Without the awareness of the existence of MIR193BHG, all previous GWAS 
connected rs246185 with its nearly coding gene MKL2 and struggled to explain 
the association of rs246185 with puberty timing as MKL2’s currently known 
function has no connection with puberty onset. Moreover MKL2 expression has a 
much weaker correlation with the rs246185 genotype compared to MIR193BHG 
(Figure 40A). Rs193536, located 1.3kb upstream of MIR193BHG TSS, has been 
reported to have strong association with male genital stage [257]. Further 
upstream at ~8.1kb from MIR193BHG TSS, another SNP rs1659127 has been 
shown to be associated with adult height in the large meta-analysis by the GIANT 
Consortium [258]. Both of these two SNPs are in high linkage Disequilibrium (LD) 
with rs246185 and their allele genotypes display a significant correlation with 
MIR193BHG level in muscle tissue (Figure 40B and 40C).  
Our study revealed that MIR193BHG is a negative regulator of cholesterol 
synthesis, which serves as the common precursor to all steroid hormones 
synthesis. Therefore, the function of MIR193BHG could potentially offer a more 
rational explanation to the abovementioned sex maturation and adult stature-
associated SNPs.  
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Figure 40. Three sex maturation and height associated SNPs are located in 
vicinity of MIR193BHG TSS. 
A. eQTL box plot showing genotype-expression relationships between rs246185 
and MIR193BHG (left) or MKL2 (right).  
B. Regional LD plot showing the SNPs in MIR193BHG promoter region. Three 
sex maturation and height associated SNPs, rs246185, rs1659127 and rs193536 
are marked in red.  
C. eQTL box plot showing genotype-expression relationships between rs193536 
(left) or rs1659127 (right) and MIR193BHG.  
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5.5 Molecular mechanism underlying MIR193BHG modulation of 
cholesterol biosynthesis genes 
Next, we sought to answer how MIR193BHG influences gene expression 
in the cholesterol biosynthesis pathway. Using bromouridine (BrU) labeling of 
nascent RNA followed by anti-BrU-RNA immunoprecipitation (Figure 41A), we 
were able to demonstrate that MIR193BHG regulates cholesterol biosynthesis 
genes mainly at the transcriptional level. Under hypoxia, MCF-7 cells with 
MIR193BHG knockdown synthesized significantly more RNA of HMGCR, 
HMGCS1 and SQLE within the 30min BrU labeling time, indicating an increased 
transcription rate of cholesterol biosynthesis genes in MIR193BHG knockdown 
cells compared to the control cells, whereas MIR193BHG transcription rate 
remained the same (Figure 41B). We also measured RNA stability of HMGCR, 
HMGCS1 and SQLE in cells with either MIR193BHG knockdown or 
overexpression to confirm that RNA stability contributed little to the observed 
differential expression of cholesterol biosynthesis genes (Figure 41C).  
Sterol regulatory element binding proteins (SREBPs) are transcription 
factors that directly activate the expression of genes in cholesterol and fatty acid 
metabolism. SREBP-2 is the isoform that is preferentially required for regulating 
cholesterol synthesis. However, neither the RNA nor protein level of SREBP-2 
was affected by MIR193BHG levels (Figure 42A). Using SREBP-2 transcription 
factor assay kit (Cayman Chemical #10007819) we also confirmed that there was 
no significant changes in SREBP-2 DNA binding activity in cells with different 
MIR193BHG level (Figure 42B). These results indicated that MIR193BHG 
regulation of cholesterol biosynthesis genes was not, at least not directly, through 
SREBP-2.  
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Figure 41. MIR193BHG knockdown increases transcription rate of genes 
involved in cholesterol biosynthesis. 
A. Diagram illustrating the main steps in BrU-RNA Immunoprecipitation: BrU was 
added to the cell culture for 30min to label the nascent RNA synthesized within 
this time period. Total RNA was extracted and BrU-labeled RNA was recovered 
by magnetic beads coated with anti-BrU antibody. BrU-RNA as well as 10% of 
the total RNA was subjected to qPCR analysis. 
B. MCF-7 cells transfected with MIR193BHG siRNA or control siRNA were 
cultured in hypoxia for 24 hours then 2mM BrU was added to label newly 
synthesized RNA. The RNA level of HMGCR, HMGCS1, SQLE and MIR193BHG 
were analyzed by qPCR. Data represents mean + SD from three biological 
replicates (*p < 0.05, **p<0.01, Student’s t-test). 
C. RNA stability of HMGCR, HMGCS1 and SQLE in MCF-7 cells with 
MIR193BHG knockdown (hypoxia) or MCF-7 cells with MIR193BHG 
overexpression was quantified by measuring the decline in transcript levels after 
actinomycin D treatment. Data represents mean + SD from three biological 
replicates. 
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Figure 42. MIR193BHG does not affect SREBP-2 level and DNA binding 
activity. 
A. MIR193BHG has no significant impact on SREBP-2 RNA and protein level. 
SREBP-2 RNA in MCF-7 cells with MIR193BHG knockdown or overexpression 
measured by RNAseq analysis is presented on the left. SREBP-2 protein level in 
MCF-7 cells with MIR193BHG knockdown or overexpression was measured by 
western blot.  
B. SREBP-2 DNA binding activity in MCF-7/MDA-MB-231 cells with MIR193BHG 
overexpression or MDA-MB-231 cells with MIR193BHG knockdown was 
measured by SREBP-2 transcription factor assay kit. Data represents mean + SD 
from three biological replicates and statistical significance was analyzed by 
Student’s t-test.  
  
141 
From the moment a RNA transcript is transcribed by an RNA polymerase 
to its ultimate degradation, it is constantly accompanied by proteins which serve 
as influential partners in every stage of its life. As for lncRNAs, diverse proteins 
have been proved to be influential partners in their functional machinery. Thus, in 
order to better understand the mechanism through which MIR193BHG exert its 
effect on cholesterol synthesis, it is critical to isolate the complex that 
MIR193BHG is involved in, which could potentially contain protein, RNA and 
DNA. We employed a RNA pulldown system termed MS2-TRAP (tagged RNA 
affinity purification) developed by our collaborator Dr. Myriam Gorospe’s group 
[259, 260]. This method involves concomitant expression of GST-tagged MS2-
BP and MS2-binding-site-tagged lncRNA, allowing the binding process to occur 
in living intact cells prior to lysis. MS2-binding site is a series of copies of hairpin 
loop-structured RNA sequences inserted at the 3’ end of the lncRNA of interest. 
This hairpin loop-structured RNA sequences, commonly referred as MS2, is a 
19-nucleotide long bacteriophage RNA sequence that can be recognized with 
high specificity and affinity by MS2-BP. The RNA-protein complex, together with 
the GST-tagged MS2-BP, is precipitated using GST pulldown (Figure 43A).  
The MS2 tag did not seem to interfere with MIR193BHG function as 
MIR193BHG_MS2 construct transfected MCF-7 cells had a reduced amount of 
HMGCR mRNA compared to MS2 empty vector transfected cells, which was 
similar to our previous data in MIR193BHG overexpressing MCF-7 cells (Figure 
43B). In the precipitated RNA-protein complex, as expected, we detected a 
significant enrichment of MIR193BHG RNA (Figure 43C). The pulldown samples 
were further sent for mass spectrometry analysis to identify the protein 
components. The absence of SREBP-2 in the pulldown samples further 
supported our initial speculation that MIR193BHG’s impact on genes expression 
in cholesterol biosynthesis pathway is not directly through SREBP-2 (Figure 43D).  
Mass spectrometry analysis identified multiple RNA transcription 
regulatory proteins in the precipitated MIR193BHG RNA-protein complexes. 
Interestingly, transcription repressor TRIM28/KAP1, TRIM28-interacting partners 
(CBX3 and CBX5), as well as the small ubiquitin-like modifier (SUMO) which 
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modifies TRIM28 to facilitate its interaction with other complex such as NuRD, 
were concomitantly present in the MIR193BHG_MS2 pulldown complex but not 
in the MS2 control. This result further supported previous observation that 
MIR193BHG regulates cholesterol biosynthesis genes at transcriptional level.  
From the MS2 pulldown material, we also detected the presence of 
several heterogeneous nuclear riboproteins (hnRNP), including hnRNPA2B1, 
hnRNPA1 and hnRNPC, which belong to a major class of splicing factors [261]. 
So far, we were able to confirm the presence of hnRNPC in the MIR193BHG 
RNA-protein complex (Figure 43D). Interaction of hnRNPC and MIR193BHG was 
also predicted using the catRAPID algorithm [262] and experimentally captured 
in HeLa cells using iCLIP (individual-nucleotide resolution Cross-Linking and 
Immunoprecipitation) [263]. There is evidence that alternative splicing may be 
another regulatory mechanism for regulating genes in the cholesterol 
biosynthesis and uptake pathways [191]. The best-documented example of 
alternative splicing events in cholesterol biosynthesis genes is the case of 
HMGCR. Alternative splicing of exon 13 of HMGCR generates a second 
transcript designated as HMGCR13(-), from which the resulting HMGCR protein 
cannot catalyze the conversion of HMG-CoA to mevalonate [264-266]. In 
MIR193BHG-protein complex, we observed a slight enrichment of the 
unprocessed HMGCR transcript (Figure 44A). Therefore we used primers 
specifically designed to detect HMGCR13(-) to evaluate the ratio of HMGCR13(-
)/total HMGCR mRNA in cells with different MIR193BHG expression status 
(Figure 44B). Both MCF-7 and MDA-MB-231 cells with MIR193BHG knockdown 
exhibited a slightly decreased ratio of HMGCR13(-) to total HMGCR mRNA, 
whereas MIR193BHG overexpressing cells showed the opposite effect. However, 
most of the difference described above was not significant (Figure 44C). In the 
tumor xenografts developed from MDA-MB-231 cells with stable MIR193BHG 
knockdown, we did see a significant decrease in the ratio of HMGCR13(-) to total 
HMGCR mRNA compared to the control samples while MIR193BHG 
overexpressing tumors showed a trend toward increase in this ratio which did not 
reach statistical significance (Figure 44D).  
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Based on our current results, we proposed a model in which MIR193BHG, 
through its interaction with multiple transcription and splicing regulatory protein 
factors, downregulates the expression of genes in the cholesterol synthesis 
pathway (Figure 45). However, at this time, we do not have sufficient information 
to address how much each mechanism contributes to the observed total outcome.  
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Figure 43. Detection of components in MIR193BHG RNA-protein complex 
using MS2-tagged RNA affinity purification. 
A. Schematic of MS2-tagged RNA affinity purification. 
B. MS2 tag did not interfere with MIR193BHG function. HMGCR expression in 
MCF-7 cells transfected with pMS2 vector or MIR193BHG_MS2 was detected by 
qPCR.  
C. The relative enrichment of MIR193BHG RNA in the precipitated complex was 
measured by qPCR. GAPDH RNA was included as a negative control. Data 
represents mean + SD from three biological replicates. 
D. The level of SREBP-2, hnRNPC and MS2-GST in the MS2 pulldown material 
and input lysate were detected by western blot.  
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Figure 44. MIR193BHG expression and HMGCR alternative splicing. 
A. The relative enrichment of HMGCR pre-mRNA in the precipitated complex 
was measured by qPCR. GAPDH RNA was included as negative control. Data 
represents mean + SD from three biological replicates. 
B. Schematic demonstration of HMGCR alternative splicing and the design of the 
primers for detection of HMGCR13(-).  
C. MCF-7 or MDA-MB-231 cells transfected with MIR193BHG siRNAs or control 
siRNA were cultured in hypoxia (1% O2) for 48 hours. MCF-7 or MDA-MB-231 
cells overexpressing MIR193BHG or control vector were cultured in normoxia for 
48 hours.  The level of HMGCR13(-) and total HMGCR mRNA were measured by 
qPCR and the ratio of HMGCR13(-) to total HMGCR mRNA was calculated for 
each condition. Data are shown as mean + SD from three biological replicates 
(one-way ANOVA with Dunnett’s test for siRNA set; Student’s t-test for OE set, 
*p < 0.05). 
D. The level of HMGCR13(-) and total HMGCR mRNA in tumor xenografts with 
MIR193BHG knockdown or overexpression were measured by qPCR. The ratio 
of HMGCR13(-) to total HMGCR mRNA was calculated in each sample. Data are 
shown as mean + SD from five tumors per group (*p < 0.05, Student’s t-test). 
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Figure 45. A schematic illustration of the proposed molecular mechanism 
of MIR193BHG’s function.  
 A model describing how MIR193BHG regulates the genes in cholesterol 
synthesis pathway was proposed based on current results. As the oxygen level 
decreases, lncRNA MIR193BHG expression is induced. MIR193BHG, through 
interaction with several transcription and splicing regulatory protein factors, 
downregulates the expression of genes in the cholesterol synthesis pathway 
which leads to the reduction in total cholesterol content in the cell.  
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Chapter IV. Discussion 
 
Our project has identified a hypoxia-induced lncRNA, MIR193BHG, from a 
previously overlooked genomic locus. Although currently named as a miRNA 
host gene, we have provided evidence suggesting that MIR193BHG functions 
beyond the presumed role of a miRNA precursor transcript. Apart from being a 
non-canonical hypoxia responsive gene, MIR193BHG further surprised us with 
its regulatory role in cholesterol metabolism and tumor metastasis. In this section, 
we will discuss the results presented in the last chapter, with focus on the data 
interpretation, limits in our experimental design, as well as the merits and limits of 
the methods we chose.   
 
1. Hypoxia-induced MIR193BHG and its genomic characterization 
1.1 Identify hypoxia-inducible lncRNAs from RNAseq data  
This project started with sifting through millions of RNA reads in an 
attempt to identify a functional noncoding transcript that is regulated by hypoxia. 
Since pervasive transcription is a confirmed feature of human genome, then the 
first challenge in our investigation would be how to distinguish functional 
lncRNAs from ‘noisy’ inconsequential transcription, such as from unconstrained 
promoters that have arisen serendipitously in genomic sequence. This question 
cannot be confidently answered in a genome-wide scale until we have 
accumulated extensive evidence of functional lncRNAs with well-dissected 
molecular mechanisms. However, this issue can be addressed experimentally at 
the individual lncRNA level following certain rationales such as: (a) RNA 
transcript arising from transcriptional noise would be unlikely to vary from one 
tissue to other; (b) under stimulation, its expressional response would echo the 
general response from its neighboring genomic loci; (c) a functional transcript 
would present at a detectable level. In the case of MIR193BHG, (a) it displayed a 
tissue-specific expression pattern distinct from its neighboring genes (Figure 
13A); (b) it is induced in hypoxia while the neighboring genes remain unchanged 
(Figure 11A); (c) its expression, at least in hypoxia, can be detected by qPCR 
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within a reasonable cycle number. These criteria would not guarantee a 
biological meaningful function in the lncRNA of choice, but they effectively 
shorten the list of potential lncRNA candidates.  
Our initial attempt in identifying hypoxia-induced lncRNAs was performed 
with a set of ‘salvaged’ RNAseq data generated from MCF-7 cells transfected 
with scramble oligonucleotides. Although only a limited number of lncRNAs came 
out of our first analysis, several of the top candidates, including MIR193BHG 
were confirmed in our later attempt with a more accurately designed 
experimental setup. Several previously confirmed hypoxia-induced lncRNAs also 
appeared on our list, which gave us confidence as to the quality of our RNAseq 
data. 
 
1.2 The confusing lncRNA gene nomenclature 
Another challenge/confusion we encountered during this project is a lack 
of a comprehensive and unified lncRNA annotation resource. Compared to the 
protein coding genes, lncRNA research is still in an early stage epitomized by a 
fast explosion in the number of lncRNA and lncRNA annotation databases. Apart 
from employing various high throughput sequencing data and assembly 
strategies, many studies even constructed their own non-coding transcriptome 
catalog from a specified cell type or a biological condition [267, 268]. Given the 
fact that lncRNAs have a much higher tissue-specific expression pattern, this 
dramatically increases the complexity of the current lncRNA annotation system. 
To date, there is at least 24 lncRNA annotation resources referring to >205,000 
lncRNAs in over 50 tissues and cell lines [269]. Even in our study, we used at 
least 3 different sets of lncRNA annotation: an early map of lncRNAs generated 
based on chromatin status; LNCipedia, an integrated database that went through 
several updates during our project time; GENCODE (V19), a more conservative 
annotation of 13,869 independent lncRNA genes by merging computationally 
derived Ensembl models of human genome and manually annotated Human and 
Vertebrate Analysis and Annotation (HAVANA).  
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A significant portion of the annotation is overlapped between resources, 
however, a great number of lncRNAs are cataloged under different names in 
different annotation databases. The current practice of renaming a lncRNA after 
a particular function or association with a specific disease by the authors who 
first reported it, only further increases the confusion and ambiguity in the field. 
This is why we are in favor of referring to a lncRNA by its name in a widely used 
resource such as GENCODE, or naming lncRNA based on its genomic context 
which is a constant feature across cell types and conditions. Multiple 
designations of one lncRNA are also a nuisance when searching through publicly 
available datasets. Access to an enormous amount of public data provides great 
momentum in researching newly identified lncRNAs, however the trick is to know 
all of the aliases of the same gene. In the case of MIR193BHG, we have 
encountered the following designation across several databases and datasets, all 
referring to the same locus: lnc-MKL2-1; ENSG00000262454.1, 
ENST00000570945.1, RP11-65J21.3, LOC100129781, 100129781, 
ILMN_3273229 (Illumina probe ID).  
 
1.3 Validation of MIR193BHG as a hypoxia-induced transcript.  
After the initial identification, we further validated MIR193BHG’s induction 
by hypoxia in cell lines from multiple sources, including some widely used cancer 
cell lines, patient-derived cancer cell lines as well as two non-tumorigenic cell 
lines. In addition to the criteria described in Chapter III.1.2, a universal response 
to hypoxia across cell lines was also one of our guidelines when narrowing down 
the list of candidate lncRNAs. In all the cell lines we tested, MIR193BHG 
exhibited a consistent induction by hypoxia, except in two glioblastoma cell lines 
U-118 (Figure 8A) and U87 (data not shown). A tissue-specific transcriptional 
control system and perhaps a highly hypoxia-resistant phenotype of these 
glioblastoma cell lines are behind the unresponsiveness to hypoxia. Interestingly, 
in a pilot lncRNA study, we identified a lncRNA (lnc424) that is only induced by 
hypoxia in glioblastoma cell lines. Although not induced by hypoxia in vitro, 
MIR193BHG did show a positive correlation with hypoxia signature genes in 
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GBM tumor samples and the strength of the correlation is comparable to the 
ones observed in other tumor types such as lung adenocarcinoma (Figure 10A).  
Using data from TCGA, we further investigated the association between 
MIR193BHG and intratumoral hypoxia. This analysis was based on previous 
publications that presented the method of using hypoxia signature genes 
expression to evaluate in vivo hypoxia [217]. However, we have to point out that 
a direct association between expression of endogenous hypoxia biomarker 
genes and intratumoral hypoxia is yet unproven. Expression of oncogenes such 
as HRAS, SRC and ERBB2 can increase HIF-target genes regardless of oxygen 
tension and tumor cells can express certain hypoxia markers such as HIF-2a 
under normoxic condition [77-79, 270, 271]. Therefore, perhaps a more accurate 
assessment of MIR193BHG level and in vivo hypoxia would be to employ In situ 
hybridization using MIR193BHG-specific probes in combination of hypoxia 
imaging agent such as pimanidazole (EF5) on tumor specimens [272].  
 
1.4 MIR193BHG and its relation with the embedded miRNAs 
The existence of two miRNAs within MIR193BHG intron challenged us to 
provide a more detailed elucidation of the RNA products which originate from this 
locus. So far, we have not come across any data during our literature searches 
suggesting that miR193b and miR365a are induced by hypoxia. Our data also 
came to the same conclusion. However, we have only tested the expression of 
these two miRNAs upon hypoxia exposure in MCF-7 cells. Based on the reads 
density from RNAseq data, the intronic region where miR193b and miR365a 
reside also produced more reads in hypoxia. However the mature miRNAs level 
tested by qPCR remained unchanged between normoxia and hypoxia. This 
discrepancy might be due to the global repressive influence on miRNA 
biogenesis by hypoxia. Nonetheless, it still remains that there is no evidence 
suggesting that miR193b and miR365a are not hypoxia-inducible miRNAs.  
So far we have not been able to confirm whether MIR193BHG transcript and the 
two embedded miRNAs are processed from a common primary transcript or two 
separate precursors. Based on the observation that siRNAs targeting the last 
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exon of MIR193BHG have no impact on miR193b and miR365a, at least we can 
claim that MIR193BHG is not transcribed solely for the purpose of producing 
miRNAs. It is also possible that MIR193BHG and the miRNA cluster are 
controlled by different regulatory regions/promoters. It is imperative to confirm 
that our genetic approaches of manipulating MIR193BHG level (knockdown or 
overexpression) do not affect the embedded miRNAs as we propose that 
MIR193BHG functions independently from these miRNAs. It is also important to 
investigate whether MIR193BHG and its enclosed miRNAs have any functional 
overlap. A similar case of a lncRNA with an embedded miRNA is the well-
characterized lncRNA H19 and miR675, which was reviewed in the chapter I 2.3. 
Unlike MIR193BHG, it has been confirmed that miR675 is processed from H19 
RNA transcript and that both RNA products share similar expressional responses 
to hypoxia and have overlapped function in EMT modulation.  
Based on the current Ensembl release, there are 236 miRNAs within 
intergenic lncRNAs loci and 4.65% of currently annotated lincRNAs contains at 
least 1 miRNA. The miRNA-hosting lncRNAs have been largely overlooked 
under the presumption that their transcripts only serve as miRNA precursor. 
However, our data supports an alternative scenario in which distinct functions are 
bestowed on the lncRNA and the enclosed miRNAs and that one genomic locus 
is capable of producing multiple functionally independent RNA products.   
 
1.5 Beyond the preliminary characterization of MIR193BHG  
Using 5’RLM-RACE and 3’RACE in combination with the partial sequence 
from the original lncRNA exon annotation, we were able to pinpoint the start and 
end locations of MIR193BHG transcription. We also confirmed that MIR193BHG 
originats from the plus strand of chromosome 16. It was quite reassuring when 
our initial results were corroborated years later by the updated genome assembly 
release. One limitation of our method of choice is that it depends on presumed 5’ 
cap and 3’ polyA structure of the RNA transcript. Given the fact that a significant 
portion of transcripts are non-polyadenylated, there is a chance that we have 
missed certain transcripts originating from this locus due to such limitations [273]. 
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In addition to the method limitation, our result was also restricted by the relative 
location of the partial sequence we had to begin with. If the distance between 
start or end sites and the partial sequence was much greater than our initial 
estimation, then we would not have been able to capture it in the PCR step. From 
the RNAseq visualization, we observed decent amount of reads beyond our 
currently determined end point. In fact, there is evidence of a third polyA site 
~10kb downstream of the two polyA signals we have captured (Figure 46). 
Considering the distance, we would not have detected this site from our 3’RACE 
even if it was a valid end site. We also have some preliminary experimental 
evidence suggesting that the transcription event might extend further beyond the 
current 3’ boundary.  
The existence of multiple transcription variants is a potential predicament 
for the quantitation and characterization of MIR193BHG. Therefore, in our current 
study, we did not take into account the potential differences between the variants. 
The oligos used for either quantification or gene knockdown were all designed 
based on the common last exon shared by all isoforms. We predicted that the 
last exon is critical for MIR193BHG function as it is shared across all currently 
identified isoforms. Presence of multiple variants was not a major issue in terms 
of knocking down MIR193BHG expression, as the siRNAs or shRNA targeting 
the common exon repressed the level of all potential variants. However, when it 
comes to overexpression, expressing only one isoform might yield an incomplete 
biological picture.  
CSHL long RNAseq of different cellular fractions of MCF-7 revealed the 
presence of MIR193BHG in both nucleus and cytoplasm. The two-exon structure 
of MIR193BHG was clearly demonstrated in the cytoplasmic fraction. Using 
primers designed based on the common exon, we showed that the majority of 
MIR193BHG RNA resides within the nucleus. However this could not be equally 
inferred from CSHL long RNAseq data. A better approach in determining the 
subcellular distribution of MIR193BHG would be using RNA FISH (fluorescence 
in situ hybridization) with MIR193BHG specific probes.  
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Figure 46. Evidence of a longer transcript isoform at MIR193BHG locus. 
poly(A) track from ENCODE Cancer genome polyA site & usage data showing 
the presence of a third polyA site downstream of the currently identified 3’end 
site. 
 
 
2. MIR193BHG: a non-canonical hypoxia-inducible gene 
2.1 De novo transcription or RNA stability 
As to whether the observed induction of MIR193BHG is an outcome of de 
novo transcription or increased RNA stability, we confirmed that there is an 
increased transcriptional rate of MIR193BHG in response to hypoxia. Our 
presented data, as well as our recently generated BrU-seq data which used 
RNAseq to analyze newly synthesized BrU-labeled RNA (data not shown), both 
confirmed this hypothesis. However, we could not completely rule out the 
contribution of RNA stability to increased MIR193BHG level in hypoxia. Although 
widely used, there is a general concern about the profound impact of actinomycin 
D on cellular physiology, and it has been shown throughout the years that 
actinomycin D alters the stability of many RNAs [274]. By comparing the fold 
change of MIR193BHG in hypoxia versus normoxia, from total RNA and BrU-
labeled nascent RNA, we believe that RNA stability is a minor, but accountable 
factor contributing to the observed MIR193BHG induction.  
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2.2 MIR193BHG induction in hypoxia: beyond a HIF-driven model 
Overall, MIR193BHG induction by hypoxia does not follow a canonical 
HIF-driven gene expression model. However, the exact roles of HIF in 
MIR193BHG’s response to hypoxia seems to be a complex issue that requires 
more cautious interpretation, depending on the cell type and HIF isoform. In 
terms of MIR193BHG expression, DMOG elicited no response in MCF-7 cells 
and a marginal induction in MDA-MB-231 cells. The slight difference in 
responses to DMOG in MCF-7 and MDA-MB-231 cells echoed the changes in 
MIR193BHG in these two cell line when HIF-1α was absent: MIR193BHG level 
remained unchanged in MCF-7 cells but it showed a moderate decrease in MDA-
MB-231 cells. Using the publicly available HIF ChIPseq data, we confirmed the 
absence of HIF binding to MIR193BHG proximal promoter in MCF-7, which is the 
cell line that showed no response to either DMOG or HIF-1α knockdown. Even 
though sequence-based transcription factor binding predictions suggested that 
there is no HIF binding sites in MIR193BHG promoter, we cannot make the same 
assertion for MDA-MB-231 cells until it is otherwise experimentally proven. 
Compared to HIF-1α, the contribution of HIF-2α to MIR193BHG’s induction in 
hypoxia is more consistent between the two cell lines tested, with a little stronger 
effect in MDA-MB-231 than in MCF-7 cells. The involvement of HIF-2α in 
regulating MIR193BHG response to hypoxia was further supported by results 
from 786-O cell lines. MIR193BHG expression exhibited a much higher basal 
level and less sensitivity to hypoxic stress in VHL- 786-O cells. A similar 
expression pattern was also observed in other HIF target gene such as GLUT1 
[275]. Therefore, although HIF is not the only transcription factor regulated by 
VHL [276], we still think that the HIF-2α is the main factor behind the observed 
expression pattern of MIR193BHG in VHL+ and VHL- 786-O cells under 
normoxia or hypoxia.  
Our persistence in seeking an explanation for what seems an indirect role 
of HIFs in MIR19BHG expression led to the revelation that both HIF-1α and HIF-
2α bind to a region 38kb downstream of the MIR193BHG locus, in the intron of 
yet another hypoxia-induced gene LOC105447648. At first glance, this HIF 
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binding seem to be an irrelevant event until the evidence of chromatin interaction 
between this HIF binding location and MIR193BHG promoter emerged. Long-
range chromatin interaction has been proven to be an important event in gene 
regulation [277]. Enhancer regulation is mediated via genome looping, which 
physically bridges enhancer element and the targeted promoter to a close 
proximity [278]. There are examples in which HIF functions as an enhancer by 
interacting with other factors to modulate gene expression [279]. The model that 
HIF modulates MIR193BHG’s response to hypoxia as an enhancer is a very 
intriguing idea but it still requires further experimental validation. Additional 
analysis of long range chromatin interaction data generated from a more relevant 
system (hypoxia versus normoxia) with a better resolution might lend more 
strength to our proposed HIF-enhancer model [280].  
In addition, there is the possibility of HIF-independent hypoxia-activated 
pathways and transcriptional factors such as AMPK, ER stress, NFκB, p53 and 
EGR-1 [281-284], as well as HIF-independent regulation of hypoxia-induced 
gene expression [285, 286]. So far we have been able to rule out the following 
factors with the methods indicated in parentheses: ER stress (Thapsigargin), 
MYC (siRNA) and EGR-1 (siRNA).  
 
2.3 MIR19BHG induction in hypoxia: a glucose-restricted hypoxia response 
In addition to being a non-canonical HIF-target gene, what made the 
transcriptional regulation of MIR193BHG even more perplexing was its glucose-
restricted hypoxia response. So far, within the limited number of genes we have 
tested, we have not come across another hypoxia-induced gene showing a 
similar response. It seems that it is the sensing of glucose or energy fluctuation 
itself, rather than how glucose is metabolized, is behind the control of this 
phenomenon, as inhibition of glycolysis (2-DG) or diverting glucose utilization to 
mitochondria (DCA) could not elicit a similar response (Figure 19A). The strength 
of MIR193BHG’s hypoxic response to glucose level does not follow a linear 
dosage-dependent model. Glucose deprivation itself seemed to be able to 
slightly induce MIR193BHG (Figure 19B). Although this result still requires more 
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extensive testing in multiple cell lines, it indicated that possibly a compensating 
mechanism will come into effect to reactivate MIR193BHG once the glucose level 
is below a certain point. Based on our data generated so far, it seems that 
glucose availability, which is jointly determined by the glucose concentration in 
the culture medium and the glucose consumption rate of the cells, lies at the 
center of this puzzle. Compared to normal cells, cancer cells have a significantly 
higher demand and consumption of glucose. This might be the reason why 
5.5mM glucose imposed a significant inhibitory effect on MIR193BHG’s hypoxia 
response in all three breast cancer cell lines tested, but not in normal human lung 
fibroblast cell line WI-38 (Figure 19C). This hypothesis would be further validated 
if we could investigate the association between MIR193BHG’s hypoxic response 
and cellular glucose consumption.  
In retrospect, considering that the MIR193BHG acts as a regulator of an 
energy-draining process such as cholesterol synthesis, it makes sense that its 
level is to some extent modulated by an energy source molecule such as glucose. 
However, the exact mechanism underneath this control and why glucose 
deprivation shut down MIR193BHG’s response to hypoxia still eludes us. 
Investigation of energy-sensing pathways such as AMPK (AMP-activated protein 
kinase) might hold the key to this unresolved puzzle. AMPK, a key metabolic 
master switch in carbohydrate and fat metabolism, has been shown to be 
induced by low oxygen and glucose deprivation [287]. It is also reported that 
reduced availability of glucose results in a decreased expression of HIF-1α 
protein and HIF-dependent genes in hypoxia [288]. If HIF acts as an enhancer of 
MIR193BHG transcriptional regulation as we hypothesized in the last section, 
then the glucose-restricted modulation could be mediated, at least partially, 
through HIF.  
High GC content is another notable feature of MIR193BHG promoter. 
Within 1kb upstream of the TSS, GC content is approximately 72%. Given such a 
high percentage of GC-rich elements, it was no surprise to see an almost 
complete shutdown of MIR193BHG expression in hypoxia in the presence of the 
GC-element blocking agent mithramycin A (Figure 20A). We think this effect was 
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most likely due to masking of the whole core promoter area by mithramycin A, 
rather than the blocking the access of a specific GC-binding transcription factor. 
The discovery of high GC-content in the promoter further led us to the 
identification of Sp1 and Sp3 as transcriptional factors involved in MIR193BHG’s 
expression regulation, which also provided an additional explanation for the 
observed glucose-modulated transcriptional response. At first glance, the 
involvement of Sp1 and Sp3 seemed to be unexciting discovery, as Sp1 and Sp3 
are ubiquitous factors of the SP transcription factor family, responsible for 
maintaining the basal and constitutive transcription such as housekeeping genes 
[289]. Sp1 and Sp3 can bind to identical sequencing binding motifs with 
differential activity depending on the promoter context [290]. Members of the SP 
family, especially Sp1, have been proposed to be required for glucose-dependent 
gene expression [291-293]. Glucose-dependent Sp1 dephosphorylation results in 
a higher DNA binding activity [243]. In the absence of adequate nutrition, Sp1 
becomes hypoglycosylated and thereby subject to proteolytic degradation [245]. 
Thus, the decreased expression of MIR193BHG observed in low glucose 
condition is, at least partly, mediated through glucose-dependent activation of 
Sp1. Knockdown of Sp1 or Sp3 did not dramatically affect MIR193BHG response 
to hypoxia, not as much as the effect of HIF knockdown on CA9 induction. This 
suggests that Sp1 and Sp3 is most likely to be the cofactors but not the ‘master’ 
transcription factor in MIR193BHG transcriptional control. In addition to Sp1 and 
Sp3, EGR-1 (early growth response gene -1) was also considered as a potential 
factor as it has been reported as a glucose-regulated transcription factor and it 
also binds to GC-rich elements [294]. However, preliminary tests using siRNA-
mediated EGR-1 knockdown showed no impact on MIR193BHG’s hypoxic 
response. A high GC-content in the promoter also opens the possibility of 
transcriptional regulation through DNA methylation, but we have not conducted 
any related experiments to explore this aspect at this time.  
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2.4 MIR193BHG induction: TGF-β  
When we analyzed pathways overrepresented by the MIR193BHG-
correlated coding genes in the BRCA dataset, we observed a significant 
enrichment of the TGF-β signaling pathway (Figure 31A). This observation led us 
to the unexpected discovery that MIR193BHG can be significantly induced by 
TGF-β. Compared to the universal effect of hypoxia on MIR193BHG across 
multiple cell types, the influence of TGF-β only manifested in selected cell lines. 
In MDA-MB-231 cells, TGF-β elicited even a slightly stronger induction of 
MIR193BHG, and such induction occurs under different combination of oxygen 
and glucose conditions (Figure 21B). In connection with Sp1, there is evidence 
suggesting that SMAD2/SMAD3/SMAD4 cooperates with Sp1 in transcriptional 
regulation [295, 296]. However, the lack of the glucose-restricted response as 
seen in hypoxia made us lean towards the idea that TGF-β and hypoxia are 
mostly likely controlling MIR193BHG through two independent pathways.  
As a potent inducer of EMT in mammary cells, TGF-β can be produced by 
tumor cells or by tumor-associated stromal and immune cells [297, 298]. What is 
interesting is that EMT is one of the top pathways overrepresented by the genes 
positively correlated with MIR193BHG in BRCA data, which can be partly 
explained by the effect of TGF-β on MIR193BHG expression. So far, the effect of 
TGF-β on MIR193BHG expression has only been tested in three breast cancer 
cell lines. If we seek to understand why such an effect occurs in a more cell-
specific fashion, we should expand our testing to include more cell types and 
compare the variation of TGF-β signaling in different cell types.  
All together, we have shown that MIR193BHG expression is under a 
complex regulatory network involving at least hypoxia, glucose and TGF-β, all of 
which are important factors in the tumor microenvironment. Hence, the in vivo 
expression of MIR193BHG is determined by intricate signals beyond hypoxia, 
which explains the relatively weak correlation between MIR193BHG and hypoxia 
signatures in some cases. However, we have to admit that despite all the 
experiments and bioinformatic analysis discussed above, the exact mechanism 
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controlling MIR193BHG transcriptional response still remains an incomplete 
puzzle and warrants further investigation.  
 
3. Functional characterization of MIR193BHG 
3.1 Knockdown and overexpression of MIR193BHG 
Depleting MIR193BHG using widely used siRNA or shRNA method was a 
challenging task. In order to achieve efficient knockdown, we tested 5 siRNAs 
and 3 shRNAs, among which only one siRNA yielded a satisfactory level of 
knockdown (~80%) while one siRNA and one shRNA managed to decrease the 
MIR193BHG level by ~40%. Compared to protein-coding genes, lncRNAs are 
much more resistant to RNAi mediated knockdown approaches. The localization 
of the lncRNA of interest has to be taken into consideration since depletion of 
lncRNA by siRNA or shRNA may be significantly hampered by their localization 
in the cell. Even though the presence of active RNAi factors in nuclei has been 
suggested and several successful cases of depleting nucleus retained lncRNAs 
using siRNA/shRNA have been reported, there is still an increasing concern in 
the use of cytoplasmic RNAi machinery to knockdown nuclear lncRNA [299]. Due 
to these considerations, antisense oligonucleotides (ASO) has been proposed as 
a more preferable choice for analysis of lncRNA function. ASO act by forming 
DNA/RNA hybrid with the nascent RNA transcript and triggering RNase H-
mediated RNA degradation in the nucleus [300].  
As discussed previously, the concerns for the MIR193BHG 
overexpression construct comes from the existence of multiple isoforms as well 
as a possible longer version of the transcript. Those issues might result in a more 
subtle phenotypical alteration in the function studies using the overexpression 
construct.  
 
3.2 MIR193BHG and clinical outcome of breast cancer patients 
Normal breast tissues, as a group, express a higher level of MIR193BHG 
than the corresponding cancerous tissue. There was a much larger variation in 
MIR193BHG level within the normal tissue group. This could be due to the 
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relatively small sample size or it may also indicate that MIR193BHG level is not 
an indicative factor to distinguish normal and tumor breast tissues. Since there is 
no evidence showing that MIR193BHG resides in a cancer-associated locus, it is 
likely to be the second case. When analyzing the MIR193BHG expression in 
BRCA subtypes, we excluded the NormLike subtype because there have been 
concerns about possible normal tissue contamination within this subtype of tumor 
samples. Basal-like BRCA expresses the lowest level of MIR193BHG, despite its 
highest degree of intratumoral hypoxia among the subtypes. This is in agreement 
with our observation that MDA-MB-231, a triple-negative breast cancer cell lines 
expresses the lowest level of MIR193BHG compared to MCF-7 and T47D cell 
lines. We cannot reach a conclusion about a possible association between 
MIR193BHG level and metastasis status from our analysis because only 15 
cases of BRCA patients with distant metastasis have been recorded in TCGA 
BRCA clinical data due to limited follow-up time. Given the estimation that 20-30% 
of all breast cancer cases will become metastatic eventually, it is very unlikely 
there would be only 15 cases of metastasis among over 900 patients [301].  
 
3.3 Assessment of MIR193BHG function 
MIR193BHG knockdown had a visible protective effect in cells cultured in 
hypoxia, especially in cells more sensitive to hypoxic stress, such as MCF-7. This 
observation was subsequently confirmed by the counting of viable cells as well 
as MTT assay. We used two MIR193BHG siRNAs with differing knockdown 
efficiency and what is interesting is that the strength of the protection was related 
to the efficiency of the knockdown. We also observed the converse effect with 
MIR193BHG overexpression, however this effect was too subtle to be discernible 
by just visible inspection of the cells under a light microscope. We analyzed the 
cell cycle and cell apoptosis, which are routine tests in most cancer studies, but 
failed to observe significant differences to explain the increased survival under 
hypoxia in cells with MIR193BHG knockdown. We have not investigated whether 
an alteration in cell proliferation rate was behind our observation using assays 
such as BrdU-incorporation. Some studies interpret MTT data as a readout of 
163 
proliferation but we do not think such interpretation is biologically accurate. 
Based on the result that there was no significant changes in S-phase and that a 
difference in survival was observed within less than 24hr of hypoxia exposure 
(which is less than MCF-7 doubling time), we believe that the ‘increased’ cell 
number was not a result of enhanced proliferation.   
In the invasion assay, as expected, we observed increased cell invasion 
under hypoxia compared to normoxia in all the cell lines tested, which again 
confirms that hypoxia promotes cell invasion [302, 303]. The fact that 
MIR193BHG knockdown was able to increase cell invasion regardless of oxygen 
status suggested that this effect is most likely mediated via a pathway 
independent from hypoxia signaling. 
Based on expressional correlation calculated from BRCA data, several 
genes encoding for cell adhesion molecules were positively correlated with 
MIR193BHG. In some cell lines, we did observe changes in E-cadherin RNA and 
protein levels in MIR193BHG manipulated cells (data not shown). However, the 
changes were subtle and inconsistent across cell types we tested. When we 
observed the resistance to trypsinization in MIR193BHG overexpressing cells, 
we developed an experiment to translate this observation into quantifiable results, 
without seeking to define the mechanism of this phenomenon. The mechanisms 
behind cell adherence to tissue culture surface and to extracellular matrix and 
other cells are very different. Similar assays with plates coated with extracellular 
matrix or cell layers would provide more information to explain the observation. In 
retrospect, considering the regulatory function of MIR193BHG in cholesterol 
synthesis, it is likely that certain physical attributes of the cell membrane were 
altered in MIR193BHG overexpressing cell lines. 
In vivo xenograft model using MIR193BHG knockdown or overexpressing 
MDA-MB-231 cell lines confirmed the effect of MIR193BHG on tumor metastasis, 
which suggested that the association between MIR193BHG expression and 
metastasis status in BRCA patients, although not significant, might not be a 
random event. When implanted in vivo, MIR193BHG knockdown MDA-MB-231 
cells did not exhibit significant advantages regarding rate of tumor growth. With 
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the hindsight that MIR193BHG is a negative regulator of cholesterol synthesis, 
we might be able to provide an explanation for this observation. Cholesterol 
derivatives 27HC has been shown to increase ER-dependent growth and LXR-
dependent metastasis in mouse models of breast cancer [213]. This may be the 
reason why we only observed changes in metastasis but not in tumor growth 
when we implanted ER-negative MDA-MB-231 cells with engineered 
MIR193BHG expression.  In addition to lung and liver, breast cancer patients 
also display bone and brain metastasis. Due to technical limitations, we did not 
evaluate the metastasis burden in either of these two organs.  
There are a few studies showing that the embedded miR193b also 
suppresses tumor metastasis in ovarian and pancreatic cancers [304, 305]. 
Although we have confirmed that miR193b level was not altered in xenograft 
tumor and hence the difference in metastasis was not due to miR193b, it is still 
interesting to observe a similar function in a microRNA and its host gene, which 
provoked us to consider this genomic locus as a tumor suppressive ‘spot’. As for 
the other embedded microRNA, miR365a, there is only one unconfirmed report 
showing an opposite oncogenic property for this miRNA. Therefore we did not 
test its level in our tumor xenografts.  
 
4. Molecular mechanism of MIR13BHG function 
4.1 Inference of MIR193BHG-associated pathway from in vivo correlation 
Pathway analysis on MIR193BHG associated coding genes could not 
provide an accurate, causal explanation for the observed function. However, it 
offered us valuable indicative information towards the real answer. Apart from the 
EMT pathway discussed in the last section, we saw a significant enrichment of 
pathways related with estrogen response. What is interesting is that according to 
our analysis, ER positive breast tumors expressed a much higher level of 
MIR193BHG then ER negative tumors. Given the connection between 
MIR193BHG function as a cholesterol regulator and that cholesterol is the 
precursor for estrogen biogenesis, it is quite tempting to investigate whether 
MIR193BHG is involved in estrogen signaling. 
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4.2 RNAseq followed by pathway analysis revealed the connection between 
MIR193BHG and cholesterol biosynthesis. 
SiRNA-mediated MIR193BHG knockdown did not affect the expression of 
nearby coding genes MKL2 and PARN. However, a closer examination of the 
RNAseq visualization revealed that the MIR193BHG siRNA targeting the last 
exon repressed a region broader than the annotated locus, including the 
suspected extended transcription area and the further downstream 
LOC105447648 (Figure 32C). Considering there is chromatin interaction 
between LOC105447648 and MIR193BHG loci, we are not surprised to see such 
a collateral inhibitory effect. Since LOC105447648 expresses at a much lower 
level than MIR193BHG, we assumed that this would not interfere with our 
functional characterization of MIR193BHG.  
We believe that the noncoding regulatory elements in gene expression 
control, such as microRNAs and lncRNAs, are more likely to play the role of fine-
tuner. As fine-tuners, when enforced or depleted in an isolated in vitro system, 
dramatic impact on individual ‘targeted’ genes can be observed. However, this 
may not be an accurate reflection of real life. Therefore, we think an approach 
focused on pathways rather than a few manually selected genes is more 
preferable. As it was in our study, a few extensively studied oncogenes including 
HRAS ranked top on the list of genes significantly upregulated by MIR193BHG 
knockdown. However, when applying pathway analysis to the RNAseq result, we 
did not perceive a significant enrichment of typical cancer-associated pathways. 
On the other hand, a negative association between MIR193BHG level and 
cholesterol homeostasis was observed consistently across all cell lines studied. 
Although on an individual gene level, the change elicited by MIR193BHG 
knockdown or overexpression was no more than 2 fold, the collective effect upon 
the whole pathway was able to influence the total cellular cholesterol content. 
One concern we have to point out is that due to limited resources, all our 
MIR193BHG knockdown testing, including RNAseq and the subsequent 
experiments, were carried out only in hypoxic cell culture and the overexpression 
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studies were performed with normoxic cell culture. We chose hypoxia cultures for 
knockdown studies because MIR193BHG level in normoxia is very low, 
especially in MDA-MB-231 cells, therefore we were concerned a knockdown of 
MIR193BHG from such a low level of expression would not yield a detectable 
effect.  
In the xenograft tumors developed from MIR193BHG knockdown MDA-
MB-231 cells, we detected increased expression of 5 out of 6 selected genes in 
the cholesterol biosynthesis pathway, except for SQLE (Figure 35C). Although 
not widely appreciated, SQLE has been proposed as a second rate-limiting 
enzyme in cholesterol synthesis [306, 307].  It is possible that for MDA-MB-231 
cells, the activation of the mevalonate pathway, but not the production of 
cholesterol itself, is more important for cancer metastasis. Hyper-activated 
mevalonate pathway has been reported to promote transformation and 
malignancy [253].  
When measuring the total cellular cholesterol content, we observed a 
decreased level of total cholesterol in hypoxic MCF-7 cells, which concurs with 
the previous studies showing that hypoxia inhibits cholesterol synthesis. However, 
a similar reduction was not observed in MDA-MB-231 cells (Figure 38A). Since 
we have not found another report in the literature performing a similar 
measurement, we cannot confirm our result. This discrepancy might be due to 
the differences in the nature of triple-negative and ER positive breast cancer cells 
and how they are adapted to hypoxia.  
TCGA has a number of high-throughput ‘omic’ data including mutations, 
DNA copy number variation, RNA expression, DNA methylation and protein 
expression analysis but metabolomic analysis has not been included as a 
standard profiling. We were fortunate to find ~20 BRCA samples with matched 
RNA expression and metabolomic data. Although a limited number of samples, 
we observed a general trend towards negative association between MIR193BHG 
and cholesterol level in vivo. One issue with the original study is that it only 
included ER positive BRCA tumors. Although we think the effect of MIR193BHG 
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on cholesterol synthesis is independent from BRCA subtype, it would still be 
more informative if ER negative tumors were incluced. 
 
4.3 MIR193BHG modulates cell survival and invasion via cholesterol 
biosynthesis pathway 
The statin treatment experiments supported the hypothesis that 
MIR193BHG carries out its function through the cholesterol synthesis pathway. 
Statin inhibits cholesterol synthesis activity by targeting the rate-limiting enzyme 
HMGCR, the third step in the synthesis process, before the branch reaction 
producing isoprenoids. Therefore, statin treatment is capable of decreasing total 
cholesterol content as well as depleting the pool of isoprenoid substrates for 
protein prenylation. At the present time, we cannot tell whether the effect of 
MIR193BHG was the result of changes in the level of cholesterol and its 
derivatives or was due to altered protein prenylation through mevalonate 
pathway, or perhaps both mechanisms. One way to answer this question is to 
test if adding back the depleted molecules (cholesterol or cholesterol derivatives 
or isoprenoids) can reverse the observed effect.  
 
4.4 Sex maturation and adult height associated SNPs are located in close 
proximity to MIR193BHG. 
Considering the relatively low expression of MIR193BHG and low 
cholesterol synthesis rate in skeletal muscle, we understand it is perhaps not the 
best tissue to assess the association between these SNP genotype and 
MIR193BHG expression but evaluation of this association in other tissues was 
hindered by the limited sample size available from GTEx. Even in this ‘poorly’ 
chosen tissue type, these sex maturation associated SNPs have much a stronger 
association with MIR193BHG than the previously assumed ‘target’ MKL2. When 
considering the function, MIR193BHG definitely offers a better explanation for the 
phenotype associated with these SNPs.  
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4.5  Molecular mechanism underlying MIR193BHG modulation of 
cholesterol biosynthesis genes 
By pulling down BrU-labelled nascent RNA, we showed that MIR193BHG 
significantly increased the transcription of several genes encoding cholesterol 
synthesis enzymes. All three genes tested showed much a higher induction of 
nascent RNA compared to the measurement from total RNA, indicating the 
presence of certain feedback mechanisms to calm down the response of 
increased transcription. We suspect that RNA stability regulation was involved as 
part of this feedback mechanism, although we cannot support this postulation by 
the RNA decay rate measured using the traditional actinomycin D method.  
Considering the coordinated changes of the whole cholesterol synthesis 
pathway in MIR193BHG knockdown cells, it was logical to hypothesize that 
SREBP2 is involved in the response, as most of the genes in this pathway are 
targeted by SREBP2. Even though our preliminary assessment suggested 
otherwise, we cannot disapprove this notion based on our current results. As was 
mentioned in the introduction, SREBPs are weak transcription factors alone and 
always require the presence of other cofactors to fulfill their function. Therefore 
the level of SREBP2 and its DNA binding activity are perhaps not suitable 
indicators for its activity.  
Identifying the interacting partners has been a great challenge in lncRNA 
studies. One commonly used method utilizes agarose conjugated streptavidin to 
purify a target lncRNA that harbors a streptavidin-binding aptamer toward its 5’ or 
3’ end [308]. This approach investigates the RNA-protein interaction in an in vitro 
condition and could potentially increase false positive results caused by free 
interaction between RNAs and proteins which otherwise would be localized in 
different cellular compartments. This concern has been demonstrated empirically 
in the case of NAF1 protein, a factor involved in small nucleolar ribonucleoprotein 
particle (snoRNPs) biogenesis. When the cells are lysed, NAF1 binds to mature 
snoRNPs while in vivo such binding could not occur due to the exclusion of NAF1 
from nucleoli and Cajal bodies [309]. Due to this reason, we decided to employ a 
method which involves binding in living cells an exogenously expressed FLAG-
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tagged MS2-phage coat protein to a series of copies of hairpin loop-structured 
MS2 RNA sequence inserted at the 3’ end of our lncRNA of interest. 
Concomitant expression of FLAG-tagged MS2-phage coat protein and MS2-
binding-site-tagged lncRNA allows the binding process to occur in living cells 
prior to lysing procedure. However, no method is perfect. The MS2-based RNA 
pulldown approach suffers from issues including whether the extra tag sequence 
interferes with lncRNA function and whether the transient transfection approach 
accurately delivers the lncRNA-tag transcript to its designated cellular 
compartment.  
Mass spectrometry analysis of the complex pulled down with MIR193BHG 
gave us a long lists of proteins, which still requires further evaluation and 
validation. The presence of several splicing-related proteins, including hnRNPC 
which has been confirmed by western blot, and the presence of the primary RNA 
of HMGCR in the complex led us to evaluate if the alternative splicing of exon 13 
of HMGCR is affected by MIR193BHG status. We used a PCR-based method 
published by Marisa W Medina et al. [264], however we do not have a positive 
control to verify how accurate this PCR-based method is in testing HMGCR 
alternative splicing. Although not significant, the proportion of unproductive 13(-) 
HMGCR transcript displayed an opposite direction of change compared to the 
changes in total HMGCR measured in MIR193BHG manipulated cells as well as 
the xenograft tumors. The difference between xenografts with control shRNA and 
MIR193BHG shRNA was significant, but the large variation in the control group 
cast some doubt on the result. Skipping of exon 13 of HMGCR is only one of 
many recorded alternative splicing events in cholesterol synthetic genes. We 
have not tested whether other alternative splicing events are also affected by 
MIR193BHG. Based only on one case, we cannot address the role of alternative 
splicing in MIR193BHG-mediated alteration of cholesterol synthesis. In fact, 
based on the testing in BrU-labeled nascent RNA, we are leaning towards a 
model in which MIR193BHG regulates transcription and RNA processing in 
parallel. The evidence of co-transcriptional RNA process provides the structural 
possibility for our model [310]. A series of experiments which verify the protein 
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complex and validate their interaction with MIR193BHG and the targeted 
RNA/DNA are still required to fill in the details of this currently loosely 
constructed model.    
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Chapter V. Future Direction 
 
1. Transcriptional regulation of MIR193BHG 
We discovered a lipid metabolism regulatory lncRNA while searching for 
novel hypoxia-responsive transcripts. So far, we have carried out a series of 
experiments in order to understand how hypoxia is controlling MIR193BHG. 
Meanwhile we have neglected to test whether MIR193BHG transcription is also 
controlled directly by stress from imbalanced lipid homeostasis, which seems to 
be a more relevant cue. It would be interesting to see whether direct 
manipulation of cholesterol content (e.g. cholesterol depletion by cyclodextrins 
[311]) would change MIR193BHG level.  
The hypothesis that HIF binds to a distant enhancer then regulates 
MIR193BHG hypoxia response through chromatin interaction is a very intriguing 
idea. However proving this idea requires some thoughtfully designed 
experiments. We will first need to confirm the interaction between the HIF-binding 
enhancer element and MIR193BHG promoter, possibly using a Chromosome 
Conformation Capture (3C) methodology. The currently tested transcription 
factors Sp1 and Sp3 are most likely to be the cofactors in the MIR193BHG 
transcriptional control because manipulation of these factors only elicited a 
moderate change in MIR193BHG level. Therefore we are still searching for other 
factor or combination of factors that drive the induction of MIR193BHG in hypoxia.  
Another aspect we wish to explore is the connection between 
MIR193BHG and estrogen response. The evidence inspired this exploration 
includes, 1) ER+ BRCA tumors contain a higher level of MIR193BHG than ER- 
tumors; 2) MIR193BHG-correlated genes showed enrichment in estrogen 
response pathway. There are several high-throughput sequencing data 
generated from breast cancer cell lines treated with estrogen in public data 
depository. We will first download and analyze these related data. If there is an 
indication of estrogen-regulated expression of MIR193BHG, we will further 
confirm and characterize this connection experimentally. 
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2. MIR193BHG and miR193b:  
As discussed in the last chapter, we have confirmed that MIR193BHG and 
miR193b respond differently to hypoxia and have independent functions in 
metabolism regulation. However, the overlaps in their tumor suppressive 
properties and lipid metabolism-related functions still demand further explanation. 
Our preliminary testing using miR193b mimic oligos suggested that 
overexpression of miR193b has no effect on the cholesterol synthetic genes. But 
we still need to confirm this conclusion from the other direction using anti-
miR193b oligos, which might also interfere with the level of MIR193BHG. This 
concern needs to be carefully addressed when testing anti-miR193b oligos.  
To solve this puzzle with a better approach, we are planning to use 
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/ 
CRISPR-associated endonuclease 9) system to independently knock out 
miR193b and MIR193BHG’s last exon (Figure 47) [312, 313]. In order to 
minimize the interference on MIR193BHG transcription, the gRNAs designed to 
cut miR193b were restricted to only the area in close vicinity to miR193b. Since 
removing the entire MIR193BHG locus would also compromise miR193b and 
miR365a, we decided to target only the last exon, which is shared by all 
MIR193BHG transcript variants. Based on our speculation of an extended 3’ 
region in at least some MIR193BHG transcript variants, we also decided to 
extend the target region to the position of the third polyA signal. This strategy 
might lead to the disruption of a separate noncoding gene in this region that is 
currently unknown to us. However, there has been no evidence suggesting the 
existence of such gene(s) so far. The abovementioned knockout design are 
currently under development in MCF-7 cells.  
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Figure 47. Illustration of CRISPR design for knockout of miR193b and 
MIR193BHG last exon. 
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3. Mechanism of MIR193BHG-mediated gene expression control 
Mass spectrometry analysis of MIR193BHG pulldown complex yielded a 
considerable amount of information regarding to the mechanism behind the 
coordinated regulation of cholesterol synthetic genes by this intriguing lncRNA. 
This information built the foundation of our current hypothesis that MIR193BHG 
is a part of specific regulatory complexes that modulate the transcription and 
RNA processing of the targeted genes. To test this hypothesis, we will first 
confirm the presence of the interacting protein components in the pulldown 
complex, then validate their interaction with MIR193BHG via RNA 
immunoprecipitation. The interaction between proteins within the sample 
regulatory complex will also require validation. We also hypothesize that the 
MIR193BHG complex is targeted to each cholesterol synthetic gene, possibly to 
the promoter or the regulatory region. To seek evidence supporting this 
hypothesis, we will exam the genomic regions bound by MIR193BHG complex 
using ChiRP (Chromatin Isolation by RNA purification) followed by DNA 
sequencing. ChiRP-Seq is a high-throughput sequencing method to discover 
regions of the genome which are bound by a specific RNA. This approach will 
provide us comprehensive information about the distribution of MIR193BHG 
involved complex in the genome and thus revealed the genes that are under 
direct control of MIR193BHG-mediated mechanism.  
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